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Chapter 1
Epidemiology of fractures
Bones have evolved throughout millions of years of evolution and perform several 
tasks. Bones provide a framework for attachment of muscles to enable movements, 
they protect soft tissues against external trauma, they serve as a reservoir for calcium 
homeostasis, host blood cells for hematopoiesis, and immune cells and store energy, 
such as fat in the bone marrow. Strong bones can resist load, such as running, jumping 
and falls. Fractures occur when the load exceeds bone strength [1,2]. Thus, fractures 
are the result of weakened bones, severe or repeated trauma’s or a combination of 
both. In 50+ subjects the most frequent trigger for fractures is a fall or an accident, in 
combination with postmenopausal and age-related bone loss. In adults, fracture risk 
increases with age and remaining lifetime fracture risk in Caucasian men and women 
of 50 years is >20% and >50% respectively [3]. With the aging of the population 
worldwide more fractures are expected [4]. The number of all fractures per year 
among the Dutch population older than 50 years is 120,000 according to data from 
health insurance companies [5]. This burden comes with approximately € 600 million 
expenses per year and will even rise with 50% by 2030 [6,7]. For the Netherlands it 
seems that the burden in costs holds trend with that of other European countries. 
However, due to Dutch demographics it seems that the expected increase in health 
care budgets for fractures is not the highest in Europe [4]. Other European countries 
like Austria, the Scandinavian countries and Belgium are already facing even higher 
future costs and, as a consequence it will have negative effects on national health care 
budgets [4]. Based on extensive prospective population and cohort studies, it has 
become clear that the risk of subsequent fractures is particularly high within the first 
years after a fracture in patients older than 50 years [8-13]. This high and immediate 
risk of having subsequent fractures is referred to as ‘imminent fracture risk’ [14,15]. 
Osteoporosis has been reported in about a third of fracture patients who are older 
than 50 years and accounts as one of the risk factors for subsequent fractures [5]. 
However, there is still a huge knowledge gap regarding this imminent subsequent 
fracture risk in daily practice among both patients and health care professionals [16-19]. 
Fragility fractures are also associated with a short- and long-term excess mortality 
[20,21]. In Dutch patients older than 50 years with a non-vertebral fracture (NVF), 
the absolute mortality was 32% of which nearly a third (17%) occurred one-year post 
fracture [22]. An increased risk for subsequent fractures and excess mortality after 
initial fractures was shown in several studies [8,11,20-22]. These findings support the 
effort to develop fracture prevention strategies soon after first fracture. Currently, the 
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fracture liaison service (FLS) is considered the most effective organizational structure 
for secondary fracture prevention [23-29].
Fracture Liaison Service (FLS) from an historical perspective
McLellan et al. introduced in 2003 a novel out-patient program for the evaluation 
and management of patients with osteoporotic fracture called the Fracture Liaison 
Service (FLS) [30]. In the Netherlands the first FLS related initiatives and outcomes 
were reported from Groningen in 2004 and from Maastricht in 2007 [31,32]. 
The Delft FLS was founded in 2007 after in-depth discussions with local GPs and 
nowadays this FLS is highly esteemed by patients, hospital specialists and general 
practitioners. In the Dutch guideline on osteoporosis and fracture prevention (2011) 
[33] it was recommended to evaluate all fracture patients of 50 years or older in 
preferentially a nurse-led structured program and in 2012 a set of quality indicators 
was developed for the evaluation of post-fracture care in Dutch Hospitals [34]. 
Internationally, the International Osteoporosis Foundation (IOF) started a global 
initiative called “Capture the Fracture®’’ [35]. Capture the Fracture® used the FLS 
concept as the fundament to prevent re-fractures propagating their so-called nurse-
coordinated multidisciplinary approach. These so-called coordinators’ or ‘local 
champions’ approach consisted of a framework of 13 best practices necessary for 
a structured combat against secondary fractures [36]. Today, the FLS initiative is 
internationally endorsed by the International Osteoporosis Foundation IOF [25], the 
American Society of Bone and Mineral Research ASBMR) [26], the European League 
against Rheumatism (EULAR) [27] and the multidisciplinary Fragility Fracture Network 
(FFN) [28]. Formal position statements by these international scientific societies 
encouraged even more FLS initiatives abroad as well as in the Netherlands [37]. 
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Fig 1. FLS-care: nationwide Quality Assessment and the FLS fi ve-step approach
FLS-care: a fi ve-step approach
In order to strive for standardized and optimal FLS-care, a fi ve-step approach has 
been proposed by van den Bergh et al. [23]. This approach was based on the 
concept of a systematic, preferably coordinator-based, approach for identifi cation, 
enrollment, evaluation, treatment and monitoring of patients with a fracture after 
the age of 50 years. After identifi cation of patients, a detailed evaluation of medical 
history, medication use, clinical risk factors, vitamin D status, dietary calcium 
intake, known contributors to secondary osteoporosis and fall risk should then be 
performed, together with assessment of BMD and VFA. Next, patients need to be 
further evaluated for undiagnosed contributors to secondary osteoporosis and 
metabolic bone disorders. Then a multifactorial intervention should follow, including 
lifestyle management recommendations, calcium and/or vitamin D supplementation if 
required, and treatment of underlying disorders. Specifi c anti-osteoporotic treatment 
should be considered in line with national guidelines with organized follow-up of 
patients after 3 months and annually, thereafter [33].
Gaps in secondary fracture prevention care
The recognition of the FLS as a well-defi ned structured outpatient clinic was a fact, but 
gaps in knowledge of both patients and doctors have not yet been resolved. Dutch 
healthcare is well organized and basic medical costs are covered by all Dutch health 
care insurance companies. Hospitals are equipped to highest standards and care 
processes and logistics are demanded by Dutch law. This unique situation provides the 
opportunity to comply with national guidelines on osteoporosis, fracture prevention 
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and falls endorsing to put maximum effort on secondary fracture prevention [33,34]. 
Unfortunately, there are still gaps in secondary fracture prevention care.
Attendance gap
In 2013, the International Osteoporosis Foundation (IOF) had recognized ‘FLS 
attendance’ as an important marker of local FLS quality (www.capturethefracture.org). 
FLS attendance was expected to be some 50% or even lower but exact data were 
not available. In many countries, FLS initiatives were initiated, but attendance was 
reported to be generally low and varying between 20-89% [37]. Patient identification 
and selection differed markedly among FLSs, in terms of proportions of inpatients 
and outpatients, age, inclusion of women and/or men and fracture selection (any 
fracture or only patients with an NVF) [37]. The reasons for these low attendance rates 
are unclear, but patient views and opinions about osteoporosis and the consequent 
underestimation of subsequent fracture risk might be of strong influence [16–19]. 
In addition, besides person-related considerations, patients may be unintentionally 
uninvited because of administrative issues [38].
Fracture risk evaluation gap
Fracture risk evaluation includes the evaluation of the presence of clinical risk factors 
based on medical history and clinical evaluation (age, sex, body weight, personal 
and family fracture history, diseases and medication use that increase fracture and 
fall risk), DXA including VFA and laboratory tests to exclude underlying illness. The 
Dutch guideline of 2011 recommend DXA to identify osteoporosis as well as VFA to 
identify subclinical VFs and fall risk assessment [33]. Given the national guideline on 
osteoporosis and fracture prevention in the Netherlands (2011) and the excellent 
access to health services and the high hospital density throughout the country, the 
Osteoporosis Quality Indicator was introduced to monitor in all Dutch hospitals. This 
Quality Indicator, based on a so called Appraisal of Indicators, Research and Evaluation 
(AIRE) tool [39,40], meaning a hospital-self-report on the proportion of patients of 
50 years and older with a recent fracture that received a DXA within 6 months post 
fracture. Over the last years, DXA was reported to be performed in 33% of patients 
on average, with a wide range (5-100%) [34,41]. In addition, the CBS data collected in 
2016 showed that DXA (with and without VFA) was performed in only 26% of 120,000 
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people older than 50 years with a fracture [7,41]. This low proportion in spite of clear 
recommendations according to national guidelines (2011) [33] underpins the notion 
of a huge gap in our national fracture risk evaluation initiative. In addition, these 
indicators do not provide in depth information on the quality of post-fracture care 
beyond DXA measurements as described in the IOF standards and according to the 
five-step approach of FLS care.
Treatment gap 
Treatment gap is defined as the proportion of truly osteoporosis prescriptions 
divided by the total number of osteoporotic fractures plus the degree of adherence 
to medication. Both aspects need to be addressed by the FLS in line with Capture 
the Fracture® Best Practice Framework and international consensus [36,26-29]. Not 
starting anti-resorptive treatment was mainly related to insufficient medical advice, 
attitudes towards medication use including concerns about side effects, and disease 
awareness [16,42-45]. In patients that started treatment, the one-year adherence 
to oral bisphosphonates in the general Dutch population was reported to be 43% 
[46]. The persistence in using anti-osteoporosis drugs in patients with a fracture 
was 75% after 1 year and 45% after 5 years [47], which is better than in the general 
Dutch population but still points at low long term persistence percentages in these 
high risk patients. Recently, it was suggested that individualized solutions, based 
on collaboration between patient and healthcare provider are needed to improve 
adherence and persistence in osteoporosis medication [48]. 
Nurse Initiatives regarding Fractures, Falls and Osteoporosis
At the time of the first introduction of FLS care in the Netherlands, there was no network 
for health care professionals and, therefore an informal network was launched by a 
small group of nurses with interest in osteoporosis and fractures. The recognition of 
the complexity of secondary fracture prevention care and the identification of several 
knowledge gaps led to a nationwide Dutch nursing initiative by the formal founding 
of the national board of FLS specialized osteoporosis and fracture prevention nurses 
(Dutch Osteoporosis Nurses Association VF&O) in 2008 [49]. The VF&O steering 
board started to initiate organized education and training on-the-job programs to 
improve the skills for FLS care, and national meetings twice a year. The vision of VF&O 
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is to become “best on the job’’ through liaising protocol-based decision making, state-
of-the-art-expertise and multidisciplinary patient care. Apart from these activities, 
there is a growing number of nurse practitioners who are traditionally registered 
in the Dutch National Council of Nurses (V&VN) [50,51]. Part of this highly trained 
group has the capability and skills to work in secondary fracture prevention care. In 
contrast to nurses, nurse practitioners and physician assistants are legally authorized 
to order diagnostic tests and to initiate medical treatments [52-54]. In parallel with 
the upcoming organization of nurses in boards and national councils there an urgent 
need was felt to establish an international vision on the daily role of nurses, nurse 
practitioners and physician assistants in the field of secondary fracture prevention 
[55-57]. Endorsed by the IOF in the Capture the Fracture® campaign “make the first 
(fracture) the last” nurses should become entitled to become ‘local champions’ i.e. key 
players in daily secondary fracture prevention practice [35,36]. Nurses who are well-
trained and capable to connect all input from disciplines (in and outside the hospital) 
in favor of individual fracture patient care [58-59] and who take the lead to ensure 
the highest FLS attendance as possible [60]. Protocols are mandatory and medical 
consultation must be well organized. Indeed, best practice today means 50% FLS 
attendance, despite the efforts and care of expert nurse and nurse practitioners in 
many FLS facilities. Therefore, firm steps and original viewpoints are necessary to 
further optimize secondary fracture prevention and it is a challenge for nurses, nurse 
practitioners and physician assistants to show leadership in the organization of FLS 
care. These ambitions form the basis of this dissertation on FLS care from a nurse 
practitioner`s perspective. 
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Aims and outline of this dissertation.
This dissertation has multiple aims regarding the five-step approach of FLS care. 
1. To gather information on the quality of FLS care in the Netherlands, beyond 
the standard Dutch DXA-based quality registrations.
2. To get a better understanding of patient characteristics and motivations 
related to FLS attendance and non-attendance.
3. To study the performance of an ultrasound prescreening tool to exclude 
FLS patients without osteoporosis or subclinical vertebral fractures for DXA 
measurement and VFA.
4. To investigate whether FLS patients complied with recommendations for 
daily calcium intake.
5. To introduce a dedicated telephone program and the use of bone 
turnover markers for the evaluation of one-year persistence in using oral 
bisphosphonates.
Outline
After the introduction in Chapter 1, we studied the Dutch FLS performance in Chapter 
2 by developing a nationwide audit to assess the implementation of FLS quality 
standards as formulated by the International Osteoporosis Foundation (IOF; CtF® 
Best Practice Framework (BPF)) in Dutch hospitals.
In Chapter 3 we studied hospital registration and patient-related factors that were 
associated with attendance and non-attendance in patients that were invited at the FLS. 
In Chapter 4 we studied the reasons for non-attendance in identified FLS eligible 
patients by a questionnaire and by home visits.
In Chapter 5 we studied whether the application of a non-ionizing peripheral Pulse 
Echo Ultrasound device enables identification of women with recent non-vertebral 
fractures at the FLS who would not need a DXA/VFA.
In Chapter 6 we studied traditional dairy intake in a FLS cohort aiming to analyze the 
recommended daily calcium allowance (RDA).
In Chapter 7 we studied the impact of telephone calls at one-year of osteoporosis 
medication and the adherence to medication was objectified by means of bone 
markers and pharmacy delivery data.
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Chapter 8 summarizes the results of this dissertation.
Chapter 9 includes a general discussion based on findings in this dissertation and 
provides future perspectives for clinical practice and research.
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Mini-abstract
The fracture liaison service (FLS) is advocated to be effective for the prevention of 
secondary fractures, but implementation is variable. A questionnaire based on the 
IOF Capture the Fracture® FLS standards was used in the current study. The results 
showed high compliancy with IOF standards in the Dutch responding hospitals.
Abstract
Introduction
The fracture liaison service (FLS) is advocated for the prevention of secondary fractures, 
but its implementation varies between hospitals and countries. The present survey 
applied the standards proposed by the International Osteoporosis Foundation (IOF) 
to evaluate the implementation of FLSs in non-university hospitals in the Netherlands. 
Methods
A questionnaire based on the IOF FLS standards was used in this study, requesting 
the selection, evaluation and treatment data of patients older than 50 years with a 
recent fracture. 
Results
Of 90 invited hospitals, 24 (27%) fully responded, providing data of 24,468 consecutive 
patients, corresponding with 25% of fracture patients in the Netherlands in the year 
2012. After excluding skull and toe fractures and patients exceeding the upper age 
limits applied by individual hospitals, 11,983 patient data were available for analysis. 
The data showed high compliance (>90%) for fracture patient identification, invitation 
for FLS, timing of assessment, identification of vertebral fractures, application of 
national guidelines, evaluation of secondary osteoporosis, drug initiation when 
indicated, communication with the general practitioner, application of follow-up 
strategy, and 70% for fall prevention. The response rate was on average 49%. 
27
Meeting international standards of secondary fracture prevention
2
Conclusions
The available data also showed that patients attending the FLS were evaluated, 
treated and followed in high compliancy with IOF standards. Some standards are 
open to different interpretations and may need further specification. The major 
shortcoming in FLS practice was that patients invited to attend the FLS showed a low 
response rate. None of the hospitals achieved the IOF standard patient response rate 
of over 90%. 
Introduction
The fracture liaison service (FLS) is advocated as the most appropriate approach 
for secondary fracture prevention [1,2,3]. This approach is managed by a central 
coordinator, mostly a qualified osteoporosis nurse [4,5]. However, the implementation 
of FLSs varies between hospitals [6] and countries [7,8]. The International Osteoporosis 
Foundation (IOF) has proposed standards to evaluate the implementation and the 
quality and performance of the FLS [9].
After a fracture, the risk of a subsequent fracture steeply increases [10,11]. Of all low 
trauma fractures in patients over 50 years of age, subsequent fractures accounted 
for 40% of fractures in women and 24% in men [12]. After any osteoporotic fracture 
in patients over 60 years of age, 24% of women (31% of survivors) and 20% of men 
(32% of survivors) had a subsequent fracture within 5 years [13]. Using composite 
risk analysis that takes into account subsequent fracture risk and mortality, the risk of 
subsequent fractures reached 40% in survivors of hip fracture during 5 year follow- 
up [14], 80% of survivors of a hip fracture during 20 years follow-up [15], and 20% of 
survivors of a hand or foot fracture during 5 year follow-up [16]. In addition, the risk of 
mortality is increased after a first and subsequent osteoporotic fracture [17].
The aim of the FLS is to reduce the risk of subsequent fractures in high risk patients. The 
first FLS was reported in Glasgow in 2003 [18]. It involved systematic identification of all 
fracture patients, adequate evaluation of their fracture risk, diagnostic evaluation with 
DXA and VFA and analysis for secondary osteoporosis or metabolic bone disorders, 
followed by prescription of calcium and vitamin D and specific anti-osteoporosis 
medication, if needed, as well as follow-up according to a 5-step approach [19].
In the Netherlands, several nationwide scientific committees have addressed the 
importance of initiating a FLS in hospitals in order to achieve adequate secondary 
fracture prevention. National guidelines on osteoporosis and fracture prevention 
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strongly advocate the identification and examination of patients with a recent 
fracture, including risk evaluation and differential diagnosis [20,21]. These initiatives 
have contributed to the development of a FLS in most Dutch hospitals. At present 85 
specialised FLS nurses are working in 68 non-university hospitals. 
In 2012 the International Osteoporosis Foundation (IOF) launched the “Capture The 
Fracture®” campaign for secondary fracture prevention [3]. In this campaign, the 
IOF presented a Best Practice Framework (BPF) with 13 standards for evaluating the 
performance of FLSs. In this study, we applied these 13 standards to evaluate the 
implementation of FLS in non-university Dutch hospitals. As far as we know, no similar 
study has been performed before.
Methods 
In the Netherlands, there are 90 FLSs in non-university teaching and non-teaching 
hospitals, and 95 osteoporosis nurses are registered in the database of VF&O (the 
Dutch association for nurses on Falls, Fractures and Osteoporosis); 85 of them are 
working in 68 of the non-university hospitals, while the remaining 10 are working in 
university hospitals or in other professional settings. 
For evaluation of the FLSs, the authors of this survey designed a digital questionnaire 
consisting of demographic questions and specific questions about the FLS organisation 
and the 13 BPF standards[3], which were translated from the original English text into 
Dutch. Next, all 90 non-university hospitals in the Netherlands were invited by mail to 
participate in this survey, providing a web link that gave access to the questionnaire. 
The questionnaire was sent to the 85 VF&O affiliated FLS coordinators working in 68 
of the non-university hospitals, and to the physicians involved in osteoporosis care in 
the remaining 22 non-university hospitals (Figure 1). 
To ensure the anonymity of participating hospitals, the questionnaire was distributed 
by DeVosJansen Research Association (DVJ), a professional, independent and 
unrelated organisation. The results of the questionnaires were sent to DVJ using 
internet-based Kinesis Survey software, and DVJ delivered the results anonymously to 
the Research group for analysis. Only descriptive statistical analyses were performed.
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Fig 1. Flowchart on inclusion of analysed FLSs
Invitation and 
Questionnaire 
68 hospitals
nurse member of 
VF&O 23 responses  
22 hospitals
not members of VF&O  
1 response 
Invitation for the study mailed to 90 non-
university hospitals by Independent 0rganisation 
(DVJ Research Association)
24 completed Questionnaires for analysis 
Collection of data sent by DVJ to the Research 
Group Fracture & Osteoporosis clinics   
Results
From 90 hospitals, 24 FLSs (27%) returned completed questionnaires (Figure 1). 
Another 6 questionnaires were incomplete and not suitable for analysis. Three 
hospitals reported not to be able to extract sufficient data from their database, and 
57 did not respond. 
Demographics
Of the included hospitals, 16 (67%) were teaching hospitals and 8 were non-teaching 
hospitals. The FLS organizing departments were the Trauma and Orthopaedic Surgery 
in 12 hospitals (50%) and Internal Medicine, Geriatrics and Rheumatology in another 
12 hospitals (50%). The lead clinician was either the Trauma and/or Orthopaedic 
Surgeon in 9 hospitals (38%), 2 of which shared leadership with internal medicine, or a 
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specialist in Internal Medicine in 15 hospitals (62%) (8 Endocrinologists, 1 Geriatrician 
and 4 Rheumatologists and 2 physicians sharing leadership with surgeons).Of the 
24 participating hospitals, 22 (92%) had a coordinating nurse. For this coordinator 
at the FLS, they reported a median of 12 working hours/week (range 4-36 hours), 
with additional secretarial help in 17 hospitals (71%) with a median of 9 working 
hours /week (range 4-20 hours). The supportive presence of a physiotherapist was 
reported in 7 hospitals. The FLS had been initiated between 2004-2006 in 6 hospitals 
(25%), between 2007-2009 in 12 (50%), and between 2010-2012 in 6 (25%). DXA was 
available in 23 hospitals (96%), and VFA in 16 hospitals (67%). (Table 1)
Table 1. Characteristics of the FLSs (following Demographics)
Yes No
Presence of a coordinating nurse 22 (92%) 2 (8%)
Teaching hospital 16 (67%) 8 (33%)
DXA scan available 23 (96%) 1 (4%)
VFA available 16 (67%) 8 (33%)
Secretarial services available 17 (71%) 7 (29%)
BPF Standard 1. Patient identification
All respondents had a system for tracking every patient who presented at their hospital 
with a fracture; 9 used hospital administration records, and 17 used emergency 
department records, with an overlap of 2 hospitals that reported the use of both 
these facilities. A total of 24,468 patients with any recent fracture were identified in 
year 2012, 18,001 between the age of 50 and 80 years, and 6,467 in patients older 
than 80 years. This represented around 25% of all fracture patients older than 50 
years in the Netherlands in that year. A median of 1,020 fracture patients were seen 
per participating hospital (range 217-3,377).
BPF Standard 2. Patient evaluation
This standard focuses on the response rate, which depends on selection criteria and 
invitation strategy. Therefore we asked for these factors, revealing that institutions 
varied in the use of selection criteria, invitation strategy and response rate, but all 
FLSs evaluated each and every responder. Of all the patients with recent fractures, the 
following categories were excluded for invitation: skull fractures in all FLSs, toe fractures 
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in 3 FLS, patients >90 yrs in 9 FLSs, >85 years in 4 FLSs and >80 years in 1 FLS.
The process of invitation was coordinated by the osteoporosis nurse in 14 FLSs, (58%), 
by the nurse practitioner/physician assistant in 3 hospitals (13%), by the physician in 3 
hospitals (13%) and by the secretarial assistant in 6 FLSs (25%). 
Six FLSs invited patients personally, during treatment in the plaster room or during the 
orthopaedic outpatient clinic visit (25%). A combination of personal and subsequently 
written invitation was reported in 5 FLSs (21%). Ten FLSs used written invitations 
first (42%), 5 of these (21%) invited patients additionally by phone. Three FLSs (13%) 
invited patients only by phone. In 6 FLSs, patients were invited within 1 month after 
fracture, in 15 between 1 and 2 months and in 3 between 2 and 3 months. 
Of the 24,468 fracture patients identified by the participating hospitals in year 2012, 
11,983 attended the FLS (49%), with a median of 499 patients per FLS (range 112-
1,050). The response rate depended on age (54% in 50-80 yrs old, 34% in 80+) and 
timing of invitation (47% after 1 month, 58% after 1-3 months). All responding patients 
were subsequently assessed for future fracture risk at the respective FLSs.
BPF Standard 3. Post fracture assessment timing
In 11 FLSs (46%) patients actually visited the FLS for assessment within 8 weeks after 
the fracture, in 11 FLSs (46%) they visited between 9 and 12 weeks after the fracture 
and in 2 (8%) more than 13 weeks after the fracture.
BPF Standard 4. Vertebral Fracture
In all participating hospitals, all patients with clinical vertebral fractures, who attended 
the FLS were assessed. Ten FLSs (42%) also reported a strategy to invite patients 
with non-clinical vertebral fractures as reported by the radiologist. In 15 hospitals, 
the FLSs reported the structural application of VFA at any BMD level in patients with 
a non-vertebral fracture. Seven FLSs reported VFA assessment only in patients with 
osteoporosis, and 6 reported VFA assessment in case of osteopenia and osteoporosis. 
One FLS reported the structural application of X-ray of the vertebral column instead 
of VFA. In 11,983 patients, 9,690 DXA scans (81%) were performed, and 7,045 of these 
(73%) included VFA. Ten FLS (42%) reported also a strategy to invite patients with non-
clinical vertebral fractures as reported by the radiologist.
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BPF Standard 5. Assessment Guidelines 
A total of 22 FLSs (92%) reported implementation of national guidelines concerning 
osteoporosis and fracture prevention. Two FLSs did not specify which guidelines 
were used.
BPF Standard 6. Secondary Causes of Osteoporosis
All FLSs assessed causes of known SECondary Osteoporosis and metabolic Bone 
disorders (SECOB) through medical history. Ten FLSs performed laboratory tests on 
all patients as standard procedure. In 22 FLSs, all the patients who required treatment 
additionally underwent investigation for SECOB, while 2 FLSs reported performing 
laboratory analyses only when secondary osteoporosis was clinically suspected. 
BPF Standard 7. Fall Prevention Services
In 17 FLSs (71%), patients were evaluated for the presence of fall risk. Implementation 
of national guidelines on fall prevention was reported by 14 FLSs (58%). The content 
of fall risk evaluation was heterogeneous. The following evaluations were reported: 
attention for mobility in general, including the use of alcohol, attention for visual 
impairments and the use of crutches (38%) and evaluation of orthostatic hypotension 
(8%). Three FLSs (13%) reported function and muscle tests, including the Timed Up 
and Go test (TUG), the Berg Balance Scale (BBS) and a Hand Grip Strength test. Three 
FLSs reported systematic referral to a falls prevention clinic (13%). 
BPF Standard 8. Multifaceted health and lifestyle risk factor assessment
Multifaceted health and lifestyle risk factor assessment was performed in 22 FLSs, 
of which 20 FLSs reported the health and lifestyle risk factors to the GP who was 
responsible for subsequent referral to the appropriate practitioner for further 
evaluation and treatment. 
BPF Standard 9. Medication Initiation Standard
In all patients not on treatment at the time of fracture presentation, medication 
was initiated at the FLS in 19 hospitals (79%) and initiated by the GP in 5 hospitals 
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(21%). For further follow-up prescription, all patients were referred to their GP. The 
analysis of this standard did not include the prescription of calcium and vitamin D 
supplements. 
BPF Standard 10. Medication Review
A total of 22 FLSs reported to be following the national guidelines for patients already 
in receipt of osteoporosis medication when they presented with a fracture. This 
included review of medication compliance, considerations of alternative osteoporosis 
medication and optimization of non-pharmacological interventions.
BPF Standard 11. Communication Strategy
A total of 22 FLSs communicated the results of all patients to the GPs, and 1 FLS did 
so in 90% of the patients (1 FLS unknown). Of the 24 FLSs, 22 reported prescription 
of osteoporosis medication, 21 reported BMD results, need for adequate calcium 
and vitamin D intake and laboratory results, 20 reported primary osteoporosis 
risk factors and lifestyle health risk factor assessment, 19 reported screening on 
secondary osteoporosis, results of X-rays of the spine and the proposed follow-up 
strategy. Seventeen reported on the duration of therapy, 15 FLSs reported fracture 
risks and 13 reported VFA results, current drug treatment and fall risk factors. 
Previous fractures/time since last fracture were reported by 11 FLSs and medication 
compliance review was reported by 12 FLSs. The FRAX score was reported by 1 FLS as 
standard procedure. (Table 2)
BPF Standard 12. Long-term Management
Eight FLSs reported a follow-up protocol in the FLS after 3 months, 7 a telephone 
call (after 1-12 months) and 15 reported that further follow-up was delegated to the 
patient’s GP. 
BPF Standard 13. Database
All FLSs used local databases for inviting fracture patients, and 12 (50%) had a local 
database on the results of examinations at the FLS. A national registry on fractures 
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is available in the Netherlands and open to the public. All hospital-reported fractures 
have specific codes which correspond with the insured coverage [22]. However, no 
nationwide hospital data is available on patients evaluated in an FLS. This survey was 
based on individual FLS databases that included around 25% of all fractures in the 
Netherlands in year 2012.
Table 2. Various aspects communicated by the FLSs to GP (following IOF CtF®BPF standard 11)
Aspects Yes No
1 Fracture risk score (FRAX) 1 (4%) 23 (96%)
2 DXA/ BMD 21 (88%) 3 (12%)
3 Vertebral column X-ray 19 (80%) 5 (20%)
4 Primary Osteoporosis risk factors 20 (84%) 4 (16%)
5 Screening on secondary Osteoporosis 19 (80%) 5 (20%
6 Laboratory tests 21 (88%) 3 (12%)
7 Fall risk factors 13 (54%) 11 (46%)
8 Current drug treatment 13 (54%) 11 (46%)
9 Medication compliance review 12 (50% 12 (50%)
10 Follow-up Plan 19 (80%) 5 (20%)
11 Follow up Plan: Duration of therapy 17 (70%) 7 (30%)
12 Lifestyle health risk-factor assessment 20 (84%) 4 (16%)
13 Former fractures/ Time since last fracture 11 (46%) 13 (54%)
14 Calcium intake or supplement 21 (88%) 3 (12%)
15 Vitamin D intake or supplement 21 (88%) 3 (12%)
16 VFA 13 (54%) 11 (46%)
17 Prescription osteoporosis medication 22 (92%) 2 (8%)
18 Fracture risks 15 (62%) 9 (38%)
Discussion
This large survey, which included one quarter of all Dutch fracture patients over 
50 years of age in the year 2012, aimed at evaluating the implementation of FLS 
according to the proposed international BPF standards in non-university hospitals 
in the Netherlands. The survey reflects the huge clinical effort in each of the 24 
participating hospitals, showing a median of 1,020 fracture patients per hospital, and 
assessing a mean of 499 fracture patients per FLS.
All the evaluated FLSs scored above 90% for the following BPF standards: identification 
of patients with a recent fracture in the hospitals, invitation for FLS, timing of 
assessment, identification of vertebral fractures, application of national guidelines, 
evaluation of secondary osteoporosis, drug initiation when indicated, communication 
with the general practitioner, and application of follow-up strategy. Our data suggest 
35
Meeting international standards of secondary fracture prevention
2
that the majority of Dutch FLSs are organized in line with the best model according to 
Ganda Type A [2,7,8], including an osteoporosis nurse, all-encompassing service and 
initiation of osteoporosis medication. These findings contrast with a previous survey 
in the Netherlands, which evaluated a smaller cohort of FLSs/hospitals before the 
year 2010 and found that patients were referred to the GP for treatment decisions 
(Ganda Type B) [2,6].
One explanation for the observed high level of FLS care is that most of the issues in 
the IOF standards were already included in national guidelines on osteoporosis and 
fracture prevention in the Netherlands [20,21]. These guidelines strongly advocate 1/ 
to identify patients with a recent fracture, 2/ to evaluate their fracture risk using DXA, 
VFA and clinical risk factors, 3/ to perform differential diagnosis, 4/ to decide about 
secondary fracture prevention and 5/ to follow up treatment. Another explanation is 
the longstanding experience of several Dutch hospitals with FLS, since 18 of the 24 
participating hospitals had already started an FLS before the Dutch guidelines were 
revised in 2011.
Some standards were applied with high variability in implementation. While some 
FLSs performed evaluation of secondary osteoporosis in all patients, other FLSs only 
did so in patients who required treatment or if secondary osteoporosis was clinically 
suspected. Fall risk evaluation consisted of questionnaires alone in 12 FLSs (50%), or 
in combination with evaluation of orthostatic hypotension (in 8%), and only 3 FLSs 
(13%) reported function and muscle tests. Also, FLSs differed in performing either 
vertebral fracture evaluation in all patients or only in patients with osteopenia or 
osteoporosis.
The major shortcoming in practices of the FLSs was the low response rate of patients 
who were invited to visit the FLS. A patient response rate of over 90%, which is 
suggested as the highest BPF standard, was nowhere achieved by any FLS in the 
current survey. With the exception of surveys in the UK, where response rates of 75 
to 85% have been reported [23-26], response rates are usually lower (between 28 
and 61%) in other countries and continents [27-32]. Further research is required to 
understand the causes of these lower response rates and to identify ways to increase 
them. Earlier studies have shown that systematic screening is more effective than 
referral, that personal communication is more effective than written information 
for patients, and that the FLS may be more effective than electronic messaging and 
communication with GPs [33].
An important limitation of this survey is that the response was relatively low, with 
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33 out of 90 hospitals responding (37%). Moreover, six of these hospitals delivered 
incomplete data and 3 indicated not to be able to generate any data. As a consequence, 
the analysis was based on 24 out of the 90 invited hospitals (27%). This could implicate 
that well performing FLSs are overrepresented. Unfortunately, any information about 
responding and non-responding FLS’s is lacking since anonymity was assured in this 
survey. The self-reporting of participants about their own hospital may be a potential 
bias although the majority of data were extracted from FLS derived databases.
This is the first attempt of a nationwide audit of standards of care delivered by the 
FLS. However, our response rate emphasizes that FLSs have to be encouraged to 
participate in these kind of surveys in order to improve our understanding how to 
optimize secondary fracture prevention per country. It is also needed to analyze and 
compare FLS implementation in other countries and among countries. Moreover, 
country-specific Quality/Clinical Standards for FLS have been published in Canada 
(adherent with the IOF BPF’s and the osteoporosis Canada Clinical Guidelines)[34] 
and the UK were the 5IQ approach is advocated to quality improvement [35]. Each 
initiative, albeit different from the IOF Capture the Fracture® will provide useful 
information about the quality of FLS care on a global scale. 
Of 68 FLSs run by osteoporosis nurses, 23 were analyzed (34%). In addition, of 22 
services run by physicians, 1 participated in the analysis (5%). Therefore, the results 
may be not representative for the FLS care throughout the Netherlands, even though 
they are based on one quarter of all fractures in Dutch patients over 50 years of age.
Conclusion
In 24 of the 90 non-university hospitals in the Netherlands, we showed that patients 
attending the FLS were evaluated, treated and followed in high compliance with 
IOF standards. Some standards are open to different interpretations and will need 
further specification. The major shortcoming in FLS practice in this survey was that 
patients invited to attend the FLS showed a low response rate. Further research 
should identify the causes of this low response rate and ways to increase it. 
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Mini-abstract:
This questionnaire-based study evaluated the reasons for attendance or non-
attendance at the fracture liaison service in patients with a recent fracture. Frailty, 
male sex, living alone and low education were associated with non-attendance, and 
the information perceived by the patient was associated with attendance. 
Keywords: Non-attendance; FLS; Attendance.
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Abstract
Introduction
The purpose of this study was to evaluate hospital registration- and patient-related factors 
associated with attendance or non-attendance to the Fracture Liaison Service (FLS).
Patients and Methods
Out of 1728 consecutive patients registered with a recent fracture at hospital entry, 
and after exclusion of 440 patients because of death, residence in a nursing home, 
already on osteoporosis treatment or recent DXA, 1288 received an FLS invitation. 
We evaluated the hospital registration of fractures at entry and exit of the hospital. 
A questionnaire was sent to all invited patients to evaluate factors related to non-
attendance (including age, gender, frailty, living alone, income, education, extrinsic 
motivations (impact of perceived information) and intrinsic motivations (patient`s 
own perceived views and opinions) and to attendance (personal impact of clinical 
professionals` advice).
Results
There were 278 more hospital exit codes than entry codes. Of the 1288 invited patients 
745 returned analyzable questionnaires (537 attenders and 208 non-attenders). 
Non-attendance was associated with male gender (OR:2.08, 95% CI:1.35;3.21), 
frailty (OR:1.62, CI:1.08;2.45), living alone (OR:2.05, CI:1.48;2.85), low education 
(OR:1.82,CI:1.27;2.63), not interested in bone strength (OR:1.85 CI:1.33;2.63) and 
being unaware of increased subsequent fracture risk (OR:1.75, CI:1.08;2.86). 
Information perceived by the patient was significantly associated with attendance 
(OR: 3.32, CI;1.75; 6.27).
Conclusion
Fracture entry registration inaccuracies, male gender, frailty, living alone, having low 
general education or low interest in bone health and subsequent fracture risk were 
independently associated with FLS non-attendance. Adequately perceived advice 
(to have a bone densitometry and attend the FLS) was strongly associated with FLS 
attendance. 
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Introduction 
The Fracture Liaison Service (FLS) is widely considered the most effective model of 
care for the prevention of subsequent fractures [1-4], and fully coordinated, intensive 
strategies are the most effective approach to secondary fracture prevention [5] and 
treatment adherence [6-7]. 
However, there is still a large evaluation and treatment gap in secondary fracture 
prevention [1-3, 8, 9], in spite of available treatments to prevent subsequent fractures 
[10]. 
The reasons for this low attendance are unclear, but patients` views and opinions 
about osteoporosis and the consequent underestimation of subsequent fracture risk 
might be of strong influence [11-14]. Besides person-related considerations there 
may be administrative pitfalls to be evaluated. 
Patient information is a key component of effective self-management [11], but it 
was not always clear whether the studies involved primary or secondary fracture 
prevention.
Also, patient characteristics can be involved in FLS attendance. Between FLSs, there 
is a high variability of selected patients according to age or sex [12]. In a study in 
the UK, socio-economic factors did not play a role in FLS participation [13]. Patient 
characteristics that could play a role in not attending the FLS include illness perception, 
frailty, living alone and low education [14-17]. We therefore evaluated the association 
of administrative fracture registration, patient characteristics and patient information 
with FLS non-attendance and attendance.
The first objective was to study the accuracy of the administrative fracture registration 
process on the proportion of patients that was or was not invited to the FLS. The 
second objective was to study the impact of demographic aspects, patients` views 
and motivations on attending. 
Patients and Methods
Patients 
This study was performed in patients older than 50 year who presented because of a 
clinical fracture between January 1st and December 31th in the year 2016 at the Reinier 
de Graaf Hospital, Delft, the Netherlands. 
Identification of patients with a recent fracture was based on the administrative 
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fracture registration that was registered by the clinical professional at the time of 
hospital entrance. Registrations were monthly reconciled by one of the FLS officers. 
After exclusion of patients who had deceased, following patients were also not 
invited according to the local FLS protocol: permanent residents in a nursing home 
and patients with medical conditions in need of anti-osteoporotic treatments (not 
including calcium or vitamin D) or who had a DXA within two years before fracture. All 
remaining patients were subsequently invited to attend the FLS. 
We used two strategies to identify these patients to invite them for a FLS visit, in line 
with the Dutch Guideline on Osteoporosis and Fracture prevention as implemented 
in our hospital protocol [18]. Strategy 1 was to invite personally as many patients 
as possible by the clinical professional at the plaster department. Strategy 2 was to 
send an invitation letter to all patients who were not personally contacted by the 
clinical professional at the plaster department or who, in spite of this, had not made 
an FLS appointment. To accomplish strategy 2, we screened all entry fracture code 
registrations from the database of the Emergency Department once every month. 
Questionnaire
In June 2017, all these patients, whether or not they had accepted the invitation 
to attend the FLS, were send a questionnaire by post mail. The content of this 
questionnaire is available in the Appendix. 
The questionnaire consisted of 1/ Patient characteristics included age, sex, marital 
status, education, country of birth, income and fracture location; 2/ Therapy: use of 
calcium and vitamin D supplements and having osteoporosis treatment; 3/ Patient 
views and opinions: Intrinsic motivations (5 questions): about fracture and bone, 
general health and questions about patients` views on bone quality and extrinsic 
motivations (11 questions): perceived advice to attend the FLS and have a DXA scan 
and motivations why they had decided to attend or not to attend the DXA and FLS 
and 4/ various aspects of frailty were evaluated, using the validated Tilburg Frailty 
Indicator (TFI) questionnaire [19]. The TFI has a scoring range between 1 and 15, 
frailty is defined by a score ≥ 5 but <10 and being very frail by a score ≥ 10 with the 
highest limit of 15 points.
Motivations for attending the FLS were evaluated for extrinsic and intrinsic 
factors. Extrinsic motivations were considered to arise from information by clinical 
professionals, for example the inclination to follow instructions by the health 
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professional to attend the FLS. Intrinsic motivations origin from self-reflection, such 
as personal judgment to strive for a better bone health.  
Administrative registration of patients with a recent fracture 
Reimbursement of treatments in Dutch hospitals is based on administrative fracture 
registration by the clinical professional. This is firstly done at the time of hospital 
admission because of a fracture (“entry registration”) [20-22], using the hospital 
electronic patient management system ChipSoft HiX 6.1[23]. In this study the FLS 
invitation process was based on entry registrations from the Emergency Departments 
database, which is common practice among many Dutch FLSs [8,9]. During the 
process of fracture care, this entry registration is reconciled by the Hospital Financial 
Dept., based on the automated collection of fracture registrations from all medical 
departments. In case of incomplete entry registration the Hospital Financial Dept. 
was entitled to make adjustments before the final registration was sent to the health 
insurance company for reimbursement (“exit registration”). The fracture registration 
accuracy was evaluated by comparing all entry fracture registration codes with all exit 
fracture registration codes. 
Fracture types (according to exit registrations) were subdivided into Non-Vertebral 
Non-Hip (NVNH) minor fractures (n= 855, 43%), NVNH major fractures (n= 740, 37%), 
hip fractures (n= 312, 15%) or clinical vertebral fractures (n= 99, 5%), based on the 
level of subsequent fracture risk as previously reported [24]. 
Statistical Analysis 
Data were analyzed using Statgraphics Centurion XVII software (Version 17.2.05 for 
MS-Windows; Statpoint, Inc., Warrenton, VA, USA).
Analyses were performed on two age strata (< 70 and >=70 yr.) in line with the Dutch 
VMS [25], gender, and on dichotomized variables of the 745 questionnaires. Medians 
of age (yr.) with respect to gender were compared with the Wilcoxon rank-sum test 
and the Micceri Normality test. Associations were assessed via crosstabulation, using 
two column-dependent variables Attending (Yes/No), and Frailty (Yes/No) using TFI.
After bivariate crosstabulation, a multivariate logistic regression model was fitted to 
identify any possible association between the binary outcome variable attending (Yes/
No) and independent predictive variables i.e. demographics as age and gender and 
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extrinsic or intrinsic motivations. We tried to decipher model enhancing and significant 
interactions applying R TREE package. The association was assessed by direction and 
absolute value of adjusted residuals. Evidence of any association in the population from 
which the sample was drawn was assessed with unconditional, uncorrected Pearson‘s 
Chi-Squared test; if significant, the association was measured using Odds Ratios and 95% 
Confidence Intervals. Multivariate Odds Ratios were estimated with logistic regression, 
with non-attendance as dependent outcome and demographics, frailty, and motivations 
as independent outcome variables after exclusion of those independent variables that 
were not significant in the univariate analysis and after testing for interaction between 
variables. Where applicable, 95% Confidence Intervals and correlation coefficients were 
used. A p-value < .05 was considered statistically significant.
Ethics
The study was carried out in accordance with the declaration of Helsinki and the 
guidelines of the International Conference on Harmonization Good Clinical Practice 
(GCP) after a certificate of no objection approved by the regional Medical Ethical 
Review Board (METC Zuidwest Holland) no. NL 17.109.
Results
A total of 2,006 patients of 50 years or older had a validated exit fracture code 
registration. As patients were only invited to attend the FLS based on entry fracture 
code registrations, we calculated that 278 (14%) were missed and therefore had not 
received the FLS invitation by post mail. Of the remaining 1728 patients, 440 patients 
were excluded from invitation because they had died or were excluded based on our 
local FLS protocol. (Fig.1). Therefore, only 1,288 patients were invited. This resulted 
in 841 attenders and 447 not attenders meaning 65% of all invited patients (Fig. 1). 
From these 1,288 patients we received 772 questionnaires (27 not analyzable). The 
remaining 745 evaluable questionnaires came from 537 attenders (72%) and from 
208 non-attenders (28%). 
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Fig 1. Flowchart of FLS patients in 2016 based on entry and exit fracture code registration and 
response to questionnaires
Legends: DXA: Dual Energy X-ray Absorptiometry; FLS: Fracture Liaison Service.
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Table 1. Characteristics of 745 FLS patients that responded to the Questionnaire.
Pooled data for men and women ATTENDING
n=537 (72%)
NOT-ATTENDING 
n=208 (28%)
Demographics
Age at Fracture 
Women
Men 
69 (50-96)
414 (77%)
123 (23%)
75 (50-95)
143 (69%)
65 (31%)
Fracture type:                                                                       
Minor fracture  
Major Fracture  
Hip Fracture  
Vertebral Fracture 
207 (39%)
250 (46%)
54 (10%)
26 (5%)
68 (32%)
99 (48%)
25 (12%)
16 (8%)
Marital status:                                                                           
Living together (married/shared living)
Not married
Divorced
Widow/Widower
343 (64%)
47 (9%)
43 (8%)
104 (19%)
98 (47%)
18 (9%)
17 (8%
75 (36%)
Education:                                                                              
No response
Primary/secondary school vs. 
High school/university
5 (1%)
342 (64%)
190 (35%)
4 (2%)
154 (74%)
50 (24%)
Country of birth:                                                                       
The Netherlands
Indonesia
Surinam and Antilles
Turkey and Morocco
507 (94%)
6 (1%)
5 (1%)
19 (4%)
194 (93%)
2 (1%)
0
6 (6%)
Income (in € per month):                                                                            
Low (€ 601 - € 1200)
Normal (€ 1200 - € 1800)
High (> € 2100) 
No response
67 (12%)
96 (18%)
275 (51%)
99 (19%)
34 (16%)
49 (24%)
70 (33%)
55 (27%)
Are you satisfied with your living/housing environment?   
Yes 
No
No response
519 (97%)
12 (2%)
6 (1%)
200 (96%)
6 (3%)
2 (1%)
Use of calcium and vitamin D supplementation and use of osteoporosis medication
Use of calcium tablets?                                                           
Yes
No
No response
113 (21%)
396 (74%)
28 (5%)
62 (30%)
137 (66%)
14 (4%)
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Pooled data for men and women ATTENDING
n=537 (72%)
NOT-ATTENDING 
n=208 (28%)
Use of Vitamin D?                                                     
Yes
No
Do not know
No response
299 (56%)
217 (40%)
10 (2%)
11(2%)
74 (36%)
116 (56%)
8 (4%)
10 (4%)
Do you take oral bisphosphonates?                                        
Yes 106 (20%) 38 (18%)
Patients views and opinions
What caused your fracture                                                      
Osteoporosis   
The fall  
The accident 
Bad physical condition  
Imbalance / dizziness  
No response
65 (12%)
240 (45%)
85 (16%)
9 (2%)
30 (6%)
108 (19%)
23 (11%)
79 (38%)
36 (17%)
3 (1%)
23 (11%)
82 (39%)
I think that my fracture risk is not increased although I had a fracture.
Yes
No/do not know
99 (18%)
432 (82)
24 (12%)
181 (88%)
Perceived advice to attend the FLS
Perceived advice to attend=Yes
Perceived advice to attend= No
428 (80%) 
109 (20%)
61 (29%) 
147 (71%)
Taking interest in Bone Quality                                                
Yes
No
Somewhat
No response
63 (12%)
236 (44%)
229 (43%)
9 (1%)
15 (7%)
118 (57%)
64 (31%)
11 (5%)
Various aspects of health and frailty
How healthy is your lifestyle?                                               
Healthy
Not healthy, not unhealthy
Unhealthy
400 (74%)
134 (25%)
3 (1%)
138 (66%)
65 (31%)
5 (3%)
Self-reported Level of Health:                                              
Good
Poor
No response
408 (76%)
101 (19%)
28 (5%)
145 (70%)
44 (21%)
19 (9%)
Do you suffer from 2 or more chronic diseases?                  
Yes
No
No response
173 (32%)
352 (66%)
12 (2%)
72 (35%)
131 63%)
8 (2%)
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Pooled data for men and women ATTENDING
n=537 (72%)
NOT-ATTENDING 
n=208 (28%)
Do you take 4 or more tablets every day?         
Yes
No
No response
179 (33%)
336 (63%)
22 (4%)
84 (40%)
112 (54%)
12 (6%)
Frailty (Tilburg Frailty Indicator scores)
Women 
TFI score > 5 (frail)
TFI score < 5 (not frail)
Men:   
TFI score > 5 (frail)
TFI score < 5 (not frail)
414 (77%)
167 (40%) 
247 (60%) 
123 (23%) 
16 (13%) 
107 (87%)
143 (69%)
60 (42%)
83 (58%)
65 (31%)
24 (37%)
41 (63%)
Legends:
Results are presented as median (range) or numbers (percentage). A Tilburg Frailty Indicator score > 5 
represents frailty.
The characteristics of attenders and non-attenders are presented in table 1. Using 
univariate analysis (Table 2), non-attendance was significantly associated with age > 
70 years, being male, living alone, having low income or low education and being 
frail. Out of the five questions concerning extrinsic and eleven questions concerning 
intrinsic motivations one extrinsic motivation and two intrinsic motivations showed 
significant associations. The extrinsic motivation “the clinical professional did not 
advise me to go for DXA” was significantly associated with non-attendance as well as 
the following two intrinsic motivations 1. “I am not interested in my bone strength” 2. 
“I do not think that my fracture risk is increased after sustaining this fracture”. On the 
other hand, patients` perceived advice by the clinical professional to go through DXA 
and visit the FLS was significantly associated with attendance (Table 2 and 3). 
In multivariate analysis, all factors that were significant in univariate analysis remained 
significant, except age and low income (table 3). Non-attendance was independently 
associated with being male, living alone, low education, frailty (OR: 1.62, CI: 1.08; 2.45), 
no perceived advice to go through DXA and visit the FLS as well as “I am not interested 
in my bone strength” and “I do not think that my fracture risk is increased after 
sustaining this fracture” with non-attendance but not with age, neither as bivariate <70 
>70 years groups, nor per decade, or categorized for highest versus lowest quartiles 
or per age category in standard deviation subgroups (table 3). Perceived advice to 
go through DXA and to visit the FLS was positively and significantly associated with 
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attendance, with an OR of 3.32 (CI: 1.75; 6.27).
Table 2. Univariate Associations of Demographics, Extrinsic and Intrinsic Motivations and Frailty 
with FLS non-attendance and attendance.
Measure of 
Association:
OR (95%CI)
Test of  
Association: 
Pearson’s  
Chi-square
p-value
FLS NON-ATTENDANCE
Demographic factors contributing to be a non-attender 
Male
Living alone
Age > 70 yr.
Low income 
Low education
1.67 (1.17; 2.42)
1.98 (1.43; 2.74)
1.87 (1.35; 2.60)
3.03 (2.00; 4.55) 
3.03 (2.00; 4.55)
.002
<.001
<.001
<.001
<.001
Extrinsic Motivations contributing to be a non-attender
No advice was perceived to have a DXA and to visit the 
FLS 
9.1 (6.7; 12.5) <.001
Intrinsic Motivations contributing to be a non-attender
I am not interested in my bone strength* 2.08 (1.50; 2.94) <.001
I do not think that my fracture risk is increased after 
sustaining this fracture**
1.72 (1.08; 2.86) .024
Frailty: Tilburg Frailty Indicator (TFI)
Frailty 2.12 (1.51; 2.98) .002
FLS ATTENDANCE
Extrinsic Motivation contributing to be an attender
Advice was perceived to have a DXA and to visit the FLS 5.9 (3.7; 9.1) <.001
Legends:
OR: Odds Ratio; 95%CI: 95% Confidence Interval, p-value < .05 is considered significant. Frailty: Tilburg Frailty 
Indicator (TFI) dichotomized: < 5 = not frail vs. > 5 = frail, Living alone: dichotomized Yes/No meaning living 
with other individual(s) vs. living alone; Age: dichotomized ≤ 70 yr. or > 70 yr.; Income: dichotomized highest 
monthly income > €2100 vs. < € 2100; Education: dichotomized high school or university grouped vs. other 
levels of education. Statistical analysis (applying R package: tree) revealed no interaction between variables.
*I am not interested in my bone strength; grouped data: I am not interested in my bone strength vs. somewhat 
interested and interested in my bone strength.
** I do not think that my fracture risk is increased after sustaining this fracture; grouped data Yes vs. No and 
I do not know.
 
55
Challenges and opportunities to improve fracture liaison service attendance
3
Table 3. Multivariate logistic regression of Demographics, Extrinsic and Intrinsic motivations 
and Frailty with FLS non-attendance or attendance.
Measure of 
Association:
OR (95%CI)
Test of 
Association:
Pearson’s Chi-
square
p-value
FLS NON-ATTENDANCE
Demographics contributing to be a non-attender
Male
Living alone
Low education
2.08 (1.35; 3.21)
2.05 (1.48; 2.85)
1.82 (1.27; 2.63)
.002
<.001
.0014
Extrinsic Motivations contributing to be a non-attender
No advice was perceived to have a DXA and to 
visit the FLS
3.23 (1.96; 5.56) <.001
Intrinsic Motivations contributing to be a non-attender
I am not interested in my bone strength.
I think that my fracture risk is not increased 
although I had a fracture
1.85 (1.33; 2.63)
1.75 (1.08; 2.86)
<.001
.002
Frailty: Tilburg Frailty Indicator (TFI)
Frailty 1.62 (1.08; 2.45) .002
FLS ATTENDANCE
Extrinsic Motivation contributing to be an attender
Advice was perceived to have a DXA and to visit 
the FLS
3.32 (1.75; 6.27) <.001
Legends: 
OR: Odds Ratio; 95%CI: 95% Confidence Interval, p-value < .05 is considered significant.
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Discussion 
The aim of our study was to gain more insight into reasons of FLS non-attending or 
attending. We identified failures in administrative fracture entry registration as well as 
being male, frail, having low general education, living alone and lack of extrinsic and 
intrinsic motivations as independent risks for FLS non-attending. Extrinsic motivation 
was an independent FLS attending factor.
There was an invitation gap of 14% in our hospital due to administrative errors. This 
finding may provide opportunities to improve this as yet unidentified factor for non-
attending the FLS.  According to a previously reported study this improvement may 
have nationwide implications for FLS attendance and consequences for fracture 
reduction and cost savings [6,26].
The Fracture Liaison Service (FLS) is considered the most effective approach for 
secondary fracture prevention, but attendance is heterogeneous [1,8,9]. Therefore, 
we evaluated the invitation process, including registration and patients’ personal views. 
It is of note that there is no reported systemic audit on FLS registration. However, 
there is literature on patients` views and considerations after fracture, highlighting 
the importance of the lack of information and low awareness to be at high risk for 
subsequent fracture. [11,27]. Since there are different degrees in FLS structures 
and populations, studies have been conducted to look for common phenotypes 
and socio-economic factors in order to better predict FLS non-attendance [5,16,17]. 
In addition to these factors we found being male, frail, living alone and being lower 
educated independently and significantly contributed to non-attendance. 
Being male revealed a significant factor for non-attending. This finding has been 
previously published in another FLS study [28]. In a recent review on osteoporosis 
in men it was found that after low trauma men are less likely to be screened due to 
mans’ reluctance to be screened, although their lifetime risk of osteoporotic fractures 
is between 13 and 25% after the age of 50 [29]. Although women have a higher risk for 
a first fracture than men, the relative risk of a subsequent fracture is higher in men, so 
that the absolute subsequent fracture risk is similar between men and women [30].
Frailty leads to a negative spiral with an increase in fall risk, hospital admissions and 
death [31-33] and was a significant determinant of non-attendance in this study. 
Frailty is operationalized into phenotypes via psychometric clinical descriptions 
[34-36] or via a scoring system according to validated indicators [37]. In this study 
the Tilburg Frailty Indicator (TFI) was used because the TFI is also designed to point 
insight into demographic variables. TFI has been propagated previously for its robust 
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validation properties, showing favorable outcomes for the relationship between 
phenotypical and psychometric properties [37]. In an intentionally similar survey on 
the use of osteoporosis medication after fracture and women’s motivation, it was 
found that frailty was 44% according to the TFI [27]. Moreover, 25-50% of people 
older than 85 years comply with the accepted definition of frailty [31,36,37]. In the 
current study, frailty was found in 40% of non-attenders (42% women and 37% 
men) who were younger (median 70 years). This underlines the importance of frailty 
including its associated functional restrictions in the prediction of fracture risk. [38-
39]. Importantly, frailty and functional restrictions are not only associated with non-
attendance but also with high imminent fracture risk [38,39].
In this FLS study we found a univariate association between age (> 70 years) and non-
attendance but the association was not significant in the multivariate model, indicating 
that other risk factors were dominant over age. This finding, although intuitively 
perceived to be associated, is not new in the field of osteoporosis. For example, in the 
Study of Osteoporotic Fractures among women of 65 years and older, age predicted 
one-year subsequent risk of hip and non-vertebral fractures, however, this predictive 
factor diminished after adjusting for functional and cognitive restrictions [39].
Low education was accounted as an independent associated factor of non-attendance 
in support with two previous studies from Canada and the UK. These studies point 
to the important role of someone’s capability for self-reflection, health literacy and 
self-management [11,16].
Living alone was also found to be a significant determinant for non-attending. In 
Western European countries e.g. The Netherlands, the number of adult people 
living alone is gradually increasing. Recent Dutch data show 43% of the elderly adult 
population to live alone (21% after divorce and 22% after death of a loved one [40]. 
Living alone should not be interpreted synonymous with loneliness but stands for 
increasing odds of losing social contacts and also the reluctance to ask support in 
general and for medical care [41].
Adequate motivation or the lack of it was a strong determinant associated with FLS 
attendance or non-attendance. Moreover, motivating patients for FLS attendance by 
health care professionals should take place shortly after sustenance of fracture [1,9]. 
Therefore, successful patient – health care professional interaction may well resolve 
part of the widely observed treatment gap. In this perspective, interfering factors like 
health professionals’ self-assurance and the need in general for up-to-date training 
and uniformity in the field of fracture prevention remain essential [7]. The beneficial 
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effect of face to face FLS promotion immediately post fracture has been shown 
effective in the current and in a previous study [8]. More than a third of all fracture 
registrations is attributable to osteoporosis [26]. Such a high proportion prompted 
to the conviction that all available instruments should be deployed to prevent new 
fractures as we have the insight, methods and medications [10,27]. Physicians, cast 
technicians and FLS nurses / nurse practitioners are encouraged to embrace this part 
of treatment to put effort in gaining patients‘ attention to accept treatment to prevent 
subsequent fractures. 
The relatively high response rate of 60% to this questionnaire study is remarkable. 
Usually lower response rates of pencil and paper studies and of anonymous internet 
surveys have been reported [42].
This study has limitations. In this retrospective study, information regarding fracture 
treatment, either conservatively or surgery, exact time between fracture and 
questionnaire and duration of in– and outpatient treatment, was not available.
In addition we were not able to correlate treatment modalities and complications 
and time of rehabilitation to attendance. 3. To ensure statistical power demographics 
were analyzed as groups i.e. Living alone, Income and Level of education. These latter 
factors are probably different per country, region or neighborhood.
In conclusion, failures in administrative fracture entry registration as well as frailty, 
male gender, having low general education, living alone and low interest in bone 
health and subsequent fracture risk were independent determinants for FLS non-
attendance. Adequate motivation of patients by the healthcare professional shortly 
after the fracture, or the lack of, was the strongest determinant associated with both 
FLS attendance and non-attendance, respectively. We advocate to increase attention 
on the fracture registration process and to put effort on a personal tailored approach 
to help patients to make an informed decision. Apart from these aspects, alternative 
strategies may be needed for those individuals who are frail, are living alone and have 
low education in order prevent subsequent fractures.
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Appendix - Questionnaire
In 2016 you were treated in the Reinier de Graaf Hospital for a broken bone. 
In order to get the best possible picture of your health and the health of your bones 
in particular, we would like you to fill in this questionnaire. In addition we find it 
important in order to continue to improve our services. If you are unable to give an 
answer to a question, you may skip it. Please make one choice per question unless 
indicated otherwise. 
1) When you think about your bones, how much are healthy bones and breaking 
bones on your mind?
They´re on my mind a lot.
They´re somewhat on my mind
They´re not on my mind at all.
2) Has your mother and/or your father ever broken a hip?
Yes
No
I don´t know
3)  In 2016 you experienced a bone fracture, please tick the bone you broke:
Collarbone
Lower arm / wrist
Middle of hand / finger
Upper arm / shoulder
Elbow
Vertebra
Rib
Pelvis
Hip / Upper leg
Lower leg / knee
Ankle
Middle of foot / toe
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4)  Since you were 50, have you previously broken another bone? 
(not counting the fracture in 2016)
Please indicate which bone that was. If you had not previously broken anything, 
please go on to question 6.
Collarbone
Lower arm / wrist
Middle of hand / finger
Upper arm / shoulder
Elbow
Vertebra
Rib
Pelvis
Hip / Upper leg
Lower leg / knee
Ankle
Middle of foot / toe
 
5) What do you think was the cause of your bone fracture in 2016? 
       Please make a choice for each possibility.    
Yes No I don´t know
Osteoporosis / Breakable bones
A fall
An accident (e.g. on the bike or in the car)
Physical weakness
Poor balance or dizziness
 
6)   Since your bone fracture in 2016, has a doctor suggested possible treatment 
       options aimed at osteoporosis in order to prevent new fractures and the 
       possibility of a DEXA scan (bone density test)?
Yes
No
I don´t know
61
Challenges and opportunities to improve fracture liaison service attendance
3
7)  Since your bone fracture in 2016, has a cast technician /nurse suggested possible 
treatment options aimed at osteoporosis in order to prevent new fractures and 
the possibility of a DEXA scan (bone density test)?
Yes
No
I don´t know
 
8)    Has your GP spoken to you about `osteoporosis` (bone density loss)?
Yes
No
I don´t know
9)  After your bone fracture were you invited to go to the Fracture and Osteoporosis 
Out Patients´ Clinic at the Reinier de Graaf Hospital? 
Yes
No
I don´t know
 
10)    Have you had a DEXA scan (bone density test) done? 
Yes
No
I don´t know
 
11)    Have you been to the Fracture and Osteoporosis Out Patients´ Clinic ?
Yes
No
I don´t know
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12)   Please will you indicate what made you decide to have a DEXA scan (bone density 
   test) done . (If you decided not to have a DEXA scan done, please go on to question 
  19)
The doctor or cast technician / nurse or other healthcare specialist advised 
me to have it done
I wanted to know how healthy my bones were but it doesn´t occur in my 
family
There is a history of osteoporosis in my family and I was concerned
I had had more breaks and now I wanted to have it checked
I take prednisolone / medicine which can cause osteoporosis
I had an early menopause
I fall now and then because of epilepsy
I fall now and then because of dizziness or muscle weakness
I sometimes fall because of Multiple Sclerosis or Parkinson´s disease
13)    Please indicate what made you decide not to go to the DEXA scan 
   (bone density test) ?
The doctor or cast technician / nurse or other healthcare specialist didn´t 
advise me to do that
The doctor or cast technician / nurse or other healthcare specialist advised 
that indeed, but I haven´t have it done yet
I don´t believe that a DEXA scan will produce any useful information
I am of the opinion that I don´t have osteoporosis: my bones are normal
I don´t need a DEXA scan, there is no osteoporosis: it was a heavy fall
I don´t want to be made anxious: I don´t want to know the results of the 
DEXA scan
I have already had that test before
I am already prescribed osteoporosis medication
I am already prescribed calcium tablets
I am already prescribed vitamin D 
I am not physically able to go to the hospital on my own for this
I don´t want to bother my children/ carers to take me to hospital for this
I don´t want it to make my health costs to increase
Other:
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14) Which source of information is the most important, in order, for finding out about 
the risk of breaking bones and osteoporosis (bone density loss)? (1=most important 
7= least important)
Medical specialist
GP
Nurse / Plaster-cast specialist
Physiotherapist
Other healthcare specialists (pharmacist / chemist)
Family and friends
Media (TV. radio, internet, magazines)
15) Are you of the opinion that once someone has broken a bone there is a higher risk 
to then break something else?
Yes
No
I don´t know
 
16) Are you of the opinion that treatment with medicine is possible against 
osteoporosis?
Yes
No
I don´t know
17)   Have you ever been prescribed any medicine against osteoporosis such as 
  alendronic acid, risedronic acid, denosumab or zoledronic acid?   
Yes
No
I don´t know
 
18)    If yes: in …….. (year)
19)    How long have you used this osteoporosis medicine?
Less than 3 months
Between 3 months and ½ a year
Between ½ a year and 1 year
Between 1 year and 3 years
Longer than 3 years
Longer than 5 years
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20)    Are you using this osteoporosis medicine (still) at the moment? 
Yes
No
I don´t know
21)   If you do not use this osteoporosis medicine (any more): what are your thoughts 
 on that? (You may tick more than one answer)
My doctor / healthcare specialist has not advised me to do that or prescribed 
that
My doctor / healthcare specialist advised me to stop
My DEXA scan was good: I do not have osteoporosis and so no increased risk 
of bone fractures
I got a prescription but I haven´t picked it up yet
I would rather not take any medicine
I am afraid of getting side effects from this medicine
At the moment I am not interested in preventing fractures caused by 
osteoporosis
I do not believe that this medicine works against preventing fractures
I have enough with calcium tablets and vitamin D
I have a lot of physical exercise and get enough calcium from my food
I cannot afford the extra cost of the medicine.
22)   Have you ever been prescribed calcium tablets? 
Yes
No
I don´t know
23)   Do you take calcium tablet at the moment?  
Yes
No
I don´t know
24)   Have you ever been prescribed vitamin D ?   
Yes
No
I don´t know
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25)   Do you take vitamin D at the moment? 
Yes
No
I don´t know
  
26)   How would you judge your general health before the bone fracture in 2016?
Excellent
Very good
Good
Reasonable
Poor
27)   How would you judge your health at the moment?
Excellent
Very good
Good
Reasonable
Poor
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Tilburg Frailty Indicator
Gobbens RJJ, van Assen MALM, Luijkx KG, Wijnen-Sponselee MTh, Schols JMGA. 
The Tilburg Frailty Indicator: psychometric properties. J Am Med Dir Assoc 2010; 
11(5):344-355.
Part A Determinants of frailty
1. Which sex are you?  0 male 0 female
2. What is your age?          ........years
3. What is your marital status?  0 married/living with partner 
 0 unmarried 
 0 separated/divorced  
 0 widow/widower
4. In which country were you born?  0 The Netherlands
 0 Former Dutch East Indies
 0 Suriname 
 0 Netherlands Antilles
 0 Turkey
 0 Morocco
 0 Other,namely................
5. What is the highest level of education you have completed? 
0 none or primary education
0 secondary education
0 higher professional or
   university education
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6. Which category indicates your net monthly household income? 
0 €600 or less
0 €601 - €900 
0 €901 - €1200
0 €1201 - €1500 
0 €1501 - €1800 
0 €1801 - €2100 
0 €2101 or more
7. Overall, how healthy would you say your lifestyle is? 
0 healthy  
0 not healthy, not unhealthy 
0 unhealthy
8. Do you have two or more diseases and/or chronic disorders?
0 yes 0 no
9. Have you experienced one or more of the following events during the past year?
- the death of a loved one  0 yes 0 no
- a serious illness yourself  0 yes 0 no
- a serious illness in a loved one  0 yes 0 no
- a divorce or ending of an important intimate relationship  
 0 yes 0 no
- a traffic accident  0 yes 0 no
- a crime  0 yes 0 no
10. Are you satisfied with your home living environment? 
0 yes 0 no
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Part B Components of frailty
B1 Physical components
11. Do you feel physically healthy?  0 yes 0 no
12. Have you lost a lot of weight recently without wishing to do so? (‘a lot’ is: 6 kg or 
more during the last six months, or 3 kg or more during the last month)
  0 yes 0 no
Do you experience problems in your daily life due to:
13. ...........difficulty in walking?  0 yes 0 no
14. ..........difficulty maintaining your balance?  0 yes 0 no
15. ..........poor hearing?  0 yes 0 no
16. ..........poor vision?  0 yes 0 no
17. ...........lack of strength in your hands?  0 yes 0 no
18. ...........physical tiredness?  0 yes 0 no
B2 Psychological components
19. Do you have problems with your memory?  0 yes 0 sometimes 0 no
20. Have you felt down during the last month?  0 yes 0 sometimes 0 no
21. Have you felt nervous or anxious during the last month?  
 0 yes 0 sometimes 0 no
22. Are you able to cope with problems well?  0 yes 0 no
B3 Social components
23. Do you live alone?  0 yes 0 no
24. Do you sometimes miss having people around you?  0 yes 0 sometimes 0 no
25. Do you receive enough support from other people?  0 yes 0 no
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* The TFI was translated into English using the method of back-translation.
Scoring Part B Components of frailty (range: 0 – 15) (Cut point: 5)
Question 11:  yes = 0, no = 1
Question 12 – 18:  no = 0, yes = 1
Question 19:  no and sometimes = 0, yes = 1
Question 20 and 21:  no = 0, yes and sometimes = 1
Question 22:  yes = 0, no = 1
Question 23:  no = 0, yes = 1
Question 24:  no = 0, yes and sometimes = 1
Question 25:  yes = 0, no = 1
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Abstract
Introduction
The proportion non-responding fracture liaison service (FLS) invitees is high but 
characteristics of FLS non-responders are unknown.
Patients and Methods
We contacted FLS non-responders by telephone to consent with home visit (HV) and 
to fill in a questionnaire or, if HV was refused, to receive a questionnaire by post (Q), 
to gain insight in believes on fracture cause and subsequent fracture risk.
Results
Out of 716 FLS invitees, 510 attended, 9 declined and 197 did not respond. Of 
these non-responders, 181 patients were consecutively traced and phoned until 
50 consented with HV. 42 declined HV but consented with Q. Excluded were 8 
Q-consenters in whom no choice was offered (either HV or Q) and 81patients who 
declined any proposition (non-HV|Q). 62% HV and Q could recall the FLS invitation 
letter. The fracture cause was differently believed between HV and Q; the fall (96% 
versus 79%, p=.02), bad physical condition (36% versus 2%, p=.0001), dizziness or 
imbalance (24% versus Q 7%, p=.03), osteoporosis (16% versus 2%, p=.02), and 
increased fracture risk (26% versus 17%, NS). Age ≥70, woman and major fracture 
were significantly associated with HV consent compared to Q (OR 2.7, 2.5 and 2.4, 
respectively) and HV compared to non-HV|Q (OR 16.8, 5.3 and 6.1).
Conclusion
FLS non-responders consider fracture risk as low. Note, 50 patients (about 25%) 
consented with a home visit after one telephone call, mainly older women with a 
major fracture. This non-responders subgroup with high subsequent fracture risk is 
therefore approachable for secondary fracture prevention.
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Introduction
Osteoporosis care in patients with a recent fracture has been improved by the 
introduction of the Fracture Liaison Service model (FLS). This hospital initiative is 
firstly reported by McLellan et al. [1] and as such gradually regarded to be an optimal 
model of care [2-5]. Today, many FLS facilities experience the issue of low attendance 
rates being approximately 50% of all eligible patients >50 years [6]. Several factors 
are considered to contribute in FLS non-attendance i.e. not interested, physically 
unable to attend such as patients after hip fracture, male gender, frailty, living alone 
and also lower education [7,8]. Lower education even accounted as independent risk 
factor and, therefore, points into the direction of anyone’s capability of self-reflection 
and self- management and also into that of health illitteracy [7,9,10]. Apart from this, 
we discovered that flaws in the hospital registration led to 14% less FLS attendance 
[7]. A strong cue for attendance is face-to-face contact between patient and health 
professional in order to convince patients to agree with a FLS visit [7]. Therefore, 
FLS policy must take care of potential errors in patient registration but also focus on 
patients` perspectives and opinions regarding fracture risk and subsequent fracture 
prevention [7,11-13].
In the current study, we were particularly interested to broaden our insight into the 
characteristics and believes of FLS non-responders [14-16]. We aimed to contact FLS 
non-responders by telephone to consent with HV during which they had to complete 
a questionnaire with help of a FLS health professional if necessary or to consent to 
fill in a questionnaire which was send by post (Q) in order to study the characteristics 
and motivations of these patients. 
Patients and Methods
Study design and objectives
This explorative study was conducted at the FLS of the Reinier de Graaf Hospital, 
Delft, The Netherlands. The intention of this FLS initiative is to encourage all patients 
> 50 years to attend the FLS immediately following a fracture, in line with the Dutch 
Guideline on Osteoporosis and Falls [17]. After exclusion of patients who were 
deceased, all following patients were not invited (according to the local FLS protocol): 
permanent nursing home residents, patients already on anti-osteoporosis treatment 
(not including calcium or vitamin D) or patients who had a DXA within two years 
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before fracture. Two strategies were followed: 1/ personal invitation by the health 
professional during fracture treatment as mandatory in the local FLS protocol and 
2/ sending invitation letters to all patients in whom the personal invitation was not 
made or to those who did not make an FLS appointment after receipt of the letter at 
2 months after first admission at the emergency department.
This invitation strategy was performed by monthly screening of all fracture code 
registrations from the database of the emergency department to identify eligible 
patients. Data was extracted from the hospital entry registry (ChipSoft HiX 6.1) [18]. 
Then, retrieved data were used to prepare a mailing list to all eligible patients without 
a verifiable FLS appointment at 2 months after first attendance at the emergency 
department. Each letter consisted out of the following items: an invitation to attend 
and an explanation about osteoporosis and information about appropriate care. For 
this study, recruitment lasted from 2017/8 to 2018/4. Non-responders were contacted 
by telephone by one experienced female FLS care health professional 8 weeks after 
the written invitation. During the phone call patients were asked to consent with a HV 
to fill in a questionnaire about their drives and motives with regard to health issues. 
In case of no consent for HV, patients were subsequently asked to consent to fill in 
the same questionnaire send by mail (Q). In case of no consent for either HV or Q, 
patients were assigned to a third group (non-HV|Q). According to protocol, patients 
were phoned until a total of 50 patients had consented with HV. Eight patients were 
given no choice but Q as completion of HV was achieved. These patients were excluded 
from analysis. Note, during telephone calls patients were not persuaded to accept 
our invitation to attend the FLS. This was on purpose in order to prevent people from 
feeling unsafe. Of all patients, available demographic data were used in the study 
(age, gender, fracture type and death within one year after fracture) (see Fig 1). After 
verification of the fracture location by X-Ray, patients were categorized according 
to the classification of fracture locations proposed by Warriner et al., based on the 
probability that fractures were associated with osteoporosis: low risk for osteoporosis 
ranked as minor fractures and higher risk for osteoporosis ranked as major fractures, 
hipfractures and vertebral fractures [19]. Categorized as minor fractures were clavicle 
/ scapula, scaphoid, metacarpal, neck and head of radius, patella, ankle / malleolus 
and metatarsal fractures. The definition for major fractures used in the models was a 
major, vertebral or hip fracture. In more detail, distal radius and lower arm, sub-capital 
humeral, rib, pelvis and acetabulum, tibia proximal / tibia plateau and calcaneal / tarsal 
fractures as well as hip and vertebral fractures are classified as major fractures [19].
80
Chapter 4
Fig 1. Flowchart of the study
Legends
Demographics used from patient charts were Age, Gender M/F, Death and Fracture type.*n=8 were excluded 
for this study (received no request for HV)
Questionnaire
The questionnaire for HV and Q patients highlighted three domains: Demographics, 
Tilburg Frailty Indicator (TFI) [20] and extrinsic/intrinsic motivations for the decision not 
to attend and personal arguments to abstain from attending, as formerly used in other 
studies [7,11-16]. The TFI (a validated indicator of Frailty) ranges from 1 to 15 (Frailty: ≥ 
5) [20]. Patients’ own judgment of their personal health was analyzed binary according 
to a score of 1-6 as ‘poor’ and 7-10 as ‘good’. Extrinsic motivations were considered to 
arise from information by clinical professionals, for example the inclination to follow 
a doctor’s or plaster cast nurses` advice or to follow the instructions by the medical 
staff  of the FLS. Intrinsic motivations were considered to be entered exclusively by self-
refl ection i.e. anyone’s personal believes to strive for a better bone health [7,9,16]. 
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Aim
The aim of the study was to make an inventory of characteristics and believes of 50 
FLS non-responders who consented with HV and to analyze factors associated with 
consent for HV or Q. 
Statistical Analysis
Data were analyzed using Statgraphics Centurion software (Version 17.2.05 for MS-
Windows; Statpoint Inc., Warrenton, VA, USA) and using R (2018, The R Foundation 
for Statistical Computing Platform, version 3.5.3). If numerical data could not be 
fitted with a Gaussian distribution (Shapiro&Wilk&Royston test or Micceri Normality 
function (in R) their mean of ranks or medians were compared using the Wilcoxon 
rank-sum test after checking for equal distributions using the Kolmogorov&Smirnov 
test. Analyses were further performed on dichotomized age (<70 or ≥70 year), gender 
and on all the (often binominal) variables of the questionnaire. In this study age is a 
variable with multiple different integer values; we transformed it (according to the 
Dutch VMS) [21] so that the new variable has only 2 different values: <70 or ≥70 years. 
Associations were assessed by crosstabulation, using as dependent variables HV 
and Q. After bivariate crosstabulations, a multivariate logistic regression model was 
fitted to identify any possible association between the binary outcome variable HV 
and Q and various independent predictor variables i.e. demographics such as age, 
gender, education, income and physical conditions. Any association was assessed 
by direction and absolute value of adjusted Pearson residuals (resembling z-scores). 
Evidence of any association in the population from which the sample was drawn was 
assessed with the unconditional, uncorrected Pearson‘s Chi-Square test, applying 
Monte Carlo sampling (10,000 resamplings) and if significant, measured using Odds 
Ratios and 95% Confidence Intervals. Multivariate Odds Ratios were estimated by 
logistic regression, with variable HV and Q as dependent outcome and Frailty (TFI 
dichotomized); age (numerical) and gender are included, and education, income and 
physical conditions as independent variables after exclusion of those independent 
variables that were not significant in the univariate analysis and after testing for 
interaction between variables. Collinearity was analyzed using R’s Condition Index 
applying a variance inflation factor (VIF) > 2.5 and at least twice an Index > .5). Where 
applicable, 95% Confidence Intervals and correlation coefficients > .5 were used. A 
p-value < .05 was considered statistically significant.
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Ethics
The study was carried out in accordance with the declaration of Helsinki and the 
guidelines of the International Conference on Harmonization Good Clinical Practice 
(GCP) after a certificate of no objection approved by the regional Medical Ethical 
Review Board (METC Zuidwest Holland) no. NL 17.108.
Results
From 945 consecutive patients with a recent fracture, 229 were not invited at the FLS: 
14 patients (1%) deceased shortly after fracture, 52 (6%) for permanent residence 
in nursery care, 33 (4%) for priory initiated anti-osteoporosis treatment and 22 (3%) 
because they had a DXA scan 24 months prior to this study, 56 (6%) because of finger, 
toe and skull fractures and 52 patients (6%) who were untraceable to our systems 
because of their residence outside the region of the hospital. Of the 716 invitees, 510 
(72%) attended the FLS, 9 patients (1%) responded but deliberately abstained from 
attending (FLS responders) and the remaining 197 patients (27%) did not respond to 
the invitation. 
The analysis of this study was focused on the 197 non-responders. Of these patients, 
181 could be traced and called, 16 patients could not be traced because of a no valid 
home address. None of these patients had a minor fracture, 4 had a major fracture, 
9 had a hip fracture and 3 had vertebral fractures. During the inclusion period to 
complete assignment of 50 patients for HV, another 42 patients declined HV but 
consented to fill in a questionnaire send by post (Q) and 81 patients declined both 
HV and Q (the so called non-HV|Q group). For the completion of this study a total of 
173 patients was called, see Fig.1. The remaining eight patients who were not given a 
choice other than to give permission for Q were excluded from the analysis because 
a HV was never offered to them. By April 2018, we finalized the recruitment of 50 
patients for HV. Meanwhile 42 agreed with Q and 81 had declined HV as well as Q 
(the non-HV|Q group). 
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Table 1. Characteristics of FLS non-responders who consented with Home visits or 
Questionnaires.
Home Visit group
n=50 (54%)
Questionnaire group
n=42 (46%)
Demographics
Age at Fracture: median (min,max)
All: no.: median (min, max)
Women: no.: median (min,max)
Men: no.: median (min,max)
81 (58,101)
n=50: 81 (58,101)
n=42: 81 (58,101)
n= 8: 83 (65,89)
63 (50,93)
n=42: 63 (50,93)
n=22: 60 (51,93)
n=20: 63 (50,88)
Fracture type
Minor fracture 
Major Fracture 
Hip Fracture 
Vertebral Fracture
6 (12%)
30 (60%
8 (16%)
6 (12%)
23 (55%)
17 (40%)
2 (5%)
-
Education                                                               
Primary/secondary school vs. 
High school/University
47 (94%)
3 (6%)
29 (69%)
13 (31%)
Country of birth
The Netherlands
Indonesia
Surinam 
49 (98%)
1 (2%)
0
39 (93%)
2 (5%)
1 (2%)
Income (in € per month)
Low/Normal: (€ 601 - € 1200)/(€ 1200 - € 
1800)
High (> € 2100)
No response
36 (72%)
3 (6%)
11 (22%)
23 (55%)
13 (31%)
6 (14%)
Marital status
Living together (married/shared living)
Not married/Divorced/Widow/Widower
26 (52%)
24 (48%)
23 (55%)
19 (45%)
Are you satisfied with your living/housing environment?
Yes 
No
47 (94%)
3 (6%)
42 (100%)
0 
Use of Calcium, Vitamin D supplementation and/or Osteoporosis medication 
Use of calcium tablets?                                                           
Yes
No
8 (16%)
42 (84%)
6 (14%)
36 (86%)
Use of Vitamin D?
Yes
No
24 (48%)
26 (52%)
15 (36%)
27 (64%)
Do you already take antiresorptive medication?
Yes 7 (14%) 2 (5%)
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Home Visit group
n=50 (54%)
Questionnaire group
n=42 (46%)
Patient opinions
What caused your fracture:                                                      
Osteoporosis (yes/no; %)   
The fall (yes/no, %)                             
The accident (yes/no, %)    
Bad physical condition (yes/no, %)
Imbalance / dizziness (yes/no, %)       
p= .02
p= .01
NS
p= .0001
p=.03
8 (16%)
48 (96%)
35 (70%)
18 (36%)
12 (24%)
42 (84%)
2 (4%)
15 (30%)
32 (64%)
38 (76%)
1 (2%)
33 (79%)
28 (67%)
1 (2%)
3 (7%)
41 (98%)
9 (21%)
14 (33%)
41 (98%)
39 (93%)
In my opinion subsequent fracture risk is increased after fracture.
Yes
No
Do not know
13 (26%)
18 (36%) 
19 (38%)
7 (17%)
22 (52%) 
13 (31%)
Perceived advice to attend the FLS
Perceived advice to attend the FLS by letter 
= Yes
Perceived advice to attend the FLS by letter 
= No
34 (68%)
16 (32%)
23 (55%)
19 (45%)
Taking interest in Bone Quality
Yes
No/Somewhat
22 (44%)
28 (56%)
14 (33%)
28 (67%)
Various aspects of health and frailty
How healthy is your lifestyle?
Healthy
Not healthy 
31 (62%)
19 (38%)
24 (57%)
18 (43%)
Self-reported Level of Health
Good
Poor
25 (50%)
25 (50%)
32 (76%)
10 (24%)
Do you suffer from 2 or more chronic diseases?
Yes
No
17 (34%)
33 (66%)
12 (29%)
30 (71%)
Do you take 4 or more tablets every day?
Yes
No
25 (50%)
25 (50%)
7 (17%)
35 (83%)
Frailty (Tilburg Frailty Indicator scores)
TFI score > 5 (frail)
TFI score < 5 (not frail)
23 (46%)
27 (54%)
13 (31%)
29 (69%)
Parental hip Fracture
Yes
No
6 (12%)
44 (88%)
6 (14%)
36 (86%)
Legends: Results are presented as median (min, max) or no. (%). 
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Table 2. Significant univariate associations to consent with Home Visit (HV) versus 
Questionnaire (Q). 
Factors OR 95%CI p-value
Age ≥ 70 year 17.3 6.03;49.7 < .001
Woman 4.77 1.81;12.6 .001
Low Income 6.78 1.74;26.4 .003
Self-rated low quality of life after fracture 4.26 1.59;11.4 .003
Loss of weight after fracture 3.09 1.09;8.78 .03
Difficulty in walking 3.97 1.58;9.99 .003
Difficulty maintaining your balance 6.83 2.31;20.2 < .001
Poor hearing 7.97 2.16;29.4 < .001
Lack of strength in your hands 3.81 1.27;11.5 .013
Age ≥ 70 years and no frailty (TFI ≥ 5) 19.2 3.6;102.0 < .001
Major fractures (no hip or vertebral fractures) 2.89 1.2;6.94 0.02
All Major fractures (all major including hip and vertebral 
fractures) 
4.27 1.88;51.59 0.04
Legends:
OR: Odds Ratio; 95%CI: 95% Confidence Interval for population Odds Ratio, p-value < .05 is considered 
significant. 
The recalls of patient information in HV or Q patients.
None of the HV and Q patients could recall any face-to-face patient information in the 
hospital during time of fracture treatment including advice to attend the FLS. Receipt of 
an FLS invitation letter was recalled by 68% of HV versus 55% of Q patients (p = .002). 
Factors associated with consent for HV or Q
The proportion of patients that perceived a poor physical condition as the main cause 
of fracture was significantly higher in the HV compared to the Q group (36% and 2%, 
p = 0.0001). The proportion of patients with a “poor” self-reported health was also 
significantly higher in HV than Q (50% vs 24%, p = .001).
HV and Q patients considered falls, the accident, bad physical condition and dizziness 
or imbalance as main cause of recent fracture. In addition, the main cause of fracture 
was differently believed between HV and Q; the fall: 96% versus 79%, p = .02, bad 
physical condition: 36% versus 2%, p = .0001, dizziness or imbalance: 24% versus 
7%, p = .03, while for osteoporosis it was 16% in HV versus 2% in Q, p = .02 and 
the belief that subsequent fracture risk was increased; 26% versus 17%, respectively 
(NS). There was no difference in patients` reports about have more than 2 chronic 
86
Chapter 4
diseases or using more than 4 tablets per day, see Table 1.
According to univariate analysis HV patients were older (age > 70 years; OR 17.3), with 
a higher contribution of women (OR 4.77) and more major fractures (OR 4.27). HV 
patients reported lower income more frequently (OR 6.78) as well as quality of life (OR 
4.26) and weight loss after fracture (OR 3.09). Finally, more HV patients had walking 
difficulties (OR 3.97) and difficulties in maintaining balance (OR 6.83), more frequent 
hearing loss (OR 7.97) and loss of grip strength (OR 3.81). In both HV and Q there was 
a moderate frailty prevalence and no significant difference between groups according 
to TFI (Frailty: ≥ 5). Only significant univariate associations to consent with HV versus 
Q are shown in Table 2.
In a multivariate model, three factors remained significantly associated with consent for 
HV versus Q: age > 70 years (OR: 16.8), gender (women, OR: 5.3) and major fractures 
(OR 6.1); the same three factors were associated with consent for HV versus non-HV|Q: 
(OR 2.7, 2.5 and 2.4, respectively). Age < 70 years and minor fractures (OR 3.2 and 5.3, 
respectively) were associated to consent with Q versus non-HV|Q (Table 3).
Table 3. Significant multivariate associations to consent with HV versus Q.
Factors - HV (n=50) versus Q (n=42) OR (95%CI) p value
Age ≥ 70 16.8 (5.0; 56.7) < .001
Women 5.3 (1.5; 19.2) .008
Major Fractures 6.1 (1.7; 22.3) .0045
Legends:
Multivariate associations in Age (dichotomized at ≥ 70 or < 70), Gender and Fracture Type. Factors were first 
analysed of association with each pair of groups using crosstabulation, using adjusted standardized residuals 
and Chi-square/Fisher Exact tests p value for significance and Odds Ratio for measure of strength. OR: Logistic 
Regression Odds Ratio; 95%CI: 95% Confidence Interval for population Odds Ratio; p value < .05 is considered 
significant.
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Distribution of fractures among FLS non-responders and the patients who attended 
the FLS.
Distribution according to fracture type (major fractures including hip and vertebral 
fractures versus minor fractures) was compared between FLS attenders and traceable 
FLS non-responders (Table 4). 
The proportion of patients with major fractures in FLS attenders and traceable non-
responders was similar 291/510 (57%) and 109/173 (63%). The proportion of major 
fractures was significantly higher in HV than in Q (p < .0001) and non-HV|Q (p = 
.0001). In the latter two groups minor and major fracture proportions were similar. 
Deceased patients
Several patients with major fractures died within 12 months after initiation of the 
study; 3 patients in HV and 1 in Q), 6 patients in non-HV|Q, 5 were deceased in 
not-reached patients and 5 were deceased in FLS attenders. In minor fractures it 
was 1 patient in HV and 1 patient in Q and 3 patients after minor fracture in the FLS 
attending group. All of the 16 untraceable individuals were elderly patients and 12 
patients in this group had died within 12 months post-fracture.
Discussion
This study was specifically designed to characterize patients who did not respond 
to FLS invitation after a recent fracture and showed that it is feasible to trace and 
contact more than 90% of non-responders by one phone call of whom more than 
25% agreed with a home visit, especially women of 70 years or older who sustained 
a major fracture. They primarily considered a fall, their bad physical condition, 
dizziness or balance problems as the main cause of the recent fracture. Only one 
in five believed that subsequent fracture risk was increased, and a small proportion 
considered osteoporosis as underlying risk factor for subsequent fractures. As far as 
we know the characteristics of FLS non responders have not been studied before by 
home visits and questionnaires. Therefore, the current study design differs entirely 
from an earlier study by our group comparing personal opinions, drives and motives 
of patients who were willing to share details of their decision to attend or not attend 
the FLS [7].
In this study, 931 fracture patients were identified of whom 716 were eligible for FLS 
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invitation. According to daily FLS protocol all of them should have received face-to-face 
invitation to attend the FLS (at any time during fracture treatment). Besides, patients 
who did not reply within 2 months had received a FLS invitation letter. Remarkably, 
most FLS non-attenders were non-responders to invitation (n=197) and there were 
only 9 responders who informed us that they refrained from FLS attendance after 
receiving the FLS invitation letter. 
None of the HV or Q assigned patients could remember information face-to-face 
given by the health professional during fracture treatment meant to remind fracture 
patients about the urgency to attend the FLS (personal patient information is 
mandatory according to the local FLS protocol). It is conceivable that this information 
was not or insufficiently given since all patients of both groups were unanimous on 
the idea of lack of any given face-to-face patient information, while receipt of the FLS 
invitation letter was recalled by 68% of HV and 55% of Q patients. In addition, our 
FLS invitation letter was not designed to ask patients to inform our department if 
they were not willing or able to attend our FLS. It is emphasized that health illiteracy 
and the consequent incapability to properly understand the content of written 
information, albeit not tested in the current study, has been reported up to 40% in 
the elderly population [9,10]. These findings point at the importance for adequate FLS 
invitation strategies.
There are several studies reporting on clinical characteristics of FLS attenders but 
published data on FLS non-responders are limited. A telephone questionnaire study 
from Australia compared the 2-year outcome of FLS attenders with FLS non-attenders 
showing that FLS attenders had fewer new fractures and were more likely to be 
on treatment for bone fragility [22]. A similarly designed Dutch study showed also 
significant lower mortality and 56% lower subsequent fracture rate in FLS attenders 
[23]. Similar results were also found in a Norwegian literature review [24]. Besides 
these outcome differences between FLS attenders and non-attenders some studies 
evaluated the reasons of differences in FLS attendance among different centers. The 
first report on this issue albeit in a limited number of centers showed that attendance 
varied widely, between 20-89%, together with a high variability in patient selection for 
FLS invitation [25]. In a study performed in the Netherlands, high compliance with the 
Capture the Fracture Framework Standards was shown in 24 analyzable FLSs. This 
study showed in particular that FLS attendance occurred in approximately half of all 
fracture patients [6].
Obtaining consent was time consuming and approximately half patients declined 
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to consent for participation. Remarkably, most HV consenters hardly needed any 
persuasion, while it took eight weeks until all questionnaires were returned by Q 
patients. This difference may be explained by stronger concerns about health issues 
and fracture risk in the HV group compared to Q. Another study of the FLS found that 
older patients reported less mobility and more dependency on their caregivers for 
transportation to the hospital [8]. We speculate therefore that older patients consider 
a home visit as a solution for their inability to attend the FLS. 
There were also similarities between both groups (HV and Q) noteworthy to report. i.e. 
a similar low frailty prevalence (according to the TFI, frailty: ≥ 5) and a similar believed 
major reasons of fracture i.e. the fall and accident. Another similar characteristic (39% 
and 31%, respectively) was the low proportion of knowledge of patients concerning 
increased subsequent fracture risk in agreement with previous reports [7,9,15,16]. 
ASBMR, IOF, EULAR and EUGMS fully endorse the importance of secondary fracture 
prevention and FLS care is considered the most optimal approach in this respect 
[2-5]. To optimize FLS care according to this vision the issue of attendance needs full 
attention. 
This study has several weaknesses. 1/ the study is an explorative study and therefore 
not based on preliminary determined statistical power. The outcome does not 
allow generalization outside this region and to other countries. 2/ Age was 
dichotomously analyzed (< or >70 years), threshold proposed by the Dutch VMS 
authority (Safety Management System) and commonly used for patient safety issues 
in hospital care. [21]. Dichotomizing data can lower power in study outcomes. 3/ we 
have no information on the exact number of patients who did or did not receive face-
to-face patient information during fracture treatment encouraging them to attend 
the FLS. 
In conclusion, a high proportion of FLS non-responders who participated in HV or Q 
consider subsequent fracture risk to be low. Nevertheless, 50 patients (about 25% 
of FLS non-responders) consented with a home visit after one telephone call, mainly 
elderly women with a major fracture. These patients have a high subsequent fracture 
risk and are approachable for evaluation. The encountered approachability of FLS 
non-responders indicates that innovative strategies in optimizing FLS invitation can 
improve secondary fracture prevention care.
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Chapter 5
Abstract: Recommendations for daily calcium intake from dairy products are variable 
and based on local consensus. To investigate whether patients with a recent fracture 
complied with these recommendations, we quantified the daily dairy calcium intake 
including milk, milk drinks, pudding, yoghurt and cheese in a Dutch cohort of fracture 
patients and compared outcomes with recent data of a healthy US cohort (80% 
Caucasians). An observational study analyzed dairy calcium intakes of 1526 female 
and 372 male Dutch fracture patients older than 50. On average, participants 
reported three dairy servings per day, independently of age, gender or population 
density. Median calcium intake from dairy was 790 mg/day in females and males. 
Based on dairy products alone, 11.3% of women and 14.2% of men complied with 
Dutch recommendations for calcium intake (adults ≤70 yrs: 1100 mg/day and >70 
yrs: 1200 mg /day). After including 450 mg calcium from basic nutrition, compliance 
raised to 60.5% and 59.1% respectively, compared to 53.2% in the U.S. cohort. Daily 
dairy calcium intake as not associated with femoral neck BMD T-scores or FRAX risk 
scores for major fracture or hip fracture. However, sub analyzing the male cohort 
these associations were weakly negative. The prevalence of maternal hip fracture 
was a factor for current fracture risks, both in women and men. While daily dairy 
calcium intakes of Dutch fracture patients was were well below the recommended 
dietary intake, they were comparable to intakes in a healthy U.S. cohort. This 
questions recommendations for adding more additional dairy products to preserve 
adult skeletal health, particularly when sufficient additional calcium is derived from 
adequate non-dairy nutrition.
Keywords: Calcium-Dense Food; Dairy products; Fracture Liaison Service; 
FRAX.
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Introduction 
In 1993, the U.S. Food and Drug Administration authorized a health claim for foods and 
supplements related to calcium to prevent osteoporosis. In January 2010, the health 
claim was expanded for the combination of calcium and vitamin D supplements. (FDA 
21CFR101.72) This claim raises questions about the amount of calcium that should 
be recommended to the adult population [1]. Today, the Recommended Dietary 
Intake (RDI) for calcium, meaning the average daily level of intake sufficient to meet 
the nutrient requirements of healthy individuals, is 1200 mg for individuals older than 
50 yrs in the US (Food Guide Pyramid FGP, US Department of Agriculture) [2]. In the 
Netherlands, RDI for total daily calcium intake is quite similar to that in the US: 1100 
mg for the age category 51-69 yrs and 1200 mg for people older than 70 yrs. Based 
on the US recommendation, the number of recommendable calcium-dense servings 
should be four per day [2,3], which is more than the actual average consumption in 
the Netherlands as well as in the USA. While extra intake of dairy servings would seem 
the most straightforward way to increase calcium intake, it is questionable whether it 
is beneficial for bone health to use more dairy servings than those taken according to 
cultural habits and traditions. Over-nutrition of dairy products may cause maldigestion 
and malabsorption, which may overrule beneficial effects of calcium intake. Besides, it 
is unclear how traditional use of liquid milk and milk products relates to bone mineral 
density (BMD) and fracture risk during adulthood.
Public health authorities [4] claim that actual calcium intake is 25 percent lower 
in Europe than in the U.S. Although a large part of the agricultural activities in the 
Netherlands is dedicated to milk production and processing, the average Dutch 
consumption of liquid milk and milk products per capita in kg/year is estimated to be 
83.5, while it is 85.1 on average in 27 other European countries and 111.4 in the U.S. 
[5]. According to the Dutch National Food Consumption Survey (DNFCS 2007-2010), 
the median habitual total calcium intake per day (51-69 yrs; P50) in Dutch men is 1109 
mg calcium and in women 985 mg [6].Non-dairy food sources contribute 42% of total 
calcium content in daily nutrition [6].
Since dairy products consumption per capita in kg/year in the Netherlands compares 
well with the average in North-Western Europe, we were interested in comparing 
calcium intake in the Dutch adult population with that of an U.S. cohort of more than 
80% Caucasians, which was extracted from the Continuing Survey of Food Intake by 
Individuals, 1994-96, 1998, (CSFII) and the National Health and Nutrition Examination 
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Survey, 1999-2000 (NHANES). We wondered whether the CSFII en NHANES reports 
would agree with the number of daily servings taken by Dutch individuals. 
In order to answer this question, we conducted the present study at the Fracture 
Liaison Service (FLS) of the Reinier de Graaf Group of Hospitals in The Netherlands. 
Our primary research goals were to determine the number of daily servings of dairy 
products in a Dutch cohort of fracture patients after partitioning for age and gender, 
but also for population density; to correlate daily calcium intake from dairy products 
with femoral neck BMD T-scores and 10-year probability of major fracture or hip 
fracture; and to compare intakes with another, mainly Caucasian cohort in the U.S., 
consisting of patients without reported fracture. We further questioned whether the 
total amount of calcium from both daily basic nutrition and daily dairy consumption is 
appropriate for fulfilling Dutch recommendations for total calcium intake.
Experimental Section 
Patients and methods
This prospective observational study was conducted at the Fracture Liaison Service 
(FLS) of the Reinier the Graaf Group of Hospitals, Delft (The Netherlands). The FLS is 
organized according to a previously reported concept [7-9]. We included women and 
men of 50 yrs and older with a recent fracture. These patients were evaluated by 
means of a structured diagnostic work up, including a detailed questionnaire regarding 
their daily calcium intake from dairy and a Dual Energy X-Ray Absorptiometry (DXA) 
measurement for femoral neck BMD T-scores. Each patient received a scan, with the 
exception of those who were already known with osteoporosis evidenced by older 
DXA measurements or with prevalent vertebral fractures evidenced by previous spinal 
radiographs. Patients using prescribed calcium and/or bisphosphonates were excluded. 
Calcium intake was assessed using a validated Dutch questionnaire on Daily Calcium 
Intake (DCI-Holland), which was developed by Het Rijksinstituut voor Volksgezondheid 
en Milieu (National Institute for Public Health and the Environment, RIVM), Bilthoven, 
the Netherlands; see: NEVO-online.rivm.nl [4]. The DCI-Holland calculated the calcium 
content of food categories such as meat, fish, poultry, eggs, vegetables, fruits, potatoes, 
pasta, and milk products. According to the DCI-Holland, the average calcium content 
is 270 mg in one glass of milk (200 ml), 400 mg in one glass of calcium-enriched 
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milk, and 240 mg in one serving of yoghourt or pudding (200 ml). Non-dairy food 
contributes (as median) 430 mg calcium in females and 443 mg calcium in males, 
based on the habitual intake distribution at P50 of calcium food sources by the Dutch 
population aged 51-69 yrs, weighted for socio-demographic factors, season and day 
of the week. 
Patients were recruited from the Emergency Department or were outpatients of the 
departments of Trauma surgery or Orthopaedic surgery. Each patient was asked to fill 
in a questionnaire that included questions about calcium intake from dairy nutrition 
categorized per product type (milk, calcium-enriched milk, yoghurt, pudding, cheese) 
as mentioned in the DCI-Holland. We estimated total daily dairy calcium intake using 
the number of glasses of milk or yoghourt/pudding servings. The calcium intake of 
cheese products was dichotomized (Yes/No). The intake of calcium from cheese 
products was calculated as half the amount in a glass of milk. The questionnaire also 
included the WHO Fracture Assessment Tool (FRAX) for evaluating fracture risks [10] 
and additional questions regarding age at menopause, daily exercise and sports 
habits. Calcium intake from dairy nutrition, per serving, was calculated using the 
formula of Fulgoni [2], one serving representing 250 mg calcium, according to the 
Dutch Standard (DCI-Holland).
FRAX risk scores were calculated according to the Dutch FRAX algorithm [11]. 
Osteoporosis was defined as a T-score ≤ -2.5*SD (SD=standard deviation) at either 
total hip, femoral neck or lumbar spine, normal BMD as a T-score ≥ -1*SD at all three 
locations and osteopenia as a T-score between -1*SD and -2.5*SD.
In patients with a T-score less than -2*SD, additional laboratory assessments and 
radiographs of lumbar and thoracic spine were performed, according to protocol. 
Vertebral fractures were scored according to the semi-quantitative method of Genant 
et al.. A vertebral fracture was defined as an infraction of at least 25% reduction in 
anterior, middle and/or posterior height and a reduction in area by 20-40% [12]. 
Analyses were performed on 5 age decades (50-59, 60-69, 70-79, 80-89 and 90-100 
yrs), gender, and on 5 (Dutch) population density categories (1: 21-250, 2: 250-500, 3: 
500-1000, 4: 1000-2500 and 5: 2500-5976 inhabitants per square kilometres (source: 
Dutch National Atlas of Public Health; see: www.zorgatlas.nl.)[13]. 
Data were analysed using Statgraphics Centurion XVI software (Version 16.2.4 for MS-
Windows; Statpoint, Inc., VA, USA). Multiple-variable correlation analysis was applied 
after partitioning of data by gender. Wilcoxon&Mann&Whitney rank-sum test was 
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applied to compare medians of numerical variables with respect to gender. Mood’s 
Median and Kruskall&Wallis tests were applied to genders in order to compare 
numerical variables between the categories of the diagnosis variable (normal, 
osteopenia, osteoporosis). Variance Components Analysis was applied, using fracture 
frequency as a dependent variable and relevant numerical variables as factors in 
order to assess their contribution to total variation in fracture frequency. To estimate 
odds ratios in genders, logistic regression with backward factor selection (p-to-enter 
.05; p-to-remove .05) was applied, with maternal hip fracture as dependent variable 
(Yes=1; No=0) and all numerical and dichotomous categorical variables as factors. 
Non-parametric correlations were then assessed again between final numerical 
factors of the best logistic regression model. Where applicable, 95% Confidence 
intervals were used and a p-value < .05 was considered statistically significant at the 
95% confidence level. The study was approved by the Medical Review Board (METC-
Zuid Holland), The Netherlands.
Results 
From March 2008 to November 2011, we included 1526 women and 372 men 
of 50 yrs and older with a recent fracture. All patients were Caucasians. Of these 
patients, 1451 women and 349 men received a Dual Energy X-Ray Absorptiometry 
(DXA: Hologic QDR 4500 C) of total hip, femoral neck and lumbar spine and had a 
consultation at the outpatient clinic with a specialised nurse practitioner. Relevant 
complete data were obtained from all 1898 patients who were originally included, 
and demographics are listed in Table 1 and 2. Calculated daily dairy calcium intakes in 
genders are graphically represented in Figure 1 and the distribution of genders into 
age decades is listed in table 3.
Table 1. Demographic data of a Dutch cohort after a recent fracture
Sex Numbers Age % Osteoporosis
(T-score<-
2.5*SD)
FRAX,%
(for major 
fracture)
FRAX,%
(for hip 
fracture)
Women 1526 66 (50-96) 13.6 11.0 (2.4-90.0) 2.6 (0.0-73.0)
Men  372 65 (50-90) 6.2 7.5 (1.6-41.0) 2.7 (0.1-37.0)
Fracture Assessment Tool (FRAX) was used to estimate FRAX risk scores for major osteoporotic fracture or hip 
fracture. Data were not normally distributed and are given as Median (Range).
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Table 2. Variables of a Dutch cohort after a recent fracture
Variables Data
Sex
Women 0
Men 1
Age decades
50-59 yrs 1
60-69 yrs 2
70-79 yrs 3:
80-89 yrs 4:
90-100 yrs 5
Age at menopause age (yrs), women only
Population density
category 1 21-250 inhabitants/km2
category 2 250-500 inhabitants/ km2
category 3 500-1000 inhabitants/ km2
category 4 1000-2500 inhabitants/ km2
category 5 2500-5967 inhabitants/ km2
Dairy calcium intake
per serving milk 270 mg calcium
per serving yoghourt 240 mg calcium
per serving cheese 160 mg calcium
Currently smoking
No 0
Yes 1
Alcohol
≥ 3 servings per day 1
≤ 2 servings per day 0 
Current use of corticosteroids
No 0
Yes 1
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Variables Data
Rheumatoid arthritis
No 0
Yes 1
Previous fracture
No 0
Yes 1
Hip fracture mother
No 0
Yes 1
Current use of calcium prescribed or as 
OTC
Excluded
Current use of any drug against 
osteoporosis #
Excluded
Length cm
Weight kg
BMI Body Mass Index: Weight/(Length*Length)
BMD Bone Mineral Density test, BMD-at-the-femoral 
neck (T-score)
FRAX 10-year probability of major osteoporotic 
fracture
FRAX Hip 10-year probability of hip fracture
Secondary causes for osteoporosis known 
to the patient
No 0
Yes 1
 
Legends: 
OTC: Over-The-Counter available drugs not prescribed by a physician.# Any drug against osteoporosis i.e. 
bisphosphonates, estrogens or Selective Estrogen Receptor Modulators
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Fig 1. Distributions of daily calcium intake (mg/day) from dairy products in women and men.
 
Histogram Females
Dairy Calcium Intake (mg/day)
0 1 2 3 4
(X 1000,0)
0
100
200
300
400
fr
eq
ue
nc
y
Histogram Males
Dairy Calcium Intake (mg/day)
0 1 2 3 4
(X 1000,0)
0
20
40
60
80
100
fr
eq
ue
nc
y
This study included more women than men, but genders were distributed equally over age decades, as is 
demonstrated in Table 2. 
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Table 3. Distribution of 1898 patients into 5 age decades (range 50-100 yrs).
Age (yrs) Women
W (N=1526)
Men
M (N=372)
Ratio of genders
F/M
50-59 399 (26.1) 113 (30.4) 3.5
60-69 528 (34.6) 125 (33.6) 4.2
70-79 428 (28.0) 96 (25.8) 4.5
80-89 161 (10.6) 37 (10.0) 4.4
90-100 10 (0.7) 1 (0.2) 10.0.
Legends: Data for women and men per age decade are given in numbers of patients and percentage of 
patients (%).
Overall, we found no significant difference in calcium intakes from dairy food products 
between women and men (median 790 (range 0-4360) and 790 (0-3435) mg/day, 
respectively, p = .80). The dairy calcium intake was also expressed as numbers of 
servings per day, which were similar for each age decade except for those patients 
who were older than 80 yrs (Table 4). Numbers of servings did not differ between 
genders, nor between female and male cohorts compared for population density 
categories (Table 5).
Table 4. Number of daily servings of dairy products in females and males distributed into 5 age 
decades 
Age 
(yrs)
Women
(N=1526)
Servings/day
50-59 399 (26.1) 3 (0-9)
60-69 528 (34.6) 3 (0-15)
70-79 428 (28.0) 3 (0-13)
80-89 161 (10.6) 3 (0-8)
90-100 10 (0.7) 3 (2-4)
Age 
(yrs)
Men
(N=372)
Servings/day
50-59 113 (30.4) 3 (0-15)
60-69 125 (33.6) 3 (0-9)
70-79 96 (25.8) 3 (0-8)
80-89 37 (10.0) 3 (1-5)
90-100 1 (0.2) 1
Legends: Data for women and men per age decade are given in numbers of patients having completed the 
questionnaire and in percentage of patients (%). Data for number of servings were not normally distributed 
and are given as median (range).
105
Quantification of Calcium Intake from Calcium-Dense Dairy Products
5
Table 5. Number of daily servings of dairy products in women and men grouped by population 
density 
Population Density Category (Inhabitants per Km2) Women (N=1526) Servings/day
2 (250 – 500) 98 (6.4) 3 (1-10)
3 (500 – 1000) 5 (0.3) 4 (3-5)
4 (1000 – 2500) 565 ( 37.0) 3 (0-9)
5 (2500 – 5976) 858 (56.3) 3 (0-15)
Population Density Category (Inhabitants per Km2) Men (N=372) Servings/day
2 (250 – 500) 19 (5.1) 3 (1-6)
3 (500 – 1000) 2 (0.5) 4 (3-5)
4 (1000 – 2500) 156 (41.9) 3 (0-15)
5 (2500 – 5976) 195 (52.5) 3 (0-9)
Legends: 
Inhabitants per Km2 per category was defined according to www.zorgatlas.nl [13]. Category 1 was not 
represented in the study region. Data for women and men per population density category are given 
in numbers of patients and in percentage of patients (%).Data for number of servings were not normally 
distributed and are given as median (range).   
Most women and men were osteopenic and used 500 -1000 mg calcium calculated 
from total dairy product intake per day. No significant differences in patients in both 
genders were found for dairy intake nor for DXA T-scores normal BMD, osteopenia or 
osteoporosis (Table 6).
Table 6. Stratified Calcium intakes from dairy products in women and men grouped by Dual 
Energy X-Ray Absorptiometry (DXA) T-scores
Dairy Calcium intake (mg/day) Women (N=1451)
DXA T-score (*SD)
≥ -1 -1.0 to -2.5 ≤ -2.5 
<500 42 (2.9) 141 (9.7) 49 (3.4)
500-1000 182 (12.5) 445 (30.7) 152 (10.5)
1000-1500 87 (6.0) 228 (15.7) 59 (4.1)
1500-2000 12 (0.8) 34 (2.3) 6 (0.4)
≥2000 4 (0.3) 7 (0.5) 3 (0.2)
Dairy Calcium intake (mg/day) Men (N=349) 
DXA [T-score (*SD)]
≥ -1 -1.0 to -2.5 ≤ -2.5
<500 12 (3.4) 37 (10.6) 9 (2.6)
500-1000 53 (15.2) 118 (33.8) 14 (4.0)
1000-1500 21 (6.0) 62 (17.8) 6 (1.7)
1500-2000 2 (0.6) 9 (2.6) 0 (0.0)
≥ 2000 0 (0.0) 6 (1.7) 0 (0.0)
Legends: There were no significant differences between calcium intake from dairy per DXA T-score category, 
neither within gender nor between genders.
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Median (range) FRAX 10-year probability for major osteoporotic fracture was 
significantly higher in women than in men (11.0% (2.4 - 90.0) and 7.5% (1.6 - 41.0) 
respectively, p < .05). 10-year probability of hip fracture (median(range)) was not 
significantly different between genders (2.6% (0.0 -73.0) in women and 2.7% (0.1 - 
37.0) in men, respectively).
In men (Figure 2), dairy calcium intake showed a weak but significant negative 
correlation with the 10-year FRAX probability of major fracture as well as of hip 
fracture (Rho: -.13 and -.14, respectively, p < .01), but no significant correlation with 
age, height, Body Mass Index (BMI), weight or BMD at the femoral neck. In females 
we found no significant correlation between dairy calcium intake and the variables 
mentioned, nor with ‘age at menopause’. 
Logistic regression analysis disclosed ̀ maternal hip fracture` as a dependent variable. 
This was not found for any of the other variables like age, BMI, age at menopause 
(women only), population density, dairy calcium intake, more than one fracture prior 
to analysis, currently smoking, currently glucocorticoids use, rheumatoid arthritis, 
secondary causes for osteoporosis known to the patient, alcohol use (either ≤2 or 
≥3 servings), BMD at the femoral neck, 10-year probability of osteoporotic major 
fracture, and 10-year probability of hip fracture. In women, logistic regression showed 
a weak relationship between `maternal hip fracture` and the independent variables 
(factors) BMD-at-the-femoral neck, 10-year probability of osteoporotic major fracture, 
10-year probability of hip fracture, BMI, height, weight, Alcohol use=0, currently 
smoking=No. In men, logistic regression showed a strong relationship between 
`maternal hip fracture` and the independent variables BMD at the femoral neck, 
10-year probability of osteoporotic major fracture, 10-year probability of hip fracture, 
BMI, and Prednisone=0.
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Fig 2. Relationship between daily dairy calcium intake and 10-year FRAX probability of 
osteoporotic major fracture or hip fracture in men.
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Comparison between the current Dutch cohort and a cohort from the U.S. 
The percentage of patients fulfilling the recommended total calcium intake of 
>1100 mg/day (≤69 yrs) or > 1200 mg/day (>70 yrs) depends on the total amount 
of calcium in Dutch basic nutrition. In this study, this would mean that focusing on 
dairy intake alone, just 11.3% of the women and 14.2% of the men complied with 
Dutch recommendation. However, assuming that Dutch basic non-dairy nutrition 
provides 42% of the total daily calcium intake (P50= 450 mg) [6], our findings mean 
that 60.5% of women and 59.1% of men complied with Dutch recommendations for 
nutritional calcium intake. U.S. data from the group of Fulgoni [2] showed a mean 
calcium intake of 674±6 mg/day from dairy products for both women and men older 
than 50 yrs; 15.2% of both women and men complied with U.S. recommendations for 
nutritional calcium intake. Moreover, U.S. non-dairy nutrition was estimated to contain 
250-475 mg calcium, and complemented with 2.93 dairy servings this would imply 
that 53.2% of this group complied with U.S. recommendations for calcium from 
dailynutrition [3].
Discussion 
The current study shows that calcium intake from dairy products in a Dutch cohort 
of Caucasians with a recent fracture was well below the Dutch RDI of 1100 mg for 
individuals between 50 and 70 yrs and of 1200 mg for older people. There were no 
differences in dairy calcium intake between age decades, genders or population density 
categories. In contrast to women in men there was a weak but significantly negative 
correlation between dairy calcium intake and 10-year probability of major fracture and 
hipfracture. Importantly, the present study showed that prevalence of `maternal hip 
fracture` was a factor for current fracture risk, both in women and men.
In spite of the fact that the esteemed calcium intake is lower in most European 
countries than in the US [2], there were no significant differences between our cohort 
of fracture patients and a comparable non-fracture cohort from the U.S. in terms 
of dairy calcium intake (expressed as the consumed amount of calcium or as daily 
number of servings).
The current study demonstrated that only 11.3% of women and 14.2% of men comply 
with Dutch recommendations for daily calcium intake from dairy products. However, 
a different picture emerges after adding 450 mg calcium from basic nutrition [4,6]. 
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Nevertheless, even in this scenario, 39.1% of women and 37.4% of men still do not 
comply with Dutch recommendations (i.e. consume less calcium than recommended). 
We emphasize that our choice for 450 mg calcium from non-dairy nutrition was 
based on previously published data by the Dutch National Institute for Public Health 
and the Environment (RIVM) [6]. These estimates are clearly higher compared with 
those made by Heaney [14] and documented in the Clinician’s Guide to Prevention 
and Treatment of Osteoporosis by the National Osteoporosis Foundation (NOF) i.e. 
250 mg per day [15].
Whether this non-compliance with Dutch recommendations should be considered 
a health risk is debatable, since there is no uniformity amongst countries in the 
recommendation of calcium intake from dairy products or supplements. The Dutch 
daily recommendations for adults are similar to those in the U.S. i.e. men 50 – 70 years: 
1000 mg, women > 50 years and men > 71: 1200 mg calcium per day (NOF Clinician’s 
guide). For Australia and New Zealand recommendations are 1300 mg, for the UK 700 
mg and for Scandinavian countries 800 mg. What calcium intake is optimal for skeletal 
health in adults remains an unresolved issue [16-20] For example, daily calcium intake 
in Asian and African countries is about a third of that in Western countries [21], and in 
Japan it is no more than 400-500 mg/day [2].
The current study found weak but significant negative correlations between dairy 
calcium intake and 10-year probability of major fracture and 10-year probability of 
hip fracture in the male cohort. This implies that males with the lowest calcium intake 
are at highest risk for fracture. 
These data agree with the age-adjusted incidence rates of hip fractures around the 
world, which show a negative association with calcium intake by country and hip 
fracture rates [17,23,26,27]. However several other cohort studies in middle-aged 
and older Caucasian women and men found no proof of beneficial effects of dairy in 
reducing hip fractures [21,23-25]. Finally, a recent study by Feskanich et al. has shown 
that the highest hip fracture risk in men appeared to be in those individuals who had 
consumed most dairy products during their teenage years [22]. 
The different outcomes of studies with regard to effects of dairy consumption and 
osteoporotic fractures are confusing, but they may possibly be explained by dual 
mode effects of dairy consumption and the incidence of osteoporotic fractures. 
This phenomenon has been previously shown in the prospective longitudinal 
mammography cohort from Sweden analysing the cumulative intake of dietary 
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calcium study amongst 61.433 participants [21]. Primary outcome measures were 
incident fractures of any type and hip fracture (6% during 19 years of follow-up). From 
these large amount of data it appeared that the risk of low calcium intake in the 
lowest quintile was associated with an increased fracture risk (for all as well as hip 
fractures). Oppositely, in the highest quintile of calcium intake there was an increased 
risk but only for hip fractures. Moreover, the investigators showed a multivariable 
adjusted spline curve for relation between cumulative average intake of dietary 
calcium and time to first hip fracture suggesting a protective effect for dairy calcium 
intake amounting to 800 mg per day, whereas, a fracture-promoting effect for intakes 
exceeding 800 mg of dietary calcium. In other words, it seems that the beneficial 
effects of dairy calcium intake followed a U-shaped pattern with calcium dose [21].
The variability of consumption of dairy products around the globe can be explained 
both by historical/cultural food aspects and biological variations, such as differences 
in intestinal lactase expression in populations. Lactase expression at infancy is 
universal, but in most mammals its activity declines after the age of weaning. Lactase 
activity in humans, however, is variable. Although most populations of the world have 
a low prevalence of lactase persistence, Northern European populations tend to have 
a high preservation of intestinal lactase expression, while it is least among Asians 
[27]. Combined databases of non-cohort studies have shown that lactose intolerance 
and malabsorption are clearly less prevalent among individuals of Northern 
European descent than in African American, Hispanic, Asian and American Indian 
populations [28].
While lactose intolerance can be a barrier to milk consumption, it has been shown 
that at least 240 ml of whole or skimmed milk per day (containing appr. 37.5g lactose) 
may be consumed by lactose maldigesters without experiencing adverse symptoms, 
especially if amounts are divided into smaller doses taken throughout the day [29,30]. 
Most individuals with lactose intolerance can tolerate up to 12g of lactose in a single 
dose, though symptoms will become more prominent at doses above 12g and 
appreciably so after 25g of lactose; 50g will induce symptoms in the vast majority of 
lactose intolerant individuals [28].
While U.S. authorities support supplemental milk feeding programs [29] it is in this 
respect remarkable to note that three servings of dairy products, uniform among 
adult populations of North-Western European descent, regardless of age, gender 
or population density, the latter at least in the Netherlands. Recommending more 
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than three daily dairy servings to protect adult bone in North-Western European 
populations does not seem to have any scientific grounds.
An important finding of the present study is that prevalence of maternal hip fracture 
was a outcome variable for current fracture risks, both in men and women. These 
findings are in line with the publication and data of Lalmohamed [11] who investigated 
and calibrated the Dutch version of the FRAX algorithm. Our calculations were based 
on logistic regression models applying numeric as well as dichotomized variables 
(i.e. smoking, alcohol use, prednisone use, rheumatoid arthritis) and applying the 
FRAX algorithm in a fracture cohort. Our data indicate that genetics may play a more 
prominent role in osteoporotic fractures, independently of gender. Moreover, when 
calibrating FRAX for our Dutch cohort, we also found that maternal hip fracture 
accounted for the greatest increase in 10-year fracture probability.
A possible limitation of our study is that the Dutch data were obtained from patients 
who sustained a fracture, while the U.S. data were obtained from healthy individuals. 
It may be argued that a recent fracture may bias memorized daily dairy intakes. Another 
limitation of our study might be the fact that we did not focus on the vitamin D levels. 
These assays were not systematically performed in the included patients.
Conclusions 
We have shown that Dutch fracture patients are used to taking on average three 
servings of dairy products per day, containing approximately 750 mg of calcium, plus 
an estimated 450 mg extra calcium from basic nutrition. There were no differences in 
daily dairy intake between age cohorts, genders or population densities. While daily 
dairy calcium intakes of Dutch fracture patients were well below the recommended 
dietary intake, they were comparable to healthy U.S. cohorts composed of mainly 
Caucasians. This questions recommendations to use additional amounts of dairy 
products to preserve adult skeletal health, particularly when sufficient additional 
calcium is derived from adequate non-dairy basic nutrition.
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Abstract
Introduction
Screening with portable devices at emergency departments or plaster rooms could be 
of interest to limit referrals for Dual X-Ray Absorptiometry (DXA) and Vertebral Fracture 
Assessment (VFA). We calculated the number of negative tests for osteoporosis and/
or subclinical vertebral fractures (VFs) using Pulse-Echo Ultrasonometry (P-UE) at 
different thresholds. 
Patients and Methods
In this cross-sectional study, 209 consecutive women of 50-70 years with a recent 
non-vertebral fracture (NVF) were studied at the Fracture Liaison Service (FLS) of one 
hospital. All women received DXA/VFA and P-EU (Bindex®) assessments. Various P-EU 
thresholds (based on the Density Index (DI, g/cm2)) were analyzed to calculate the 
best balance between true negative (indeed no osteoporosis and/or subclinical VF) 
and false negative tests (osteoporosis and/or subclinical VF according to DXA/VFA).
Results
83 women had osteoporosis (40%) and 17 women at least one VF (8%). Applying the 
manufacturer’s recommended P-EU threshold (DI 0.844g/cm2) being their proposed 
cut-off for not having hip osteoporosis resulted in 77 negative tests (37%, 31% true 
negative and 6% false negative tests). A DI of 0.896 g/cm2 resulted in 40 negative tests 
(19.3%) (38 true negative (18.3%) and 2 false negative tests (1.0%). 
Conclusion
The application of P-EU enables the identification of a substantial proportion of 
women with recent non-vertebral fractures at the FLS who would not need a DXA/
VFA referral because they had no osteoporosis and/or subclinical vertebral fractures. 
The most conservative P-EU threshold resulted in 18.3% true negative tests verified 
by DXA/VFA against 1% false negative test results.
120
Chapter 6
Introduction
The burden of Osteoporotic fractures increases worldwide due to aging and the 
contribution of the subsequent in part preventable fractures [1-3]. Osteoporotic 
fractures not only represent a large disease burden but it is also associated with 
increased mortality [4,5]. Secondary fracture prevention care is considered to be best 
organized at a Fracture Liaison Service (FLS) [6] and this is therefore propagated by 
the International Osteoporosis Foundation, the ASBMR and EULAR/EFORT [1,3,7]. 
However, a substantial work-up and treatment gap still remains due to limited or even 
low attendance rates [8]. Lack of recalled patient information (extrinsic motivation) 
and lack of patient’s interest into personal health issues (intrinsic motivation) have 
been shown to be major clues for FLS non-attendance [9-12]. Screening for the 
presence of osteoporosis with peripheral devices in patients with a fracture intending 
to improve the proportion of patients that get further analyzed and treated with anti 
– osteoporosis medication has been previously highlighted, but did not yet result 
in guidelines worldwide [12]. Fast track diagnosis and treatment shortly after the 
index fracture could be efficacious regarding subsequent fracture risk reduction in 
any fracture patient > 50 years [13]. Because of the imminent subsequent fracture 
risk [14,15] it could be of added value to use a mobile peripheral screening imaging 
technique shortly after index fracture during fracture treatment procedures, 
on the one hand to rule out patients with a “negative” screening test for having 
osteoporosis or prevalent subclinical VFs in order to reduce the number of DXA and 
VFA measurements and, on the other hand to motivate, hence rule in, those with a 
“positive” screening test for further assessment at the FLS.
Screening at emergency departments and plaster rooms may be achievable and 
advantageous with peripheral portable non-ionizing ultrasound devices. Accuracy 
of quantitative ultrasound (QUS) in diagnosing osteoporosis as found by DXA has 
been reported in a number of studies [16,17]. In a meta-analysis that explored the 
usability of QUS as a pre-screen stratification tool for assessment of osteoporosis 
on DXA of the spine and hip showed a wide range of supposed DXA scan savings 
ranging from 3 to 69% at the expense of false negative tests ranging from 0 to 12%, 
depending on the screening strategy and study characteristics, device, measured 
variable and cut-off values [18,19]. In contrast to QUS, P-EU (Bindex®) measurements 
are performed at the proximal tibia and measures mainly cortical bone properties. 
In earlier studies, the P-EU outcomes showed reproducible a good and significant 
correlation coefficient, between r = 0.86 and r = 0.89 with BMD at the femoral neck 
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[20,21]. Diagnostic accuracy studies using this device at a single site showed a 
specificity of 82% and a sensitivity of 80% for detection of osteoporosis at the femoral 
neck or total hip [22,23].
According to our knowledge there are no data published on prescreening with QUS 
and/or P-EU in FLS cohorts and there are also no studies prescreening P-EU to predict 
subclinical VFs [16-18]. The rationale to use ultrasound to predict BMD - a different 
technique - is based on significant fracture prediction for both techniques [20-23]. 
However, DXA/VFA is the golden standard. Efficient and safe prediction of a negative 
test (i.e. low numbers of false negative tests) was held to be feasible in 50-70 year old 
women with reference to subclinical vertebral fractures of 11% < 70 years versus 23% 
>70 years. [24,25]. Besides, most data reported is in heterogeneous cohorts with or 
without previous fractures [20,22].
Recently a handheld CE approved Pulse-Echo Ultrasonometer device (P-EU Bindex 
®) that measures cortical thickness (CTh) has been developed. The application of the 
P-EU Bindex® is based on the Density Index (DI), a composite value for sonographically 
measured cortical thickness (CTh) adjusted for age and body mass index (BMI) [20-
22]. High prediction was reported for a DI threshold of 0.844 g/cm2 to differentiate 
BMD femoral neck t-scores below or above - 2.5*SD [22]. The NICE guideline on 
osteoporosis care recommends FRAX for fracture risk assessment [26,27]. In case 
of a calculated risk above the threshold for intervention a DXA including VFA is 
recommended. However, NICE leaves the application of Bindex® optional providing 
that it becomes adopted into NHS guidelines. In that scenario Bindex could be used 
after FRAX as an adjunct tool to screen before DXA referral [27].
We aimed to study the number of avoidable DXA/VFA referrals applying different P-EU 
cut-off levels for DI. The approach was to calculate the proportion of DXA/VFA scan 
savings based on the calculated true as well as false negative tests per DI threshold in 
parallel. The study was performed in 50-70 year old women who recently sustained 
a traumatic or non-traumatic NVF, a group considered to be at relative low risk of 
osteoporosis and subclinical VFs. [24,25].
Patients and methods
A total of 591 consecutive women with a recent NVF and between 50 and 70 yr. 
were identified between September 1st 2016 and June 30th 2017 at the emergency 
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department and plaster room of the Reinier de Graaf Hospital, Delft, The Netherlands. 
After exclusion of women with toe, finger and skull fractures, all women (except for 
women with fractures due to high velocity traumata) were invited to attend the FLS 
both after exchanging patient information at the emergency and plaster room or 
outpatient clinic and in case of no attendance within 1 month by written invitation. 
As a pilot we studied women between 50-70 years after recent fracture expecting 
their risk on osteoporosis and non-clinical vertebral fractures to be low [24,25]. For 
this study we excluded patients with clinical VFs since treatment is started in these 
patients regardless of the DXA outcome, according to the Dutch guideline [28]. 
DXA and Vertebral Fracture Assessments (VFA) were standard clinical procedures 
in all FLS patients. For this study, women were separately asked permission for a 
P-EU (Bindex®) measurement. Patients and health care professionals had no insight 
in the outcome at the time of this measurement. Anti-osteoporosis treatment was 
recommended according to the Dutch guidelines (the presence of osteoporosis and/
or a grade II/III subclinical prevalent VF) [28]. 
Index fractures were categorized in non-vertebral/non-hip minor, non-vertebral/non-
hip major, hip and VFs according to Warriner [29].
The study was carried out in accordance with Good Clinical Practice (GCP; Medical 
Ethical Review Board: METC Zuidwest Holland; approval 16.190).
DXA and VFA
Patients had a DXA/VFA measurement (Hologic Discovery QDR®) at the lumbar spine, 
total hip and femoral neck and a VFA. Osteoporosis was defined according to the WHO 
as a t-score < -2.5 *SD at the femoral neck, total hip or lumbar spine. Prevalent subclinical 
VF severity was graded according the classification of Genant i.e., grade I (mild) > 20% - < 
25%, grade II (moderate) > 25% - <40% and grade III (severe) > 40% height loss [30]. 
P-EU (Bindex®)
P-EU (Bindex®; Bone Index Finland, Kuopio, Finland) was used for this study [20-22]. 
Cortical Thickness (CTh) was calculated by multiplying the time of flight between the 
ultrasound echoes from the periosteal and endosteal surfaces by the speed of sound 
(SOS) [31]. According to manufacturers’ recommendation, CTh is measured at one-
third of the proximal tibia, meaning a third of the distance from the knee joint space 
123
The use of Pulse-Echo Ultrasound in women with a recent non-vertebral fracture
6
to the medial malleolus. First, the participant was asked to bend the knee in order to 
palpate the knee joint. The leg was returned to a flat position while keeping contact 
with the medial knee joint gap. The joint was marked using a ball pen. Then the ruler 
was held next to the lower leg with the lower end at the most distal side of the medial 
malleolus. We used a manufacturer’s ruler to indicate the measuring exactly at one 
third of the tibia length. Echo gel was applied at this site and the transducer was 
moved over the tibia in a slight angle. This movement was repeated five times to 
obtain five valid signals. All measurements were performed by the same operating 
technician who was trained by the manufacturer. These 5 results were averaged, 
computed further in the software (Bindex® software v2.0) using CTh, age, weight and 
height. Density Index (DI) g/cm2) was calculated with Bindex® software [20-22]. After 
two days training of the local operating technician by the manufacturer the inter-rater 
agreement between the manufacturer’s instructor and the local operator was tested 
(Inter Rater Reliability - IRR) was 87% (R^2= 0.8716, CV= 3.2%) measuring 16 patients, 
which reflects a high agreement [32].
Aims of the Study 
We studied various P-EU cut-off levels to determine the proportion of women with 
a true negative P-EU test for having no osteoporosis at femoral neck, total hip or 
lumbar spine and/or a subclinical VF with the consequent proportion of women with 
a false negative P-UE test i.e. the confirmed presence of osteoporosis or at least one 
subclinical prevalent VF according to DXA/VFA. The first step in this research was to 
study the manufacturer`s recommended P-EU (Bindex) DI score of > 0.844 g/cm2 that 
was originally developed and tested for osteoporosis at the hip and femoral neck. The 
second step was to determine the P-EU DI threshold with the highest proportion of 
true negative tests at the expense of the lowest proportion of false negative tests. 
Statistical methods
Statistical analyses were performed using StatGraphics Centurion software (Version 
17.2.05 for MS-Windows; Statpoint, Inc., Warrenton, VA, USA) and R (2018, The R 
Foundation for Statistical Computing Platform, version 3.5) [33]. All DXA and VFA scores 
were dichotomized being Yes=1 (t-score < -2.5*SD and/or at least one prevalent VF > 
25% and No=0 (t-score > -2.5*SD and no prevalent VF > 25%).
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The Wilcoxon-Mann-Whitney rank-sum test was used to compare two groups formed 
by censoring via DXA Spine, Total Hip and Femoral Neck (osteoporosis and osteopenia/
normal) and dichotomized DI as outcome variable. The Kruskall-Wallis test was used 
to compare these groups among the various numerical variables DI and DXA spine, 
DXA total hip and femoral neck t-scores. Pearson’s Chi Square test or Fisher’s Exact 
Probability test were used to examine the significance of the association between 
dichotomized DI and dichotomized DXA total hip, DXA femoral neck, DXA lumbar 
spine, DI t-scores and Genant classifications. OR and 95%CI were calculated to assess 
the effect size of a significant association. The diagnostic accuracies of varying DI 
threshold levels to predict t-score defined osteoporosis and/or subclinical VF grade 
II and III were analyzed performing ROC analyses aiming to find DI threshold values 
corresponding with AUC > 80%.
Spearman’s rank correlations were calculated between DXA lumbar spine, femoral neck 
and total hip, DI t-scores and Genant classification vs. numerical DI as outcome variable 
before establishing the most adequate logistic regression model, as well as for the 
interpretation of the Inter-rater reliability. Collinearity and interactions were analyzed 
using R and judged by interpretation of VIF, Condition Indices and interaction trees and 
plots. Receiver Operator Curve (ROC) analyses were performed using library pROC in R 
aiming to achieve an Area under the ROC curve (AUC=auroc) > 80% [34].
The best DI threshold (method Youden), all other thresholds and adhering diagnostics 
like sensitivity, specificity, NPV, PPV and their respective 95%CI were calculated by 
bootstrapping using typically 10,000 replicates to obtain good estimates of statistics 
and adequate significant figures [35].
For the calculation of the proportion of correctly and incorrectly non-referred women 
for DXA/VFA, we calculated by tabulation the number of women who are above or 
below a specific threshold DI (g/cm^2) and had a dichotomous score in DXAVFAALL 
and related that number to N (the total number of women). P-value < .05 was 
considered statistically significant at the 95 % confidence level.
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Results
Of a total of 591 consecutive women with a NVF we excluded 122 women with finger, 
toe, and skull fractures (fig 1). Therefore, 469 patients were invited at the FLS resulting 
in 263 attenders (56%) and 206 FLS non-attenders (44%). After exclusion of 54 women 
(18 with a clinical VF, 9 no informed consent, 20 with unreadable or incomplete data, 
7 not accessible for P-UE measurement), the study population consisted out of 209 
women. Patient characteristics are provided in table 1. Median age was 62.2 ± 6.0 
years, 19 women (9%) had a hip fracture, 94 (45%) a non-vertebral/non-hip major 
fracture and 96 (46%) a non-vertebral/non-hip minor fracture. Osteoporosis was 
present in 83 women (40%) and/or at least one prevalent subclinical VF was present 
in 10 women while 7 women had a VF without osteoporosis. 73 women (35%) had 
osteoporosis but no prevalent subclinical VFs.
Table 1. 
Characteristics of 209 women, 50-70 years old, with a recent Non-Vertebral Fracture at the FLS 
Number (%) Median Range (min/max)
Age (yr) 209 (100%) 62.2 50 70
Osteoporosis
Osteopenia
Normal BMD
83 (40%) 
92 (44%) 
34 (16%)
At least one Prevalent VF (Genant grade II/III)
Grade II (> 25% but <40%) 13 (6%)
Grade III (> 40%) 4 (2%)
Hip fracture*                                                                                                    19 (9%)
Major fractures* n= 94 (45%)
- Distal radius and lower arm 
- Sub-capital humerus
- Rib
- Pelvis and Acetabulum
- Tibia proximal / plateau 
- Calcaneal / tarsal 
52 (55%)
16 (17%)
6 (6%)
6 (6%)
10 (11%)
10 (11%)
 Minor fractures* n= 96 (46%) 
- Clavicle / scapula 
- Scaphoid 
- Metacarpal 
- Radius neck / head 
- Patella 
- Ankle / malleolus 
- Metatarsal
6 (6%)
7 (7%)
12 (13%)
9 (9%)
7 (7%)
25 (26%)
18 (19%)
Age at menopause (self-reported; yr.) 50 41 61
DXA femoral neck t-score (SD) -1.9 -4.4 +1.3
DXA total hip t-score (SD) -1.6 -5.2 +2.4
DXA t-score lumbar spine (SD) -1.6 -5.2  +2.4
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Number (%) Median Range (min/max)
Cortical Thickness (CTh) (mm) 2.1  1     2.3
Density Index (DI) (g/cm2) 0.82 0.667     1.183
Density Index t-score (SD) -1.6 -3.4    +2.7
BMI (kg / cm*cm) 21.8 16.1        23.1
Weight (kg) 68 45      130
Height (cm) 168 149            188
Smoking (Yes) 44 (19%)
Alcohol (> 2 U/daily) 33 (15%)
Previous fracture(s): Yes (self-reported) 53 (23%)
Previous fall: Yes (self-reported) 23 (10%)
Parental hip fracture (mother: Yes) 23 (10%)
Parental hip fracture (father: Yes) 9 (4%)
Rheumatoid arthritis (existing) 11 (5%)
Diabetes (existing) 9 (4%)
Hyperthyroidism (existing) 2 (1%)
COPD 16 (7%)
Vitamin D supplementation (Yes). Nr. conc. nmol/l) 105 (46%) 68 18 175
Legends:
* Fractures were categorized according to Warriner [20].
Fig 1. Flowchart of the current study
127
The use of Pulse-Echo Ultrasound in women with a recent non-vertebral fracture
6
Applying the manufacturer`s standard P-EU threshold (DI 0.844g/cm2) resulted in 
130 women with a DI ≤ 0.844 g/cm2 (62%) and 79 with women with a DI > 0.844 
(38%). Odds Ratios of a DI > 0.844 g/cm2 for not having osteoporosis at the femoral 
neck, total hip or lumbar spine and for not having osteoporosis or subclinical VFs, 
respectively, are presented in table 2.
Table 2. Odds Ratio’s (OR) using manufacturer’s Density Index (DI) > 0.844 g/cm2 to exclude for 
osteoporosis and/or subclinical vertebral fractures in 209 women who sustained a recent non-
vertebral fracture.
DXA per site p-value 95%CI OR
DXA femoral neck < .001 7.46;61.76 21.47
DXA total hip < .001 3.43;38.31 11.47
DXA spine < .001 3.69;25.14 9.68
DXA ALL sites < .001 2.69;10.23 5.25
DXA all sites including subclinical vertebral fractures
DXA ALL sites  
(including subclinical vertebral fractures Grade II and III)
< .001 2.54;9.61 4.94
Legends:
DI measures (g/cm2) in women with and without osteoporosis (dichotomized DI > 0.844: 0 and 1 resp.). DXA 
measures were dichotomized for osteoporosis (t-score < -2.5*SD: 1) at least at one of the DXA sites (femoral 
neck, total hip and spine) and/or grade II and III prevalent vertebral fractures. OR: Odds Ratio; 95%CI: 95% 
Confidence Interval. p-value < .05 is considered significant.
The diagnostic accuracy of DI thresholds for any combined DXA/VFA outcome 
according to the ROC analyses are presented in table 3. The ROC diagnostic accuracy 
analysis of P-EU (Bindex®) is depicted in figure 2. 
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Fig 2. ROC curves
Fig. A ROC curves: Three DXA-based predictors vs. dichotomized Bindex® Density Index predictors.
Legends:
The area under each ROC curve (i.e. auroc) quantifies the overall ability of each “diagnostic test” to discriminate 
between women (50-70 yr.) with suspicion of osteoporosis (dichotomized DI < 0.844) and those without 
osteoporosis (dichotomized DI > 0.844). From the three curves it can be seen that the 3 predictors may be 
able to discriminate between the two groups of women. The 95% Confidence Intervals of the aurocs are not 
significantly different between Femoral Neck (auroc: 0.8116, 95% CI: 0.7506-0.8726) and Total hip (auroc: 0.7841, 
95% CI: 0.7209-0.8473) and between Total hip and Lumbar Spine (auroc: 0.7337, 95% CI: 0.6656-0.8017). 
However, aurocs of Femoral Neck and Lumbar spine are significantly different (bootstrap method; p-value .02).
Fig. B ROC curve: Density Index (numerical) vs. 
dichotomized DXA ALL sites
Fig. C ROC curve: Density Index (numerical) vs. 
dichotomized DXAVFAALL sites including all 
subclinical vertebral fractures grade II and III
Legends Fig. B and C:
The area under the ROC curve (i.e. auroc) quantifies the overall ability of the “diagnostic test” DI to discriminate 
between women (50-70 yr.) with and without osteoporosis and clinical vertebral fractures with DXAVFA ALL sites-
based absence of osteoporosis with and without vertebral fractures grade II and III. Each point on the ROC curve 
represents a sensitivity/specificity pair corresponding to a particular decision threshold of the respective predictor. 
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Table 3. Calculated Bindex Density Index (DI) cut-off for achieving the optimal AUCs according 
to DXA with or without subclinical Grade II and III on VFA, using ROC analyses. 
DXA sites DXAVFAALL 
including 
VFs Grade II/III 
DXA ALL 
sites
DXA  
Lumbar 
Spine (L1-4)
DXA  
Femoral 
Neck
DXA  
Total hip
Optimal DI Cut-off 0.837 0.837 0.822 0.812 0.837
AUC (= auroc) 0.7844 0.7878 0.7337 0.7841 0.8116
Specificity (%) 60.2 60.0 59.4 63.5 59.9
Sensitivity (%) 87.2 88.1 81.5 78.6 92.5
NPV (%) 87.1 88.2 90.2 92.2 93.6
PPV (%) 60.5 59.7 41.1 35.1 55.6
Legends:
Optimal DI cut-offs (numerical, g/cm2) are obtained from Receiver Operator Curve (ROC) analyses. Auroc: 
Area under the Receiver Operator Curve. NPV: Negative predictive value. PPV: positive predictive value. The 
calculated optimal DI cut-off agreed with that of the manufacturers recommended cut-off.
Table 4 shows the number and proportion of true negative and false negative tests 
for a range of DI thresholds including that formulated by the manufacturer (from 
0.844 to 0.896 g/cm2). Use of the manufacturer’s recommended DI cut-off of > 0.844 
g/cm2 resulted in 77/209 true negative (37.8%) and 12 (5.8%) false negative tests. The 
lowest proportion of false negative tests was achieved at a DI of 0.896 g/cm2 being 
true negative in 38 women (18.3%) and false negative in 2 women (1%) in whom one 
with a subclinical VF and one women with osteoporosis but no subclinical VF. 
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Table 4. Proportion of true positive and false negative tests in women 50-70 year for not having 
osteoporosis and/or prevalent morphometric vertebral fractures according to different Density 
Index (DI) cut-offs.
True negative and false negative tests Test characteristics.
Measured 
DI
True 
negative 
(nr.)
True  
negative 
(%)
False  
negative 
(nr.)
False 
negative 
(%)
NPV (%) PPV 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
0.844 65 31.3 12 5.8 84.40 58.80 54.60 86.50
0.846 65 31.3 11 5.3 85.50 59.10 54.60 87.60
0.848 63 30.3 11 5.3 85.10 58.20 52.90 87.60
0.851 60 28.8 11 5.3 84.50 56.90 50.40 87.60
0.854 60 28.8 10 4.8 85.70 57.20 50.40 88.80
0.855 59 28.4 9 4.3 86.80 57.10 49.60 89.90
0.857 58 27.9 9 4.3 86.60 56.70 48.70 89.90
0.860 57 27.4 9 4.3 86.40 56.30 47.90 89.90
0.862 57 27.4 8 3.8 87.70 56.60 47.90 91.00
0.864 56 26.9 7 3.4 88.90 56.60 47.10 92.10
0.866 54 26.0 7 3.4 88.50 55.80 45.40 92.10
0.868 52 25.0 7 3.4 88.10 55.00 43.70 92.10
0.870 51 24.5 7 3.4 87.90 54.70 42.90 92.10
0.872 49 23.6 7 3.4 87.50 53.90 41.20 92.10
0.875 47 22.6 7 3.4 87.00 53.20 39.50 92.10
0.876 46 22.1 7 3.4 86.80 52.90 38.70 92.10
0.879 45 21.6 6 2.9 88.20 52.90 37.80 93.30
0.881 44 21.2 6 2.9 88.00 52.50 37.00 93.30
0.883 43 20.7 5 2.4 89.60 52.50 36.10 94.40
0.884 41 19.7 5 2.4 89.10 51.90 34.50 94.40
0.886 41 19.7 3 1.4 93.20 52.40 34.50 96.60
0.890 40 19.2 3 1.4 93.00 52.10 33.60 96.60
0.893 39 18.8 3 1.4 92.90 51.80 32.80 96.60
0.895 38 18.3 3 1.4 92.70 51.50 31.90 96.60
0.896 38 18.3 2 1.0 95.00 51.80 31.90 97.80
Legends:
True Negative and False Negative tests in women 50-70 year not having osteoporosis and/or grade II or 
III vertebral fractures by application of various (higher) DI cut-offs. DI cut-offs are obtained from Receiver 
Operator Curve (ROC) analyses in DXAVFAALL. NPV: negative predictive value. PPV: positive predictive value.
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Discussion
In this cross-sectional pilot study we showed outcome results of several P-UE 
DI thresholds (including the cut-off DI (0.844 g/cm2) as recommended by the 
manufacturer. The proportions of true negative and false negative tests were 
calculated to get a first notion about potential DXA/VFA non-referrals because of no 
suspicion of osteoporosis and/or a subclinical vertebral fracture on VFA in parallel 
with proportions of false negative results down to 1%. The results are relevant since 
there are no previous studies performed in high risk FLS patients that focused on 
screening with peripheral ultrasound technology showing a 18.3% proportion of true 
negative tests (indeed no osteoporosis and/or prevalent subclinical VFs grade II/III).
Previous studies were limited in reporting the accuracy of peripheral ultrasound 
devices with a more general approach to find optimal cut-off thresholds for 
‘osteoporosis’ based on central DXA, but not to additionally diagnose those patients 
with a subclinical VF. In this context it has been shown that the diagnostic inaccuracy 
of ultrasound techniques mostly using ROCs ranged from 0 to 12.4% with DXA savings 
from 3 up to 69% [16-18,20,21].
In this study, Bindex® showed a good diagnostic accuracy for DXA-defined femoral 
neck osteoporosis (AUC >0.81) and a fair accuracy for DXA measurements at the 
lumbar spine and total hip and for the combination of the three locations and 
subclinical VFs >25% (Table 2 and 3, Fig. 2). ROC analysis comparing P-UE versus DXA/
VFA outcomes showed an optimal AUC of 78.4% at a DI of 0.837 g/cm2, which is 
almost equivalent to manufacturers’ recommended DI 0.844 g/cm2. However, the aim 
of the study was not to test accuracy of P-UE but to identify a specific DI threshold 
that covers optimal balance between true negative and false negative test results as 
compared to the results generated by DXA/VFA. The lowest DI threshold reported 
here was the manufacturers’ recommended DI of 0.844 g/cm2 followed by a range 
of higher DI cut-off steps up to 0.896 g/cm2. Using the composite DXA at all sites/
VFA measure (DXAVFAALL; see table 3) a calculated range of true negative and false 
negative results is shown in table 4. In this single center FLS cross-sectional study 
and according to current definition we found true and false test negative outcomes 
to be optimally balanced at a DI cut-off of 0.896g/cm2. By doing so, we found 
18.3% true negative and 1% false negative P-UE tests. This higher DI as compared 
to recommendation enables safely the identification of a substantial proportion of 
women who may be in no need for DXA/VFA referral. However, prospective studies 
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are further needed. This pilot study was performed in a small FLS group of women 
among 50 to 70 years of age, assuming that the prevalence of subclinical VFs was not 
very high in this group of women and that it therefore could be of additional value to 
perform screening with a peripheral device in this group of women. By doing so, the 
prevalence of osteoporosis was 40% and of one or more subclinical VFs 8%, which is 
similar to previous Dutch studies and also to a UK cohort [15,24,36].
It is of note that the attendance rate in most FLSs is only around 50% of all patients 
with a fracture regardless of face-to-face patient information and of FLS invitations 
by letter afterwards [8,36]. Besides the fact that 18.3% of women had a true negative 
test based on DI of 0.896 g/cm2 and may be confidently not in need for DXA/VFA, 
there may be another advantageous aspect of immediate post-fracture screening 
with a mobile device. A ‘positive’ Bindex test could promote the awareness for having 
a condition in order to motivate them for further assessment at the FLS. In fact, of the 
women with a DI < 0.896 g/cm2, 50% had osteoporosis and/or a VF. Screening may, 
therefore, be promising to encourage a proportion of individuals to attend the FLS, 
who would have decided otherwise not to attend the FLS [8]. This easy to operate 
hand-held non-ionizing tool offers an important opportunity as it can be used during 
the early stages of fracture care, being the optimum moment when the patient 
realizes that there might be a problem with skeletal health.
This study has several limitations. First, it was conducted in a small group of women of 
50-70 years and not among older women and men. FLS attendance was again confirmed 
to be low. Therefore, the results cannot be extrapolated to elderly women or men. 
Second, the percentage of osteoporosis was higher than expected. Third, the number of 
subclinical VFs was smaller than expected, the prevalence of grade II and III VFs increases 
with age [24,25]. This low number as found may be a confounder in the interpretation 
of the results. However, the higher the prevalence of patients with osteoporosis or 
subclinical VFs, the lower will be the proportion of subjects that is correctly excluded for 
DXA/VFA referral. Secondly, data were obtained from FLS attenders and not from FLS 
non-attenders. FLS attenders who were requested to consent with a scientific study are 
probably different from FLS non-attenders [36]. Since this study was post-hoc analyzed 
this discrepancy may have caused selection bias. Therefore, further studies in a complete 
consecutive cohort of patients of 50 years and older including men with a recent fracture 
are needed. In addition, it has to be further studied whether the screening approach 
would result in a higher FLS attendance. Finally, this is a single-FLS study; comparisons 
with and experiences from other FLS centers are still needed.
133
The use of Pulse-Echo Ultrasound in women with a recent non-vertebral fracture
6
In conclusion, based on specific P-EU thresholds, a substantial proportion of women 
between 50 and 70 years with a recent NVF could confidently not be referred for 
further assessment with DXA/VFA. Moreover the strategy of immediate screening 
during post-fracture care may help to improve FLS attendance and DXA/VFA testing 
in patients with a positive screening outcome.
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Mini-abstract
Telephone call intervention did not improve alendronate persistence in FLS patients 
in this study. A bone turnover marker cut-off point for alendronate persistence is 
proposed for individual FLS patients.
Abstract
Introduction
A Fracture Liaison Service (FLS) aims to prevent subsequent fractures, which should 
include improving patients’ persistence with prescribed oral bisphosphonates. We 
studied the influence of telephone calls and the predictive value of changes in bone 
turnover markers (BTMs) for evaluating persistence with alendronate.
Methods
Postmenopausal women with a recent fracture and osteoporosis who started 
alendronate were randomized to receive three Phone Calls (PC) (after 1, 4 and 12 
months) or No Phone Calls (no PC). S-CTX and PINP were measured at baseline and 
after 3, 6, 9 and 12 months. As a reference group, thirty postmenopausal osteopenic 
patients with a recent fracture were analyzed as well. Persistence was assessed using 
the Dutch National Switch Point Pharmacies-GPs database and cross-referenced with 
PC, no PC and BTM changes. Cut-off values of BTMs were calculated based on least 
significant change (LSC) and also on underrunning median values of the untreated 
osteopenic postmenopausal reference group with a recent fracture. 
Results
Out of 119 patients, 93 (78 %) completed 12 months follow-up (45 PC and 48 No 
PC). Mean age was 69 years. Persistence was similar in PC and no PC participants. 
The cut-off value >29% (<415 ng/L) as LSC of s-CTX and >36% (<53,1 µg/L) as LSC 
of PINP was determined optimally showing alendronate persistence after one year 
(being 93 and 88% respectively).
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Conclusions
In this context, telephone calls did not improve persistence. In around 90% of 
patients, one-year alendronate persistence was confirmed by achieving LSC of s-CTX 
and of PINP at 12 months. 
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Introduction
The Fracture Liaison Service (FLS) is advocated as the most appropriate approach for 
secondary fracture prevention in patients with osteoporosis [1,2]. Besides successful 
prevention of subsequent fractures, FLS activities have been shown to reduce 
mortality [3]. The FLS concept and its necessity were first reported by the Glasgow 
group [4,5]. The concept includes full diagnostic evaluation with a focus on detecting 
underlying disorders and determining the appropriate tailor-made treatment. The 
International Osteoporosis Foundation (IOF) introduced the Capture The Fracture® 
(CtF) Best Practice Framework (BPF), which consists of 13 standards for evaluating 
the performance of any FLS, however not including telephone intervention nor taking 
lab samples for BTMs.[6]. The current study pertains to BPF standard 12, i.e. to 
ascertaining what processes are in place to ensure that long-term management of 
fracture risk is reliably provided [6]. 
Recently, inventories on CtF criteria analyzed FLS qualities worldwide [7-9], and our 
own group reported nationwide on 24,418 Dutch patients [10]. The principal weakness 
was an FLS attendance of 49% [10]. Notably, all recent fracture patients older than 
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50 received invitations for follow-up in line with the Dutch Guideline on Osteoporosis 
and Falls [11]. Besides low numbers of patients attending, a second concern is the low 
persistence with treatments. In the Netherlands, a nationwide survey of medication 
dispensation showed up to 40% persistence for anti-osteoporosis medication during 
12 months [12]. These findings were obtained from the medication dispensation 
database on osteoporosis medication, which was generated by IMS Health based 
on Dutch nationwide data of most pharmacies’ sales to patients. Contrarily, a recent 
study indicated a much higher persistence of 75% in patients with a recent fracture 
[13]. Therefore, we hypothesized that persistence in recently fractured patients may 
be improved by means of telephone calls during the first year of follow-up. Telephone 
initiatives to improve persistence with bisphosphonates have been tested previously, 
yet not in patients attending FLS [14-26] (Table 1).
In this study, the primary objective was to compare the effect of a dedicated telephone 
call intervention with standard FLS care on persistence with bisphosphonates at 12 
months. The secondary objective was to analyze if BTMs are markers of persistence 
verified by pharmacy deliveries in LSP.
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Patients and methods 
Study procedure 
Consecutive female patients who attended the FLS due to a recent non-vertebral 
or clinical vertebral fracture were included if they were 50 years or older. In each 
patient, treatment was initiated in line with the Dutch Guideline on Osteoporosis 
and Falls [11]. This guideline recommends treatment in case of a T-score of - 2.5*SD 
or less, or a T-score between -1.0 and 2.5*SD and prevalent vertebral fractures on 
Vertebral Fracture Assessment (VFA). Patients were excluded in case of metabolic 
bone disorders. Vitamin D deficiency without secondary hyperparathyroidism was 
not an exclusion criterion.
All patients with osteoporosis and osteopenia received FLS standard care, including 
lifestyle and nutrition education according to the Dutch National Guideline [11]. 
Patients with vitamin D deficiency (< 50 nmol/l) were prescribed a daily dose of 
calcium (500 mg) and vitamin D3 (800 IU)[11]. Each patient received alendronate 70 
mg once weekly.
After obtaining informed consent, patients who agreed to participate in the study 
were randomized to either Phone Calls intervention (PC) or no Phone Calls (No PC). 
Besides, we selected a reference group of thirty postmenopausal osteopenic patients 
with a recent fracture to observe the course of BTMs during fracture repair. In all 
patients in the randomized groups and in the reference group, blood was drawn for 
BTM assessment at study start and after 3, 6, 9, and 12 months. Patients in the PC 
group were called after 1, 4 and 12 months. All telephone calls were made by the 
same experienced FLS nurse. These calls were particularly meant to remind patients 
not to forget medication and to exchange views about side effects. In case of clear 
evidence of drug intolerance, patients were withdrawn from the study and alternative 
treatments were offered.
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Fig 1. Study Flowchart
Bone density measurement and VFA
A patient was diagnosed with osteoporosis if she fulfi lled the WHO criteria for osteoporosis 
(a T-score of ≤ -2.5SD at the total hip, femoral neck or lumbar spine) or if she had had 
at least one vertebral fracture and a loss of height of more than 25% on radiography 
or of more than 40% on VFA, according to Genant’s classifi cation [27]. Criteria for 
osteopenia were a T-score between -1.0 and - 2.5SD at the lumbar spine and/or hip and 
no morphometric abnormalities (Hologic DXA equipment, Hologic Discovery QDR Series).
Bone Turnover Markers (BTMs)
P1NP was measured by means of radioimmunoassay (RIA; Orion Diagnostica, Espoo, 
Finland), and s-CTX by means of electrochemiluminescence immunoassay (ECLIA; Elecsys 
2010 Roche Mannheim, Germany). Fasting serum samples were stored frozen at -20ºC 
within one hour after blood sampling until analysis. P1NP and s-CTX were assayed and 
expressed in concentrations and in z-scores, using a Dutch Reference Values Group (350 
women older than 50) [28]. Blood collection took place at baseline (study start) and after 
3, 6, 9 and 12 months, and all samples were fi nally sent off  as one batch for analysis at the 
laboratory of the University Medical Centre, Groningen, the Netherlands. 
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Evaluation of persistence with alendronate based on the Dutch National Exchange 
Point Pharmacies-GPs. (LSP) 
After study completion, dispensation data of all participants were collected from the 
Dutch Landelijk Schakel Punt (LSP), translated in English as National Exchange Point 
Pharmacies-GPs.) [29] after verifying whether each patient had consented to the use 
of personalized data stored in this database. Since patients in the Netherlands are 
encouraged to store their identifiable healthcare and pharmacy data in the LSP, this 
database offers accurate information on prescriptions and data on deliveries, including 
the name of the pharmacy, the date of prescription, the number of prescribed tablets, 
the prescriber and the dosage regimen. Thus far, nationwide more than 11 million 
Dutch citizens (which is over 70% of the population) consented to giving access to 
LSP. Pharmacy staff are legally bound to request informed consent regarding the 
review of individual dispense data. 
Statistics
Data were analyzed using Statgraphics Centurion XVII software (Version 17.1.08 for 
MS-Windows; Statpoint, Inc., Warrenton, VA, USA).
A power analysis was conducted using G*Power software (Germany, version 3.1) to 
determine the number of patients needed in this study. Two groups of women would 
have bisphosphonates prescribed. Sample sizes per group were estimated a priori for 
two-sided significance level alpha= .05 and Power= 80% using Fisher’s exact test for 
unequal proportions in two independent groups. Proportions of patients (= % medication 
compliant) with phone calls versus no phone calls were compared in the analysis: the first 
proportion was 40% (no phone calls) and the second proportion was 70% (phone calls). 
Compliancy was scored by calculating the biologically and statistically significant decrease 
(so-called Least Significant Change) in the two serum BTMs. The output indicated that 42 
patients would be needed in each group to have a power of 80%. These numbers were 
corrected by 15% both for non-parametric statistical tests and Losts-to-Follow-up: the 
final numbers of patients estimated were (rounded up) 50 per group.
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Comparison of Phone Call (PC) vs. No Phone Call (No PC) intervention effects on 
persistence 
We used a logistic regression model comparing the binominal variable Intervention 
(PC=1; No PC= 0) and persistence with alendronate at 12 months (LSP Yes vs. No) as 
a binary outcome variable. Besides least significant change (LSC), other censors were 
studied using data from the reference group after showing statistical feasibility of 
pooling. The outcomes of LSC and censors applied in our FLS patients were compared 
to the LSC criterion proposed by the IOF/ECTS Working Group [30]. BTM levels and 
both the age- and gender-adjusted near-Gaussian z-scores were analyzed. BTMs and 
LSP results were analyzed separately according to time since fracture, study start 
and a fixed time of 180 days (as time outcome variables). For this, linear models were 
used analyzing BTMs at various time points with the fracture codes as categorical 
factors. Since the outcomes at these various timepoints were similar, we only report 
those at 180 days after fracture (see Fig.2). Measuring data of the reference group 
were repeated at the various time points and pooled for further analysis. Statistical 
changes between the BTM level or z-score at study start before treatment and after 
alendronate treatment were analyzed in order to find medication-compliant BTM 
measures in accordance with LSP Yes or No. The binominal censors explored were 
LSC, underrunning the Median estimates (< Median; abbr. MedREF) from the pooled 
BTM levels of the reference Group as previously described [31] and underrunning 
the calculated outcome BTM level of the Median after correction for outliers (< 
Median Absolute Deviation; abbr. MedMAD) [32]. Since near-Gaussian distribution 
was observed and tested for the BTM levels of the reference group at the various 
points in time, we applied a consistency factor of 1.4826. For this study, we used 
LSCs (95% confidence, 2-sided) as previously reported for another Dutch cohort, i.e. 
z-scores of 36% for P1NP and 29% for s-CTX [33]. Logistic regression was applied to 
estimate odds ratios and their 95% confidence intervals, using completed medication 
dispensation at 12 months (LSP Yes or No) and BTMs and PC and No PC and the 
separate persistence parameter for both P1NP and s-CTX Yes=1;No=0) and fractures. 
Where applicable, a p-value of p < .05 was considered statistically significant at the 
95% confidence level.
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Ethics
The study with number NL 35164.098.11 was approved by the regional Medical 
Ethical Review Board (METC Zuidwest Holland) and was carried out in accordance 
with the declaration of Helsinki and the guidelines of the International Conference on 
Harmonization Good Clinical Practice (GCP). Written informed consent was obtained 
from all participants included in the study and in the reference group. 
Results
From June 2012 to January 2014, 881 postmenopausal women that attended the 
FLS of the Reinier de Graaf Gasthuis, Delft, the Netherlands were evaluated: 350 
(40%) with osteoporosis, 399 (45%) with osteopenia and 132 (15%) with a normal 
T-score. Of the 350 osteoporotic patients, 119 (34%; mean age 69.5yrs (range 53-
86)) consented to participate in our telephone intervention study. After withdrawal 
for several reasons, 45 completed the study in the PC group and 48 in the No PC 
group. Obviously, reasons for dropping-out were known in the PC group (12 patients 
dropped out for GI reasons and 3 patients dropped out for motivational issues). In 
each case, dropping out did occur within the first 4 months of the study based on 
self-reporting. Other non-oral osteoporosis treatments were offered and accepted by 
6 patients. In the NoPC group dropping out was registered in LSP at 12 months (LSP 
does not include documentation about the cases who dropped out from the study). 
Subsequently none of these patients received other osteoporosis medication.
Of 30 osteopenic reference group patients, 23 gave the adequate number of blood 
samples according to study protocol, see Fig 1. Base-line characteristics of all 
participants are listed in Table 2.
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Fig. 2 (2.1 – 2.6) P1NP and s-CTX z-scores versus Time Period 180 days post-fracture. 
Legenda: 
Scatterplots of P1NP and s-CTX z-scores depicted at 180 days post-fracture. Each line represents an individual 
patient. Data of the PC group and the No PC group on alendronate are depicted in the upper panels (2.1 and 
2.2) resp. the middle panels (2.3 and 2.4). Data of the post-menopausal reference group without alendronate 
therapy are depicted in the lower panels (2.5 and 2.6), Lines at z-Score= 0.0 show the mean of the applied 
parametric 95% Reference Interval.
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PC versus No PC
Censors indicate significant bisphosphonate-induced lowering of the respective BTMs 
and were described as proportions at each point in time using Intention-To-Treat (ITT) 
(n= 119) and Per Protocol (PP) (n= 93) analyses. LSP analysis according to ITT revealed: 
LSP PC: 71.2% and No PC: 67.9% (p>0.05).
Moreover, the 93 patients who completed the study (PP) also showed no significant 
difference in LSP between the PC group and the no PC group (PC: 75% and No PC: 
76%, p>0.05). 
Bone Turnover Markers and LSP
Logistic regression using the binominal variable intervention PC and No PC disclosed 
no significant relationship between intervention and LSP Yes or No, thus allowing data 
from both interventions to be combined (n=93). In this group analysis, we found an 
LSP Yes in more than 85% (range 85-94) of those patients who had a P1NP decrease 
of more than 36% LSC and an LSP Yes in nearly 100% of those who had an s-CTX 
decrease of more than 29% LSC. Looking for a single optimal BTM for persistence 
prediction, we compared previously reported LSCs and two other censors: Median 
of Reference group (MedREF) and Median Absolute Deviation of Reference group 
(MedMAD). (see Table 3). 
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Listed data represent optimal LSC cut-off values for alendronate persistence at 12 
months according to LSP for P1NP and s-CTX. The outcomes P1NP and s-CTX levels 
were expressed as identifiable patient numbers (Yes/No). Censors were expressed 
at 3 and 12 months after study start. Besides the data obtained in the current study, 
IOF recommended cut-off values were also listed (see Table 3) [30,34]. The results for 
PINP and s-CTX at 3,6,9 months are comparable with the 12 month results (data not 
shown). Using underrunning median values obtained from the reference group led to 
similar results, but only with use of the MedREF censor. 
Discussion
In this study, we found no favorable effects of a dedicated telephone call intervention 
on standard care regarding persistence with bisphosphonates at 12 months. Note 
that this study was executed and analyzed within an FLS setting, which to our 
knowledge has not been studied before. This study as a whole encompasses real-life 
FLS practice with or without telephone calls and also BTMs for monitoring medication 
persistence per individual patient. 
We were able to study persistence with BTMs for the analysis of identifiable pharmacy 
deliveries in the early post-fracture phase and at one-year follow-up. BTMs in the first 
3 months post-fracture are notoriously hard to interpret because of the bias caused 
by fracture repair in this phase. As we are interested in the effects of treatment in 
that early post-fracture phase, we studied BTMs in the randomized study groups on 
alendronate and as a surplus in a group of postmenopausal osteopenic women (as 
a non-treated reference group) reflecting the natural course of BTMs post-fracture.
To substantiate BTMs and the pharmacy deliveries in the analysis of individual 
persistence, we cross-referenced the identifiable patients in our study groups to 
a Dutch exchange system on pharmacy deliveries (LSP). This system enables the 
exchange of healthcare data on pharmacy deliveries among authorized health care 
staff. First of all, the LSP system offers an overview of prescribed medication, but 
secondly it generates monitoring facilities of persistence, as nationwide more than 
11 million Dutch citizens (which is over 70% of the population) consented to giving 
healthcare staff access to their personal LSP data.
At the end of this study we found out firstly that telephone support of patients with 
an alendronate prescription after a recent fracture is not of importance regarding 
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persistence, which was about 75% (after exclusion of 26 patients who stopped taking 
bisphosphonates due to GI-related complaints or motivational issues) in both the PC 
and the no PC groups at one year. This finding differs entirely from the persistence of 
40% that was previously reported by Netelenbos and Geusens [12]. However, their 
study was based on the general osteoporotic population-based pharmacy deliveries 
of alendronate and is not a reflection of those patients starting alendronate soon 
after sustaining a fracture. Moreover, this difference in persistence could also be 
explained by the less intensive supervision of patients outside the closely monitored 
conditions of an RCT. Our findings are in line with the persistence of 74 to 88% found 
in the study on osteoporosis medication and persistence of Klop [13], who provided 
more differentiated data on persistence, taking a recent fracture into account as a 
discerning variable. 
Although telephone interventions did not influence persistence in our study, an 
important favorable effect of these phone calls was that patients who stopped taking 
alendronate were identified at an early stage. Of the patients who recently started 
taking alendronate and then stopped, the majority reported GI side effects as reason 
for stopping this medication. Any undetected cessation of alendronate therapy 
should be considered an FLS failure, which might be prevented by telephone calls at 
an early stage and offering alternatives, such as liquid or non-oral medication. 
Alendronate persistence is crucial in the long-term treatment for osteoporosis 
patients. Medication persistence in general regarding chronic conditions is reported 
to be low, and the World Health Organization (WHO) as well as the International 
Osteoporosis Foundation (IOF) declared the matter of persistence a major challenge 
to effective long-term management [35]. It is unfortunate that no effects of telephone 
intervention were confirmed. Finding no effects is, however, in line with other non-FLS 
initiated studies, see Table 1 [14-26,34].
Nevertheless, a number of FLS-initiated actions need to be taken to ensure persistence 
[36]. Firstly, personal encouragement of taking medication should continue shortly 
after any traumatic and painful event [37]. Secondly, it is important to try and solve the 
matter of underestimating the impact of sustaining a fracture and the low attendance 
of FLS patients, as we have shown previously in an FLS questionnaire study [11]. This 
low attendance at FLSs is a world-wide phenomenon, resulting in a major care gap. 
This notion was one of the main starting points for the CtF campaign. 
For observing persistence after initiating alendronate, BTMs can be used. However, 
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any biomarker used to monitor persistence may be influenced by fracture repair 
and bone union. Moreover, the effects of fracture repair could last for more than 
800 days, as was shown by data of our untreated reference group ((Fig. 2 (2.4 and 
2.5)). Therefore, we compared the course of BTMs since fracture, since start of study 
and also at 180 days post-fracture, based on data of the minimal wash-out period of 
fracture effects [38,39]. Notably, the outcomes at the various timepoints were similar.
Our findings support the results of the previous TRIO study that compared the 
persistence with several oral bisphosphonates by assessing P1NP and s-CTX and 
found that the use of BTMs is feasible [36]. In addition, we studied the individual 
persistence and our study revealed a promising exactness for s-CTX at 3 months. 
Compared to s-CTX precision, the reliability of P1NP for individual persistence at 12 
months is somewhat lower, as is shown in Table 3.
Notably, data of the current study are based on LSP outcomes per identifiable patient, 
while previous data were reported at group level. In general, persistence indicated via 
P1NP and s-CTX agreed fairly well for P1NP, i.e. 36% (current study) vs. 38% (TRIO 
study), but the LSC cut-off point for s-CTX was clearly low in the current study (29% vs. 
56% (TRIO study)). Note the importance of the time point at which the BTM samples 
were taken and of the patient’s physical condition at that moment. In our study, blood 
samples for BTM analysis were taken in recent fracture patients. Our next step was 
to study individual persistence after correction for outlying data due to biological 
variations caused by the very long wash-out period of fracture and fracture repair. 
Besides the Median of the reference group (MedREF) to calculate underrunning BTMs 
on alendronate treatment, we also compared persistence after correction for outliers 
as calculated with the MedMAD (see statistical paragraph) with most commonly used 
LSCs. Reference group-derived censors were compared to rule out effects for existing 
skewness and kurtosis of alendronate BTMs suppression and to avoid statistical bias 
of existing outliers and small sample size. However, use of reference-group-derived 
censors revealed no improvement in the prediction of alendronate persistence.
Several LSC thresholds have been reported using automated as well as manual 
assays. Roche Elecsys as used for this study is a commercially available assay and 
is widely used. Previously reported LSC declines were s-CTX lower than 27% and 
P1NP lower than 20% [30]. Clearly different LSCs have also been reported for several 
bisphosphonates, those for alendronate ranging from 38% to 56% [30,36]. These 
variations make it questionable whether the percentages reported for the same 
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bisphosphonate can also be ascribed to related factors, for example retrospective 
or prospective cohort analysis, ethnicity or time of fracture repair. Moreover, in 
previous studies calculations were based on patients with older osteoporotic 
fractures [28,30,33,36]. Therefore, we decided to study real-life outcome data from 
this RCT describing a prospective Dutch FLS treated group shortly after fracture using 
previously reported Dutch LSC cut-off levels. 
In our study, the presumed cut-off values reflecting persistence were rather similar to 
those reported by Rogers [30], which were 28% for P1NP and 25% for s-CTX versus 
36% and 29%, respectively, in our study. Regarding our calculated cut-off values, 
assessment of s-CTX at 3 months revealed to be best predictive on BTMs for one-year 
alendronate persistence. In more detail, in our study, an LSC of s-CTX lower than 29% 
or a level of less than 415 ng/L (MedREF) at 3 months agreed with nearly all except 
7 non-delivery cases. By contrast, these s-CTX cut-offs failed in 4 LSP-confirmed 
deliveries, see Table 3.
Comparing our results with the IOF-proposed LSCs showed less favorable results on 
pharmacy deliveries. The IOF cut-off levels, however, were not based on osteoporotic 
women with recent fractures [30,36].
In comparison to the high agreement regarding LSCs for both the time points 3 and 
12 months, similarity in results was found in using the reference-group-based censor 
MedREF (s-CTX <415 ng/L and P1NP <53 ug/L); at 3 and 12 months, s-CTX was 96% 
and 98% respectively, and P1NP was 76% and 97%, respectively. 
By contrast, less agreement was found at 3 months using the reference-group-based 
censor corrected for outliers MedMAD (s-CTX lower than 233 ng/L and P1NP lower 
than 30 µg/L); this was 75% for s-CTX and 42% for P1NP, respectively, although the 
difference decreased at 12 months and went up to 83% for s-CTX and 81% for P1NP. 
This study has some important limitations. Firstly, the sample size is fairly small but 
our results on the absence of effects of telephone calls are in our opinion robust and 
clear. A second limitation is the use of the non-treated reference group, which is small 
as well, but accepted statistical techniques such as pooling data made the outcome 
of the reference group useful and valuable, especially for the calculated MedREF and 
MedMAD besides LSC. Thirdly, a limitation worth mentioning may be the introduction 
of a potential Hawthorne effect (5 blood drawings) towards persistence. 
An important strength of this study was the use of identifiable LSP data, which served 
as proxy for persistence with any medication, for example treatment with alendronate. 
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To conclude, this FLS-initiated study showed an alendronate persistence of 75% 
after correction for individuals who had to stop taking bisphosphonates. Telephone 
intervention did not have an add-on eff ect to alendronate persistence in this study, 
but off ered the advantage of early detection of any reason for stopping medication. 
LSC, particularly that of s-CTX (compared to baseline BTMs level) after early drop-out 
(1 to 3 months) is a practical measure to be used in an FLS real-life situation to analyze 
persistence with alendronate after one year providing use of adequate cut-off  points. 
The weakness of this study is that outcome results have been reported in a small 
number of patients. Therefore, more FLS studies are needed to strengthen LSC data 
while comparing outcomes for diff erent treatments and diff erent populations. 
Fig 3. Algorithm on Alendronate Persistence Follow-up
Contributions.
PVDB, DHS and PVH are responsible for the study design. EVDV analyzed the BTMs 
and provided Reference Intervals and z-scores. PVDB and DHS were the authors, 
strongly supported by PVH, who also performed all statistical analyses. PG and JVDB 
supported the process with important scientifi c contributions during the analyses.
161
A dedicated Fracture Liaison Service telephone program and use of bone turnover markers
7
References
1. Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, Mitchell PJ, Silverman 
S, Singleton R, Siris E. Making the first fracture the last fracture: ASBMR task force report on 
secondary fracture prevention. J Bone Miner Res. 2012 Oct;27(10):2039-46. doi: 10.1002/
jbmr.1698. 
2. Lems WF, Dreinhöfer KE, Bischoff-Ferrari H, Blauth M, Czerwinski E, da Silva J, Herrera A, 
Hoffmeyer P, Kvien T, Maalouf G, Marsh D, Puget J, Puhl W, Poor G, Rasch L, Roux C, Schüler S, 
Seriolo B, Tarantino U, van Geel T, Woolf , Wyers C, Geusens P. EULAR/EFORT recommendations 
for management of patients older than 50 years with a fragility fracture and prevention of 
subsequent fractures. Ann Rheum Dis. 2016 Dec 22. pii: annrheumdis-2016-210289. doi: 
10.1136/annrheumdis-2016-210289. 
3. Huntjens KM, van Geel TA, van den Bergh JP, van Helden S, Willems P, Winkens B, Eisman JA, 
Geusens PP, Brink PR. Fracture liaison service: impact on subsequent nonvertebral fracture 
incidence and mortality. J Bone Joint Surg Am. 2014 19:96(4):e29. doi: 10.2106/JBJS.L.00223.
4.  Marsh D, Akesson K, Beaton DE, Bogoch ER, Boonen S, Brandi ML, McLellan AR, Mitchell PJ, Sale 
JE, Wahl DA; IOF CSA Fracture Working Group. Osteoporos Int. 2011 22(7):2051-65. doi: 10.1007/
s00198-011-1642-x.
5. Svedbom A, Hernlund E, Ivergård, M Compston J, Cooper C, Stenmark J, McCloskey EV, Jönsson B, 
Kanis JA & the EU review panel of the IOF Osteoporosis in the European Union: a compendium of 
country-specific reports. Arch Osteoporos. 2013 8:137 doi 10.1007/s11657-013-0137-0
6. Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, Kyer C, Cooper C (IOF 
Fracture Working Group). Capture the Fracture®: a Best Practice Framework and global 
campaign to break the fragility fracture cycle. Osteoporos Int. 2013 24(8):2135-52. doi: 10.1007/
s00198-013-2348-z.
7. Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, Eisman JA, March L, Seibel MJ (2013) 
Models of care for the secondary prevention of osteoporotic fractures: a systematic review and 
meta-analysis. Osteoporos Int. 24(2):393-406. doi: 10.1007/s00198-012-2090-y.
8. Mitchell PJ (2013) Best practices in secondary fracture prevention: fracture liaison services. Curr 
Osteoporos Rep. 11(1):52-60. doi: 10.1007/s11914-012-0130-3
9. Javaid MK, Kyer C, Mitchell PJ, Chana J, Moss C, Edwards MH, McLellan AR, Stenmark J, Pierroz 
DD, Schneider MC, Kanis JA, Akesson K, Cooper C; IOF Fracture Working Group; EXCO. Effective 
secondary fracture prevention: implementation of a global benchmarking of clinical quality 
using the IOF Capture the Fracture® Best Practice Framework tool. Osteoporos Int. 2015 
Nov;26(11):2573-8. doi: 10.1007/s00198-015-3192-0.
10. van den Berg P, Schweitzer DH, van Haard PM, van den Bergh JP, Geusens PP. Meeting 
international standards of secondary fracture prevention: a survey on Fracture Liaison Services 
in the Netherlands. Osteoporos Int. 2015 Sep;26(9):2257-63. doi: 10.1007/s00198-015-3117-y. 
11. Dutch Institute for Healthcare Improvement CBO (2011) Richtlijn Osteoporose en 
Fractuurpreventie. www.diliguide.nl/document/1015/file/pdf/. (Dutch) Accessed 19 December 
2015
12. Netelenbos JC, Geusens PP, Ypma G, Buijs SJ. Adherence and profile of non-persistence in patients 
treated for osteoporosis - a large-scale, long-term retrospective study in The Netherlands. 
Osteoporos Int. 2011 May;22(5):1537-46. doi: 10.1007/s00198-010-1372-5. 
13. Klop C, Welsing PM, Elders PJ, Overbeek JA, Souverein PC, Burden AM, van Onzenoort HA, 
Leufkens HG, Bijlsma JW, de Vries F. Long-term persistence with anti-osteoporosis drugs after 
fracture. Osteoporos Int. 2015 Jun;26(6):1831-40. doi: 10.1007/s00198-015-3084-3.
162
Chapter 7
14. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with 
antiresorptive treatment for postmenopausal osteoporosis: a randomised controlled trial. J Clin 
Endocrinol Metab. 2004;89(3):1117-1123. 
15. Schousboe JT, DeBold RC, Kuno LS, Weiss TW, Chen Y-T, Abbott TA III. Education and phone 
follow-up in postmenopausal women at risk for osteoporosis: effects on calcium intake, exercise 
frequency, and medication use. Dis Manag Health Outcomes. 2005;13(6):395-404 
16. Cooper A, Drake J, Brankin E; PERSIST Investigators. Treatment persistence with once-monthly 
ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. 
Int J Clin Pract. 2006;60(8):896-905.  
17. Delmas PD, Vrijens B, Eastell R, et al; Improving Measurements of Persistence on Actonel 
Treatment (IMPACT) Investigators. Effect of monitoring bone turnover markers on persistence 
with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 
2007;92(4):1296-1304. 
18. Cook PF, Emiliozzi S, McCabe MM. Telephone counselling to improve osteoporosis treatment 
adherence: an effectiveness study in community practice settings. Am J Med Qual. 2007;22(6): 
445-456. 
19. Shu AD1, Stedman MR, Polinski JM, Jan SA, Patel M, Truppo C, Breiner L, Chen YY, Weiss TW, 
Solomon DH. Adherence to osteoporosis medications after patient and physician brief education: 
post hoc analysis of a randomized controlled trial. Am J Manag Care. 2009 Jul;15(7):417-24. 
20. Waalen J, Bruning AL, Peters MJ, Blau EM. A telephone-based intervention for increasing the use 
of osteoporosis medication: a randomized controlled trial. Am J Manag Care. 2009;15(8):e60-e70. 
21. Solomon DH, Iversen MD, Avorn J, et al. Osteoporosis telephonic intervention to improve 
medication regimen adherence: a large, pragmatic, randomized controlled trial. Arch Intern Med. 
2012;172(6):477-483.
22. Tamone C, Fonte G, Panico A, Molinatti PA, D’Amelio P, Isaia GC. Impact of a phone follow-up 
program on persistence with teriparatide or PTH(1-84) treatment. Calcif Tissue Int. 2012;90(4): 
272-278. 
23. Stuurman-Bieze AG, Hiddink EG, van Boven JF, Vegter S. Proactive pharmaceutical care 
interventions decrease patients’ nonadherence to osteoporosis medication. Osteoporos Int. 
2014 Jun;25(6):1807-12. doi: 10.1007/s00198-014-2659-8.
24. Bianchi ML, Duca P, Vai S, Guglielmi G, Viti R, Battista C, Scillitani A, Muscarella S, Luisetto G, 
Camozzi V, Nuti R, Caffarelli C, Gonnelli S, Albanese C, De Tullio V, Isaia G, D’Amelio P, Broggi 
F, Croci M. Improving adherence to and persistence with oral therapy of osteoporosis. 2015 
May;26(5):1629-38. doi: 10.1007/s00198-015-3038-9. 
25. Hiligsmann M, Salas M, Hughes DA, Manias E, Gwadry-Sridhar FH, Linck P, Cowell W. Interventions 
to improve osteoporosis medication adherence and persistence: a systematic review and 
literature appraisal by the ISPOR Medication Adherence & Persistence Special Interest Group. 
Osteoporos Int. 2013 Dec;24(12):2907-18. doi: 10.1007/s00198-013-2364-z.
26. Gleeson T, Iversen MD, Avorn J, et al. Interventions to improve adherence and persistence with 
osteoporosis medications: a systematic literature review. Osteoporos Int. 2009; 20(12):2127-2134.
27. Genant HK, Wu CY, van Kuijk C, Nevitt MC. Vertebral fracture assessment using a semiquantitative 
technique. J Bone Miner Res. 1993 Sep;8(9):1137-48. 
28. Arends S, Spoorenberg A, Bruyn GA, Houtman PM, Leijsma MK, Kallenberg CG, Brouwer E, van der 
Veer E. The relation between bone mineral density, bone turnover markers, and vitamin D status 
in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int. 
2011 May;22(5):1431-9. doi: 10.1007/s00198-010-1338-7. 
163
A dedicated Fracture Liaison Service telephone program and use of bone turnover markers
7
29. https://www.vzvz.nl/uploaded/FILES/htmlcontent/Voorlichtingsmateriaal/Folder%20met%20
toestemmingsformulier%20-%20Engels.pdf. Assessed February 2017.
30. Diez-Perez A, Naylor KE, Abrahamsen B, Agnusdei D, Brandi ML, Cooper C, Dennison E, Eriksen EF, 
Gold DT, Guañabens N, Hadji P, Hiligsmann M, Horne R, Josse R, Kanis JA, Obermayer-Pietsch B, 
Prieto-Alhambra D, Reginster JY, Rizzoli R, Silverman S, Zillikens MC, Eastell R; Adherence Working 
Group of the International Osteoporosis Foundation and the European Calcified Tissue Society 
Working Group. Recommendations for the screening of adherence to oral bisphosphonates. 
Osteoporos Int. 2017 Mar;28(3):767-774. doi: 10.1007/s00198-017-3906-6. Epub 2017 Jan 16. 
31. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, 
Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA; IOF-IFCC Bone Marker Standards Working 
Group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis 
treatment: a need for international reference standards. Osteoporos Int. 2011 Feb;22(2):391-
420. doi: 10.1007/s00198-010-1501-1.
32. Leys, C., et al., Detecting outliers: Do not use standard deviation around the mean, use absolute 
deviation around the median, Journal of Experimental Social Psychology, Volume 49, Issue 4, July 
2013, pp. 764-766. 
33. Eekman DA, Bultink IE, Heijboer AC, Dijkmans BA, Lems WF. Bone turnover is adequately 
suppressed in osteoporotic patients treated with bisphosphonates in daily practice. BMC 
Musculoskelet Disord. 2011 Jul 21;12:167. doi: 10.1186/1471-2474-12-167.
34. Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R. Response of 
bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: 
the TRIO study. Osteoporos Int. 2016 Jan;27(1):21-31. doi: 10.1007/s00198-015-3145-
35. Sabaté E. Adherence to long-term therapies. Evidence for action. Geneva: World Health 
Organization, 2003 http://www.who.int/chp/knowledge/publications/adherence_report/en/. 
Published 2003. Accessed December 2015.
36. Ganda K, Schaffer A, Pearson S, Seibel MJ. Compliance and persistence to oral bisphosphonate 
therapy following initiation within a secondary fracture prevention program: a randomised 
controlled trial of specialist vs. non-specialist management. Osteoporos Int. 2014 Apr;25(4):1345-
55. doi: 10.1007/s00198-013-2610-4. 
37. Jacob L, Dreher M, Kostev K, Hadji P. Increased treatment persistence and its determinants in 
women with osteoporosis with prior fracture compared to those without fracture. Osteoporos 
Int. 2016 Mar;27(3):963-9. doi: 10.1007/s00198-015-3378-5. 
38. Wölfl C, Schweppenhäuser D, Gühring T, Takur C, Höner B, Kneser U, Grützner PA, Kolios L. 
Characteristics of bone turnover in the long bone metaphysis fractured patients with normal 
or low Bone Mineral Density (BMD). PLoS One. 2014 May 1;9(5):e96058. doi: 10.1371/journal.
pone.0096058. eCollection 2014.
39. Ivaska KK, Gerdhem P, Akesson K, Garnero P, Obrant KJ. Effect of fracture on bone turnover 
markers: a longitudinal study comparing marker levels before and after injury in 113 elderly 
women. J Bone Miner Res. 2007 Aug;22(8):1155-64.
164
8
165
SUMMARY
CHAPTER 8
166
Chapter 8
In order to strive for standardized and optimal FLS-care, a systematic, preferably 
coordinator-based, approach for identification, enrollment, evaluation, treatment 
and monitoring of patients with a fracture after the age of 50 years has been 
proposed (van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: 
implications for case finding and therapy. Nat Rev Rheumatol. 2012). After identification 
of patients, a detailed evaluation of medical history, medication use, clinical risk 
factors, vitamin D status, dietary calcium intake, known contributors to secondary 
osteoporosis and fall risk should then be performed, together with assessment 
of BMD and VFA. Next, patients need to be further evaluated for undiagnosed 
contributors to secondary osteoporosis and metabolic bone disorders. Then 
a multifactorial intervention should follow, including lifestyle management 
recommendations, calcium and/or vitamin D supplementation if required, and 
treatment of underlying disorders. Specific anti-osteoporotic treatment should be 
considered in line with national guidelines with organized follow-up of patients after 
3 months and annually, thereafter (Richtlijn Osteoporose en Fractuurpreventie - Dutch 
Institute for Healthcare Improvement - CBO 2011).
This dissertation consists of six studies on several aspects of secondary fracture 
prevention. We studied the Dutch FLS performance in Chapter 2. The hospital 
registration and patient-related factors that were associated with FLS attendance and 
non-attendance were studied in chapter 3 and in chapter 4 we further studied the 
reasons for non-attendance. In Chapter 5 we assessed if a Pulse Echo Ultrasound 
device enables identification of women with recent non-vertebral fractures at the FLS 
who would not need a DXA/VFA. In Chapter 6 we analyzed the daily calcium intake in 
FLS patients and in Chapter 7 the impact of telephone calls on one-year osteoporosis 
medication adherence was studied.
In Chapter 2 we evaluated the implementation of the “Capture the Fracture” 
standards proposed by the IOF in non-university hospitals in the Netherlands by 
questionnaire to gather information on the selection, evaluation and treatment 
of patients older than 50 years with a recent fracture. All 90 Dutch non-university 
hospitals received the invitation to participate in this survey which resulted in 24 
(27%) full responses, providing data of 24,468 consecutive patients, corresponding 
with 25% of fracture patients in the Netherlands in the year 2012. The data showed 
that all FLSs in the participating hospitals scored above 90% for the following Best 
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Practice Framework standards: identification of patients with a recent fracture in 
the hospitals, invitation for FLS, timing of assessment, identification of vertebral 
fractures, application of national guidelines, evaluation of secondary osteoporosis, 
drug initiation when indicated, communication with the general practitioner and 
application of follow-up strategy. Our data suggest that patients attending the 
Dutch FLSs were evaluated, treated and followed in high compliance with the IOF 
standards but with the major shortcoming that FLS’s attendance rates are low 
and that future research should focus on identification of the causes of this low 
attendance rate and ways to improve it.
In Chapter 3 we studied hospital registration and patient-related factors that were 
associated with attendance or non-attendance to the Fracture Liaison Service (FLS). 
During the process of this study, we found that there was an important invitation gap, 
indicating that 14% (278 out of 2006 consecutive patients with a fracture) was not 
invited at the FLS due to administrative errors. All 1288 patients that were invited at the 
FLS received a questionnaire. A total of 745 patients (of whom 537 attended and 208 
did not attend the FLS) returned an analyzable questionnaire. Non-attendance was 
associated with male gender, frailty, living alone, low education, being not interested 
in bone strength and being unaware of increased subsequent fracture risk (with 
Odds Ratios (ORs) between 1.62 and 2.08). Attendance was significantly associated 
with information perceived by the patient (OR: 3.32). Based on this study, failures 
in administrative fracture entry registration as well as frailty, male gender, having 
low general education, living alone, and low interest in bone health and subsequent 
fracture risk were independent determinants for FLS non-attendance. Adequate 
motivation of patients by the healthcare professional shortly after the fracture, or the 
lack of it, was the strongest determinant associated with both FLS attendance and 
non-attendance. Therefore, adequate registration processes and a more personal 
tailored approach with adequate patient information and shared decision making 
may improve FLS attendance rates.
In Chapter 4 we further analyzed the characteristics of patients who did not respond 
to an invitation for an FLS visit. Non-responders were traced and contacted by phone 
to consent with a home visit (HV) and to fill in a questionnaire or, if HV was refused, to 
receive a questionnaire by post (Q), in order to gain insight in their believes on fracture 
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cause and subsequent fracture risk. Of the 197 non-responders, 181 patients were 
traced and phoned until 50 consented with HV; 42 declined HV but consented with 
Q. Excluded were 8 Q-consenters to whom no choice was offered (either HV or Q) 
and 81patients who declined any proposition (non-HV|Q); 62% could recall the initial 
FLS invitation letter. Patient believes about the main causes of fracture significantly 
differed between HV and Q with regard to a fall (96% vs 79%), bad physical condition 
(36% vs 2%), dizziness or imbalance (24% vs Q 7%) and osteoporosis (16% vs 2%). Age 
≥70, woman gender and major fracture were significantly associated with consent for 
HV compared to Q (OR 2.7, 2.5 and 2.4, respectively) and HV compared to non-HV|Q 
(OR 16.8, 5.3 and 6.1). This study showed that FLS non-responders consider their 
fracture risk to be low. Note, 50 patients (about 25%) consented with a home visit 
after one telephone call, mainly older women with a major fracture. This subgroup 
of non-responders with high subsequent fracture risk is therefore presumably still 
approachable for secondary fracture prevention.
In Chapter 5 we evaluated whether the application of Pulse-Echo Ultrasound (P-EU) 
enables the identification of women with recent non-vertebral fractures at the FLS 
who would not need a DXA/VFA referral because they had no osteoporosis and/or 
subclinical vertebral fractures. In this cross-sectional study, 209 consecutive women 
of 50-70 years with a recent non-vertebral fracture (NVF) were studied at the Fracture 
Liaison Service (FLS) of one hospital. All women received DXA/VFA and P-EU (Bindex®) 
assessments. Various P-EU thresholds (based on the Density Index (DI, g/cm2)) were 
analyzed to calculate the best balance between true negative (indeed no osteoporosis 
and/or subclinical VF) and false negative tests (osteoporosis and/or subclinical VF 
according to DXA/VFA). 83 women had osteoporosis (40%) and 17 women at least one 
VF (8%). Applying the manufacturer’s recommended P-EU threshold (DI 0.844g/cm2) 
being their proposed cut-off for not having hip osteoporosis resulted in 77 negative 
tests (37%, 31% true negative and 6% false negative tests). A DI of 0.896 g/cm2 
resulted in 40 negative tests (19.3%) (38 true negative (18.3%) and 2 false negative 
tests (1.0%)). The application of P-EU enabled the identification of a proportion of 
women with recent non-vertebral fractures at the FLS who would not need a DXA/
VFA referral because they had no osteoporosis and/or subclinical vertebral fractures. 
The most conservative P-EU threshold resulted in 18.3% true negative tests verified 
by DXA/VFA against 1% false negative test results.
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In a dairy producing country such as the Netherlands (globally the second provider of 
dairy and agricultural products after the USA) milk consumption has been considered 
healthy and indispensable in a bone supporting menu mainly for the elderly. In 
Chapter 6 we investigated whether FLS patients complied with recommendations for 
daily calcium intake, and quantified the daily dairy calcium intake including milk, milk 
drinks, pudding, yoghurt, and cheese and compared outcomes with recent data of a 
healthy U.S. cohort (80% Caucasians). We collected data of 1526 female and 372 male 
FLS patients older than 50 years of age. On average, participants reported three dairy 
servings per day, independently of age, gender or population density. Median calcium 
intake from dairy was 790 mg/day in women and men. Based on dairy products 
alone, 11.3% of women and 14.2% of men complied with Dutch recommendations 
for calcium intake (adults ≤ 70 years: 1100 mg/day and >70 years: 1200 mg/day). After 
including 450 mg calcium from basic nutrition, compliance with the recommendation 
raised to 60.5% and 59.1%, respectively, compared to 53.2% in the U.S. cohort. While 
daily dairy calcium intake of Dutch fracture patients was well below the recommended 
dietary intake, it was comparable to intakes in a healthy U.S. cohort. These findings 
question recommendations for additional dairy products to preserve adult skeletal 
health, particularly when sufficient additional calcium is derived from adequate non-
dairy nutrition.
In Chapter 7 we focused on the treatment persistence in FLS patients who started 
with alendronate. Postmenopausal women with a recent fracture and osteoporosis 
who started alendronate were randomized to receive three phone calls (PC) (after 
1, 4, and 12 months) or no phone calls (no PC). s-CTX and P1NP were measured at 
baseline and after 3, 6, 9, and 12 months. As a reference group, 30 postmenopausal 
osteopenic patients with a recent fracture were analyzed as well. Persistence was 
assessed using the Dutch National Switch Point Pharmacies-GPs database and cross-
referenced with PC, no PC, and BTM changes. Cut-off values of BTMs were calculated 
based on least significant change (LSC) and also on underrunning median values of 
the untreated osteopenic postmenopausal reference group with a recent fracture. 
Out of 119 patients, 93 (78%) completed 12 months follow-up (45 PC and 48 no PC). 
Mean age was 69 years. Persistence was similar in PC and no PC participants. Using 
an optimal cut-off value > 29% (< 415 ng/L) as LSC of s-CTX and > 36% (< 53.1 μg/L) 
as LSC of P1NP, alendronate persistence after 1 year was 93 and 88% for PC and 
no PC, respectively. It was concluded that in this context, telephone calls did not 
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improve persistence. In around 90% of patients, the 1-year alendronate persistence 
was confirmed by levels beyond the LSC of s-CTX and P1NP at 12 months compared 
to baseline values.
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The work presented in this dissertation is focused on the key steps of secondary 
fracture prevention at the Fracture Liaison Service (FLS) (Fig.1) [1]. First, in Chapter 
2 a nationwide survey was performed on the implementation of quality standards in 
Dutch FLSs. Next, in Chapters 3 to 7 specifi c studies addressing FLS attendance and 
non-attendance, screening with peripheral ultrasound, evaluation of daily calcium 
intake and treatment persistence were performed based on data from the FLS of the 
‘Reinier de Graaf Gasthuis’ Delft, in the Netherlands.
Fig 1. The 5- key steps for secondary fracture prevention and the items addressed in this 
dissertation.
The FLS is supported by international and national scientifi c organizations as the 
most appropriate care model for secondary fracture prevention [2-6]. According to 
the Dutch guidelines, fracture risk assessment including clinical risk factors, DXA, VFA, 
laboratory testing and appropriate anti-osteoporosis treatment with adequate follow-
up is considered as standard service to off er to patients older than 50 years with 
a recent fracture [7]. The primary FLS objective is obviously to prevent subsequent 
fractures. Published data that originate from FLS initiatives with high quality standards 
and excellent rankings have shown favorable outcomes with regard to subsequent 
fracture risk and mortality risk after introduction of FLS care [8-11].
According to information from the Dutch nationwide hospital quality indicator sets, in 
2016 there were 90 non-university hospitals [12]. Although it is known that almost all 
Dutch hospitals deliver FLS care, detailed information about the implementation of 
quality standards was lacking. We, therefore performed a nationwide audit of Dutch 
FLSs, based on the 13 quality indicators defi ned by the Capture the Fracture® Best 
Practice Framework (CtF®-BPF) by the International Osteoporosis Foundation (IOF), 
[13-15] as described in Chapter 2 of this dissertation. Our fi ndings suggest that patients 
attending Dutch FLSs were evaluated, treated and followed-up with high compliancy 
using these IOF standards but with the major shortcoming that FLS attendance rates 
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were low. Although the outcomes in Chapter 2 are promising since responding FLSs 
showed optimal level CtF®-BPF related results, there may be bias to be accounted for 
since only 24 out of 90 FLSs responded to the questionnaire. Non-response bias to 
questionnaire studies is a well-known phenomenon and often under-estimated [16]. 
In particular respondents who perform well usually complete questionnaires [17,18]. 
Additionally non-response bias may also be caused by questionnaires that are too 
complex or extensive [17], which may be the case regarding the audit in Chapter 
2 since it was based on the rather complex IOF CtF®-BPF questionnaire. Access to 
detailed hospital and registration data was a requisite for completing many questions 
in this audit and this could have attributed to non-response bias. [18,19]. Finally, 
predefined criteria on how to calculate FLS-attendance were not provided.
The number of patients that attended the FLS as numerator in the calculation is 
usually well registered. However, for the denominator various numbers can be used 
depending on identification and selection of patients (such as the total number of 
patients with a fracture or the total number of patients with a fracture minus number 
of deceased patients or number of otherwise intentionally not invited for FLS visit for 
various reasons or other combinations).
Since 2012, Dutch hospitals have to provide FLS-related data based on “osteoporosis 
Quality Indicators” requested by Dutch healthcare authorities wherein the number 
of patients with a fracture (based on DBC fracture type codes) and the proportion 
of those patients that had a DXA should be reported yearly [12]. In general, this 
proportion is reported to be near 33% of all patients, with a range between 5-100% 
[12,20]. This Quality Indicator does only provide limited information and is not 
consistent with internationally propagated standards of care quality measuring tools. 
In addition, as in our audit, response bias is also likely to be present regarding the 
yearly reports of this indicator.
Attempting to overcome non-response bias due to complex audit tools and to avoid 
low quality audits, a patient-level key performance indicator (KPI) set was developed 
on behalf of the IOF [21]. This set of KPIs adds simple numerical data to process-
related scores by mentioning practical and comprehensible issues. For example, 
rather than measuring DXA numbers alone, it adds quality issues to FLS’s DXA 
performance (i.e. quality of readings, arrival of readings in time, active performance of 
fracture and fall risk assessment, consequent initiation of treatment after diagnosis 
and follow-up). It is important to note that any KPI-type audit is only feasible in case of 
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adequate registration of available data, software support and suffi  cient personnel to 
handle the extra workload [21]. This further emphasizes the importance of integrated 
registration and management of hospital data.
Case fi nding
Based on the fi ndings from our national audit as described in Chapter 2 and the 
Dutch national osteoporosis Quality Indicator set [12], we studied FLS attendance 
and non-attendance in more depth at the FLS in Delft in Chapter 3 and 4 of the 
dissertation. In these Chapters, we studied hospital registration and patient-related 
factors that were associated with attendance or non-attendance and we found 
that 14% of consecutive patients with a fracture was not invited at the FLS due to 
administrative errors. We also found that frailty, male gender, having low general 
education, living alone, and low interest in bone health and subsequent fracture 
risk were independent determinants of FLS non-attendance. Additionally, adequate 
patient information provided by the healthcare professional shortly after the fracture, 
or the lack of it, was the strongest determinant associated with both FLS attendance 
and non-attendance. As mentioned before, there are no uniform criteria for selection 
of patients to be invited at the FLS and for calculation of FLS’s attendance rates. 
Based on previously reported literature and on the Delft FLS experience described 
in Chapter 3 we developed the following fl owchart from fracture registration to 
attendance to characterize case fi nding for FLS invitation.
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Fig 2. Flow chart for FLS invitation of patients 50 years or older with a recent fracture.
While the IOF/Capture the Fracture® Best Practice Framework (CtF®-BPF) calls to 
strive for a 90% FLS attendance [13-15], it appears that in real life FLS attendance 
rates in the Netherlands are on average 30% and below 60% at its best [12,20]. We 
questioned whether the defi nition of ‘FLS-attendance’ attributes to misinterpretations. 
As presented in Fig 2, there can be various reasons that patients are not attending the 
FLS (Fig. 2). Subsequently, based on the way FLS attendance is calculated with N as 
nominator and a variation of combinations from A, C and F as denominator there is a 
need for a clear defi nition of FLS attendance rate.
In the IOF CtF®-BPF Questionnaire, the total number of attenders is divided by the 
total number of fracture registrations in patients => 50 years (N/A), while in the Dutch 
Quality Indicator, it is the total number of performed DXA scans divided by the total
number of fracture registrations in patients => 50 years (A). In both calculations, a 
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substantial proportion of registration errors are not included (B), being 14% in our 
study (Ch 3). Additionally, a substantial proportion of patients are intentionally not 
invited, depending on local FLS protocols (D + E). In our study this was 22% (Ch 3).
Obviously, the number of unintentional exclusions (B) must be kept as low as 
possible. Based on our own experience we calculated FLS-attendance based on entry 
(emergency dept. medical codes) and exit registrations (hospital financial codes). 
Calculations based on financial codes showed 65% FLS attendance (N/F) (see Fig 2.). 
However, if predetermined exclusions were not taken into account in the calculation, 
this number would drop to 41.9% (N/A).
In our opinion, uniformity in the definition of FLS attendance is needed, and this 
can be achieved by implementing a generally accepted formula. We propose to use 
the number of FLS attenders as nominator and the number of patients invited as 
denominator (N/F). When using this calculation, the number of patients intentionally 
not invited for FLS (D+E) also have to be provided.
After reviewing our invitation strategy, our FLS attendance rate was 65% using the 
formula N/F, which implied that one-third of patients we invited at the FLS did not 
receive FLS care. These patients can be divided in two groups, namely patients who 
responded and indicated that they did not feel the need for a FLS visit (G), which was 
only 1% of patients in our study (Ch 3). Therefore, almost all FLS non-attenders were 
non-responders to FLS invitation.
In Chapter 4 we intended to study the reasons for non-response by questionnaire 
and by home visits. We were able to reach 181 (92%) of 197 non-responders of whom 
50 patients (28%) consented with a home visit, while 42 patients declined our request 
but completed a posted questionnaire. Remarkably, in terms of time effort it was far 
easier to collect patients who consented with a home visit than those who refused a 
home visit but consented to complete the posted questionnaire. This finding may be 
a novel opportunity to be used in future FLS initiated secondary fracture prevention. 
The patients that consented with a home visit were mainly elderly women and most 
of them had sustained a major fracture. These women considered a fall, their bad 
physical condition, dizziness or balance problems to be the main cause of fracture 
and underestimated their bone condition as well as subsequent fracture risk. None 
of the patients could remember that information was provided face-to-face by the 
health professional during fracture treatment, despite the fact this is a standard 
procedure according to our local FLS protocol.
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Most (88%) of the FLS non-responders that agreed with a home visit had a hip, 
vertebral of major fracture (according to Warriner et al.) [22] reflecting index fractures 
with high subsequent fracture risk. In spite of this, many of these patients perceived 
their subsequent fracture risk being low or even neglectable. The findings in Chapter 
4 imply that a substantial proportion of FLS non-responders is approachable for 
secondary fracture prevention. Since these are mainly elderly women with perceived 
bad physical condition, dizziness or balance problems it may be important to 
involve general practitioners in providing optimal care for these patients and to 
consider home visits as an extension of the traditionally hospital based FLS care. 
Risk Evaluation
The risk of subsequent fractures is particularly high within the first years after a 
fracture in patients of 50 years and older [23,24]. This high and immediate risk of 
having subsequent fractures is referred to as ‘imminent fracture risk’[25,26].
This high imminent fracture risk stresses the need for evaluation and treatment 
decisions shortly after a fracture. Disappointingly, as shown in Chapter 4 there still is 
a knowledge gap among patients regarding the imminent subsequent fracture risk. 
Ideally, fracture risk evaluation is initiated as soon as possible during initial fracture 
treatment, preferably at the emergency or plaster room department. 
In Chapter 5 we studied whether the application of a non-ionizing peripheral Pulse 
Echo Ultrasound device (P-EU Bindex®) enables identification of women with recent 
non-vertebral fractures at the FLS who would not need a DXA/VFA. 
There is a wide variability of reports comparing peripheral ultrasound and central 
DXA outcomes [27-30], but to the best of our knowledge there are no data comparing 
peripheral ultrasound with DXA outcomes (osteoporosis Yes/No) including VFA 
(prevalent vertebral fractures Yes/No). Additionally. and in contrast to previous 
studies using the same device (P-EU Bindex®), we focused on the identification of 
women who would not need a DXA/VFA referral because they had no osteoporosis 
and/or subclinical vertebral fractures and not to use the P-EU outcomes for fracture 
risk prediction. We performed this study in 50 to 70 years old women with a recent 
fracture because we expected a priori low probability for osteoporosis and/or 
subsequent vertebral fractures on VFA [31,32]. We found that the most conservative 
P-EU threshold resulted in 18.3% true negative DXA/VFA results against 1% false 
negative results.
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Since this was a study performed at the FLS, in a small group of women of 50–70 
years and not among older women and/or men, the results cannot be extrapolated 
to the total group of patients with a fracture, especially elderly women or men. Also, 
the percentage of osteoporosis was higher and the number of subclinical VFs was 
smaller than expected. Therefore, further studies in a larger cohort of patients of 
50 years and older including men are needed. In addition, this study was performed 
at the FLS, but should be ideally performed in the ER or plaster room setting. This 
would also allow to study a potential added value of screening patients in the early 
phase of fracture care, namely if a ‘positive’ P-EU test would attribute to a higher FLS 
attendance rate. Since “nudging”, meaning influencing people’s behavior is promising 
as it usually does not rely on the transfer of often complex health information [33], 
it is easier to reach patients with limited health literacy [34]. Therefore, the effect of 
“nudging” by a ‘positive’ P-EU test at the plaster room on FLS attendance rates is one 
of the future directives of our Delft FLS research planning.
Differential diagnosis
The 3rd of the 5 key steps of secondary fracture prevention (Fig. 1) was not a part of 
the dissertation.
Therapy: calcium intake
In the context of the 4th step, we aimed to analyze whether FLS patients complied 
with recommendations for daily calcium intake with specific focus on calcium 
intake from dairy products and complete nutrition in chapter 6. Today, there is still 
debate in the necessary amount of dietary calcium intake i.e. in dairy products and 
in non-dairy nutrition to preserve adult skeletal health and advices on intake are 
variable and country dependent [35]. Like in many other Western countries, Dutch 
recommendations on dairy consumption are based on authority-based opinions [36].
In chapter 6, we found that mean calcium intake from dairy products was 790 mg/day 
in both female and male FLS attenders older than 50 years. Based on calcium intake 
from dairy products alone, 11.3% of women and 14.2% of men complied with Dutch 
recommendations (adults ≤ 70 years: 1100 mg/day and >70 years: 1200 mg/day) [7]. 
There were no differences between urbanized and countryside living patients. We 
calculated the total nutritional calcium intake based on the number of dairy servings 
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per day plus 450 mg calcium from non-dairy nutrition based on the RIVM “Dutch 
National Food Consumption Survey 2007-2010: Diet of children and adults aged 7 
to 69 years” (DNFCS)) [37]. When daily calcium intake was calculated based on the 
average 450 mg from basic nutrition plus dairy intake, 60.5% of women and 59.1% of 
men complied with Dutch recommendations.
Based on the ease to estimate calcium intake from nutrition and our study outcome, 
we recommend that FLS nurse specialists (i.e. nurses, nurse practitioners and 
physician assistants) implement the assessment of dietary calcium intake of FLS 
patients in their daily routine. Additionally, tailor made dietary advices and, if needed 
prescribing calcium supplements should be provided in order to strive for a total daily 
calcium intake of 1100-1200 mg per day. If there appears to be any food intolerance, 
consultation of a dietician and oral calcium supplementation should be considered.
Follow-up
In the 5-step approach, treatment with anti-osteoporosis medication and adequate 
follow-up is the last and major pillar of fracture prevention. Initiation of medication 
at the FLS is encouraged by international and national experts, however if FLS 
attendance remains low, the treatment gap will not be closed. Another important 
issue regarding the treatment gap is treatment persistence. In the Netherlands, the 
one-year persistence of oral anti-osteoporosis medication was reported to be 45-
50%, and about a third of patients stopped taking anti-osteoporosis medication by 3 
months [38]. A higher persistence of 75% was found in FLS patients [39].
The concepts of adherence and persistence are regularly used interchangeably 
but basically medication adherence refers to ‘the extent to which a patient acts 
in accordance with the prescribed interval and dose of a dosing regimen’ while 
persistence refers to ‘the duration of time from initiation to discontinuation of 
therapy’. Reasons for medication non-adherence and non-persistence are numerous 
and multidimensional and it is mandatory to understand the problem and the extent 
in order to identify solutions. Promising tailor-made actions include patient education 
with counselling, adherence monitoring with feedback and dose simplification 
including flexible dosing regimen [40]. A number of methods to improve medication 
persistence have been reported, such as telephone-based interventions [41,42] and 
tailored pharmaceutical care interventions including counseling sessions with non-
adherent patients [43]. Since the response of bone turnover markers (BTMs) can be 
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used to monitor the effect of anti-osteoporosis treatment [44], this response can also 
be used to counsel patients during treatment [45].
In a recent systematic review, it was reported that patient education, monitoring 
and supervision, changing drugs regimens and interdisciplinary collaboration 
had mixed results on persistence and adherence [46]. More positive effects were 
found for multicomponent interventions with active patient involvement, including 
individualized solutions based on patient and healthcare providers` collaboration, 
counseling and shared decision making [46]. In the Netherlands the National Switch 
Point infrastructure (Landelijk Schakelpunt (LSP)) can be used to verify the last 
medication delivery to patients that consented with registration of their medication 
in this system [47].
In Chapter 7, we studied the influence of telephone calls and the predictive value 
of changes in bone turnover markers for evaluating persistence with alendronate. 
Persistence was objectified by LSP data. In this study, one-year alendronate persistence 
was 75% after correction for individuals who had to stop taking bisphosphonates (GI-
effects and motivational issues to take oral bisphosphonates). These findings are in 
line with of another Dutch study in FLS patients [39]. We found that telephone calls did 
not have an add-on effect to alendronate persistence, but they offered the advantage 
of early detection of patients that stopped taking medication and the reason for it. 
An important contributive effect was that side effects could be detected at an early 
phase of treatment with the opportunity to switch to IV or SC administration of anti-
osteoporosis medication.
A decrease of the BTMs CTX and PINP at 3 months below the cut-off level that 
represented the least significant change, predicted nearly all LSP confirmed deliveries. 
This finding shows that monitoring of BTMs can be used in clinical practice in FLS 
patients using oral alendronate, despite the fact that BTMs are increased shortly 
after a fracture and gradually decrease over a period of months [44]. Apparently, the 
suppression of BTMs during treatment with alendronate is strong enough to induce 
a decrease greater than the least significant change.
According to the Dutch guidelines, a visit or telephone call at 3 months after 
treatment initiation is advocated [7]. This study (Chapter 7) showed that a contact at 
3 months offered the advantage of early detection of side effects allowing a switch 
of medication before patients stop taking medication and early detection of patients 
that already stopped taking medication. We believe that it would be of additional 
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value to evaluate treatment persistence by measuring BTMs at this timepoint in 
combination with verification of pharmacy deliveries in patients that gave permission 
for this registration (LSP).
Future perspectives.
FLS care is widely available and accessible in the Netherlands. FLSs increase the 
likelihood of BMD testing and treatment initiation. In this dissertation we studied 
a number of knowledge gaps in case finding strategies and in patient knowledge 
about the cause of their fracture and risk of subsequent fracture. Overall there is the 
need for efforts to reduce gaps regarding the implementation of case finding and to 
improve patients’ knowledge gaps on subsequent fracture risk.
First, in order to further improve FLS care and to evaluate its performance in 
approaching patients for secondary fracture prevention in the Netherlands, we will 
need a standardized method for calculation of FLS attendance, taking into account 
exact and timely fracture registration as well as the in- and exclusion criteria for 
invitation. Our proposed FLS-attendance calculation aims at standardization and 
therefore adequate comparison of attendance rates between and within FLS facilities 
based on adequate reporting.
Second, there is need for evaluation of how information procedures can be improved 
towards patients with a recent fracture. There is a need for improving access to early 
diagnostic procedures during fracture treatment including immediate evaluation of 
clinical risk factors, scheduling immediate appointments for DXA, VFA and lab, and to 
intensify collaboration with Geriatric Trauma Units after hip or other major fractures 
that require hospitalization. Possibly screening strategies with peripheral devices such 
as ultrasound may contribute to further improvement of the diagnostic evaluation. 
Initiatives enabling early diagnostic procedures will contribute to the application of 
personalized medicine in the FLS. Questions such as in which patients one can omit 
diagnostics or start treatment immediately must be answered by scientific evidence. 
These questions are still to be studied in the clinic and at patients’ private homes. 
Herein, further studies by and with FLS nurse specialists are needed to evaluate its 
effects on secondary fracture prevention.
The Multidisciplinary Trauma Unit (MTU) is a mandatory collaboration to be started in 
2020 on behalf of the scientific associations of trauma (NVT) and orthopedic surgeons 
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(NOV). Being in close cooperation with the MTU, it should be evaluated how FLS 
nurse specialists can establish and maintain contact with general practitioners and 
geriatricians or physicians in nursery homes. This new concept of MTU-care and its 
impact on FLS care should be evaluated.
This is the one of the first dissertations on nurse practitioner’s-initiated research at 
the FLS. In this dissertation, we intended to contribute to FLS-related research from 
a nurse specialist’s perspective. We believe that FLS nurse specialists (nurses, nurse 
practitioners and physician assistants) play an important role in secondary fracture 
prevention. In total 145 nurse specialists (of whom 66 nurse practitioners and/
or physician assistants) are (part-time) active in 74 FLSs divided amongst 72 non-
academic and 8 academic hospitals in the Netherlands. It is therefore important that 
nurse specialists are united in a solid organization focusing on further improvement 
of quality and knowledge of FLS care by combining patient care, management and 
research. In this context, future research should not only focus on adequate diagnosis, 
initiation and follow-up of treatment but also on other outcomes of FLS care such as 
improvement of quality of life and the reduction of fracture risk and mortality risk.
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SAMENVATTING
Met als doel een gestandaardiseerde en optimale zorg op een Fractuur & 
Osteoporose polikliniek (Fracture Liaison Service, FLS) na te streven, wordt een 
systematische, en bij voorkeur coördinator gestuurde aanpak voor identificatie, FLS 
aanmelding, evaluatie, behandeling en monitoring van patiënten met een recente 
fractuur van 50 jaar en ouder geadviseerd*. Na identificatie van de patiënten met een 
recente fractuur, wordt aanbevolen een gedetailleerde evaluatie van de medische 
voorgeschiedenis, medicatiegebruik, klinische risicofactoren, vitamine D-status, 
calciuminname met de voeding, bekende veroorzakers van secundaire osteoporose 
en valrisico uit te voeren, gelijktijdig met een beoordeling van botmineraaldichtheid 
(BMD) en Vertebral Fracture Assessment (VFA, beeldvorming van de wervelkolom). 
Vervolgens wordt aanbevolen dat patiënten verder worden geëvalueerd op niet 
eerder gediagnosticeerde oorzaken van secundaire osteoporose en metabole 
botaandoeningen. Aansluitend volgt een multifactoriële interventie, inclusief 
aanbevelingen voor leefstijl, calcium- en / of vitamine D-suppletie indien vereist en 
indien nodig een behandeling van onderliggende aandoeningen. Specifieke anti-
osteoporose behandeling moet worden aangeboden in overeenstemming met 
nationale richtlijnen en met een georganiseerde patiënten follow-up na 3 maanden 
en daarna jaarlijks (Richtlijn Osteoporose en Fractuurpreventie; Nederlands Instituut 
voor Verbetering van de Gezondheidszorg; CBO 2011).
Dit proefschrift bestaat uit zes onderzoeken naar verschillende aspecten van secundaire 
fractuurpreventie. We hebben de implementatie van FLS in Nederlandse Fractuur & 
Osteoporose poliklinieken bestudeerd in Hoofdstuk 2. De ziekenhuisregistratie en 
patiënt-gerelateerde factoren die geassocieerd waren met het al dan niet bezoeken 
van de FLS werden bestudeerd in Hoofdstuk 3 en in Hoofdstuk 4 hebben we de 
redenen voor het niet bezoeken van de FLS verder onderzocht. In Hoofdstuk 5 hebben 
we onderzocht of een Pulse-Echo Ultrasound apparaat de identificatie mogelijk maakt 
van vrouwen met een recente niet-wervel fractuur op de FLS die geen DXA/VFA nodig 
zouden hebben. In Hoofdstuk 6 hebben we de dagelijkse calciuminname bij FLS 
patiënten geanalyseerd en in Hoofdstuk 7 werd de impact van telefoongesprekken op 
de therapietrouw van osteoporose medicatie gedurende één jaar bestudeerd.
* van den Bergh JP, van Geel TA, Geusens PP. Osteoporosis, frailty and fracture: implications 
for case finding and therapy. Nat Rev Rheumatol. 2012
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In Hoofdstuk 2 hebben we de implementatie van de fractuur en osteoporosezorg 
in Nederlandse niet-universitaire ziekenhuizen geëvalueerd met gebruik van een 
vragenlijst aan de hand van de vastgestelde FLS zorgstandaarden geformuleerd door 
de International Osteoporosis Foundation (IOF) in het Capture the Fracture Best 
Practice Framework (CtF-BPF) om informatie te verzamelen over de behandelsituatie 
in Nederland ten aanzien van casefinding, de risico evaluatie en de ingestelde 
behandelingen bij patiënten van 50 jaar en ouder na een recente fractuur. Alle 
(toen nog) 90 Nederlandse niet-universitaire ziekenhuizen kregen de uitnodiging om 
deel te nemen aan dit onderzoek. Dit resulteerde in 24 (27%) volledig evalueerbare 
vragenlijsten, met gegevens van 24.468 opeenvolgende patiënten, wat overeenkomt 
met 25% van alle patiënten ouder dan 50 jaar met een fractuur in Nederland, in het 
jaar 2012. De gegevens toonden aan dat alle deelnemende ziekenhuizen boven de 
90% scoorden voor de volgende CtF-BPF normen: identificatie van patiënten met een 
recente fractuur in de ziekenhuizen, uitnodiging voor FLS, timing van beoordeling, 
identificatie van wervelfracturen, toepassing van nationale richtlijnen, evaluatie van 
secundaire osteoporose, start met medicatie indien geïndiceerd, communicatie 
met de huisarts en de toepassing van een vervolgstrategie. Deze bevindingen 
suggereren dat het merendeel van de Nederlandse FLS-en die de vragenlijst 
invulden voldoen aan de criteria van het `beste FLS-model` (gebaseerd op de CtF-
BPF zorgstandaarden), waaronder de aanwezigheid van een gespecialiseerde FLS 
verpleegkundige, een hoogwaardige FLS service en wanneer geïndiceerd de start van 
anti-osteoporosemedicatie. Een ander belangrijk onderzoeksresultaat was dat van 
alle geïdentificeerde fractuurpatiënten slechts 50% op de uitnodiging inging en de FLS 
bezocht. We concludeerden dat patiënten die deze FLS-en bezochten, in hoge mate 
werden geëvalueerd, behandeld en opgevolgd volgens de CtF-BPF zorgstandaarden. 
Een belangrijke tekortkoming blijkt te zijn dat te weinig uitgenodigde patiënten 
daadwerkelijk de FLS bezochten. Toekomstig onderzoek zou zich zou moeten 
concentreren op het identificeren van de oorzaken van deze lage komst naar de FLS 
en het zoeken naar manieren om het te verbeteren.
In Hoofdstuk 3 hebben we ziekenhuisregistratie en patiënt-gerelateerde factoren 
bestudeerd die verband hielden met het al dan niet bezoeken van de FLS door 
fractuurpatiënten die waren uitgenodigd in 2016.  Tijdens deze studie werd aangetoond 
dat 14% van de fractuurpatiënten, 278 van 2006 opeenvolgende patiënten, vanwege 
administratieve fouten niet was uitgenodigd de FLS te bezoeken. Alle 1288 patiënten 
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die wèl werden uitgenodigd voor FLS bezoek kregen een vragenlijst toegestuurd. In 
totaal stuurden 745 patiënten (van wie 537 wèl de FLS bezochten en 208 de FLS niet 
bezochten) een analyseerbare vragenlijst terug. Het niet bezoeken van de FLS kon 
worden geassocieerd met mannelijk geslacht, een kwetsbare gezondheid, het alleen 
wonen, een laag opleidingsniveau, het niet geïnteresseerd zijn in de kwaliteit van 
het bot en het niet op de hoogte zijn van een toegenomen opvolgend fractuurrisico 
(met Odds Ratio’s; OR’s) tussen 1.62 en 2.08). Het wèl bezoeken van de FLS was 
significant geassocieerd met aan de patiënt verstrekte informatie (OR: 3.32). Uitkomst 
van deze studie toonde aan dat uitnodigen op basis van een onvolledige registratie 
leidde tot het onterecht niet oproepen van 14% van alle patiënten. Daarnaast 
toonde dit onderzoek dat mannelijk geslacht, kwetsbare gezondheid, een lage 
algemene opleiding, het alleen-wonen en een lage interesse in botgezondheid en het 
opvolgende fractuurrisico onafhankelijke determinanten zijn voor het niet ingaan op 
de FLS uitnodiging.  Het al dan niet motiveren van patiënten door de behandelende 
zorgverlener kort na het doormaken van de fractuur was de sterkste determinant 
geassocieerd met het wel of niet bezoeken van de FLS. Het is van belang de DBC 
registratie te gebruiken die het ziekenhuis ook gebruikt voor de facturatie voor 
het uitnodigingsproces op de FLS en te werken aan een FLS uitnodigingstraject op 
maat waarin de zorgverlener met hulp van adequate patiëntinformatie en gedeelde 
besluitvorming het FLS bezoek kan verbeteren.
In Hoofdstuk 4 hebben we onderzocht of screening met een draagbaar ultrasound 
apparaat interessant zou kunnen zijn om verwijzingen voor Dual X-Ray Absorptiometry 
(DXA) en Vertebral Fracture Assessment (VFA) te beperken. We hebben het aantal 
negatieve DXA/VFA uitkomsten voor osteoporose en/of subklinische wervelfracturen 
(VF’s) berekend en vergeleken met uitkomsten van Pulse-Echo Ultrasonometry (P-UE) 
op basis van verschillende drempelwaarden. In deze cross-sectionele studie werden 
209 opeenvolgende vrouwen van 50-70 jaar met een recente niet-wervelfractuur (NVF) 
onderzocht op de Fracture Liaison Service (FLS) van het Reinier de Graaf gasthuis in 
Delft. Deze vrouwen kregen naast DXA / VFA ook een P-EU (Bindex®) -beoordeling. 
Verschillende P-EU-drempelwaarden (gebaseerd op de P-EU dichtheidsindex 
(DI, g/cm2)) werden geanalyseerd om de beste balans te berekenen tussen echt-
negatief (inderdaad geen osteoporose en/of subklinische VF) en fout-negatieve 
tests (osteoporose en/of subklinische VF volgens DXA / VFA). 83 vrouwen hadden 
osteoporose (40%) en 17 vrouwen tenminste één VF (8%). Het toepassen van de 
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door de fabrikant aanbevolen P-EU drempelwaarde (DI 0.844 g/cm2) als voorgestelde 
grenswaarde voor het niet hebben van osteoporose in de heup(hals) resulteerde 
bij 77 vrouwen in negatieve testen (37%, 31% echt-negatieve en 6% fout-negatieve 
tests). Een DI van 0.896 g/cm2 resulteerde bij 40 deelnemende vrouwen in een 
negatieve test (19.3%) (38 echt-negatieve (18.3%) en 2 fout-negatieve testen (1.0%). 
Uit de onderzoeksresultaten blijkt dat door de toepassing van P-EU een deel van de 
deelnemende vrouwelijke fractuurpatiënten tussen 50-70 jaar geen DXA/VFA nodig 
zou hebben omdat er geen osteoporose en/of subklinische wervelfracturen werden 
aangetoond. De toepassing van de meest conservatieve P-EU drempelwaarde (0.896 
g/cm2) resulteerde in 18.3% echt-negatieve testresultaten tegen 1% fout-negatieve 
testresultaten geverifieerd door DXA/VFA in de onderzochte groep vrouwen 50-70 na 
een recente fractuur. 
In Hoofdstuk 5 hebben we de kenmerken van patiënten die niet ingingen op de FLS 
uitnodiging verder geanalyseerd door hen tijdens een huisbezoek (HV) door een 
FLS medewerkster een vragenlijst in te laten vullen of, als HV werd geweigerd, een 
vragenlijst per post toe te sturen (Q) om inzicht te krijgen in hun mening over de 
oorzaak van de fractuur en hun mening te vragen over het opvolgende fractuurrisico. 
Van deze 197 fractuurpatiënten die niet reageerden op de FLS uitnodiging (non-
responders) werden 181 patiënten opgespoord en gebeld totdat 50 van hen met 
HV instemden. 42 patiënten weigerden HV, maar stemden in met Q, 81 patiënten 
wezen elk voorstel af (non-HV | Q). Van de HV en Q-patiënten kon 62% zich de eerste 
FLS uitnodigingsbrief herinneren. De mening van de patiënt over de belangrijkste 
oorzaak van fracturen verschilde tussen HV en Q en was: de val (HV 96% versus Q 
79%, p = .02), slechte fysieke conditie (HV 36% versus Q 2%, p = .0001), duizeligheid 
of disbalans (HV 24% versus Q 7%, p = .03), osteoporose (HV16% versus Q 2%, p = 
.02) en verhoogd fractuurrisico (HV 26% versus Q 17%, NS). Leeftijd ≥70, vrouwelijk 
geslacht en een ernstige fractuur waren significant geassocieerd met toestemming 
voor HV in vergelijking met Q (respectievelijk OR 2.7, 2.5 en 2.4) alsook HV vergeleken 
met non-HV|Q (OR 16.8, 5.3 en 6.1). FLS non-responders achten hun opvolgende 
fractuurrisico laag. Toch stemde 25% in met een huisbezoek na één telefoontje, 
voornamelijk oudere vrouwen na een ernstige fractuur. Deze subgroep van FLS 
non-responders met een hoog daaropvolgend fractuurrisico lijkt dan ook goed 
benaderbaar voor secundaire fractuurpreventie.
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In Hoofdstuk 6 hebben we onderzocht of patiënten met een recente fractuur voldeden 
aan de aanbevelingen voor dagelijkse calciuminname en de gekwantificeerde 
dagelijkse calciuminname uit zuivel (melk, melkdranken, pudding, yoghurt en kaas) 
in een Nederlands cohort van fractuurpatiënten en de resultaten vergeleken 
met recente gegevens van een gezond Amerikaans cohort (80% kaukasisch). Dit 
observationele onderzoek analyseerde de calciuminname van 1526 vrouwelijke en 
372 mannelijke Nederlandse fractuurpatiënten van 50 jaar en ouder die de FLS van 
het Reinier de Graaf Gasthuis bezochten. De deelnemers namen  gemiddeld drie 
porties melk per dag, onafhankelijk van leeftijd, geslacht of bevolkingsdichtheid. De 
mediane calciuminname uit zuivel was 790 mg/dag bij vrouwen en mannen. Op basis 
van zuivelproducten alleen voldeed 11,3% van de vrouwen en 14,2% van de mannen 
aan de Nederlandse aanbevelingen voor calciuminname (volwassenen ≤ 70 jaar: 
1100 mg / dag en >70 jaar: 1200 mg / dag). Met een aanvullende berekening waarbij 
uitgegaan werd van 450 mg calcium uit de basisvoeding voldeed respectievelijk 
60.5% en 59.1% aan de Nederlandse aanbevelingen vergeleken met 53.2% in 
Amerikaanse cohort. Hoewel de dagelijkse zuivelcalciuminname van Nederlandse 
fractuurpatiënten ver onder de aanbevolen inname lag, was deze vergelijkbaar met 
de inname in een Amerikaans cohort (met/zonder fracturen) uit een studie van 
Fulgoni. Tijdens de anamnese naar de consumptie van calcium dient men niet alleen 
het aantal zuivelproducten maar ook de overige voeding mee te tellen. 
In Hoofdstuk 7 hebben we ons gericht op de medicatie persistentie van patiënten 
die na FLS bezoek met orale anti-osteoporose behandeling (alendronaat) waren 
begonnen. Postmenopauzale vrouwen na een recente fractuur en osteoporose 
die met alendronaat begonnen, werden gerandomiseerd om drie ondersteunende 
telefoongesprekken te krijgen (PC) (na 1, 4 en 12 maanden) of geen ondersteunende 
telefoongesprekken (no PC) te krijgen. De botombouw merkstoffen (BM) s-CTX en 
P1NP werden gemeten bij aanvang van het onderzoek (vóór medicatiestart) en na 3, 6, 
9 en 12 maanden. Als referentiegroep werden ook 30 postmenopauzale osteopenie 
patiënten met een recente fractuur geanalyseerd. De medicatie persistentie werd 
beoordeeld met behulp van het Landelijk Schakelpunt (LSP) waarin de afleverdata 
van apotheken door geauthoriseerde zorgverleners kunnen worden ingezien) en 
vergeleken met PC, no PC en de veranderingen in de BM. De afkapwaarden van 
de BM werden berekend op basis van de “kleinste significante verandering” (Least 
Significant Change, LSC) evenals op het onderschrijden van de mediane waarden 
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van de onbehandelde postmenopauzale osteopenie referentiegroep na een 
recente fractuur. De onderzoeksresultaten toonden dat van de 119 patiënten, 93 
patiënten (78%), gemiddelde leeftijd 69 jaar, na 12 maanden medicatie persistent 
waren (45 PC en 48 no PC). Deze persistentie was vergelijkbaar tussen de PC en 
de no PC deelnemers. De BM afkapwaarde voor s-CTX werd bepaald op >29% 
(<415 ng/L) als LSC en voor P1NP op >36% (<53,1 μg/L) als LSC. De afkapwaarden 
toonden alendronaat persistentie bij respectievelijk 93 en 88 % van de patiënten. 
Wij concludeerden dat telefoongesprekken in dit verband de medicatie persistentie 
niet verbeterden. Bij ongeveer 90% van de patiënten werd de 1-jaars persistentie 
ten aanzien van alendronaat bevestigd door het bereiken van LSC van s-CTX en van 
P1NP, waarbij de uitgangswaarden werden vergeleken met waarden na 3,6,9 en 12 
maanden.
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Valorization
VALORIZATION
Introduction
This chapter describes valorization of a number of our findings in this dissertation, 
focusing on secondary fracture prevention and the Fracture Liaison Service (FLS), from 
a nurse practitioner`s perspective. The importance of Secondary fracture prevention 
in general is recognized and supported by the International Osteoporosis Foundation 
(IOF) and by other international and national scientific organizations and authorities. 
In view of effectiveness, FLS care has become highly recommended. However, the 
low FLS attendance rate of patients with a recent fracture has been recognized as 
a huge problem needing further exploration. In this dissertation, we examined the 
following topics related to secondary fracture prevention: hospital registration, patient 
information and patient knowledge about their subsequent fracture risk, value of a 
portable ultrasound device in screening, nutritional calcium intake and medication 
adherence. 
Valorization
In the Reinier de Graaf Hospital, we discovered that 14% of patients older than 
50 years with a fracture were not invited at the FLS, due to hospital registration 
inaccuracies. The cause is that FLS invitation strategies are traditionally based 
on hospital registrations at entry, not on exit registration and between these time 
points a diagnosis of fracture could have been added. Use of financial department 
registrations (using exit DBC registrations) is recommended to increase the accuracy 
of FLS invitation.  
The second topic studied is patient information, which is part of our invitation strategy 
to attend the FLS. Surprisingly, our personal information given to the patient was 
not recalled by any of our non-attending fracture patients. In contrast, more than 
half of FLS attenders could recall the information letter received as a reason to 
attend the FLS. We also observed a major knowledge gap regarding the increased 
imminent subsequent fracture risk, which was often grossly underestimated.  The 
main reasons were low interest in bone health and (according to the literature) low 
health illiteracy. These findings emphasize the need for a systematic FLS nurse-led 
approach to ensure adequate and timely information to patients, preferentially as 
soon as possible after the initial fracture, e.g. during the fracture healing phase. This 
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practice has been routinely implemented in the Reinier de Graaf Hospital FLS setting. 
Patient information is given by our plaster nurses and/or orthopedic and trauma 
surgeons, but still needs improvement so that patients recall this information. 
Another topic addressed in this dissertation is the reinforcement of screening 
procedures. By using a portable ultrasound device, we yielded a 19 percent benefit 
by avoiding the performance of DXA and VFA in low risk women of 50-70 years. 
In addition, this might be attractive as a moment of persuasion to strengthen the 
message to our patients, since a ‘positive’ outcome could motivate patients to agree 
with further assessment by DXA and VFA, while a negative outcome could reassure 
patients without the need of further assessments. However, it should be further 
evaluated whether the same holds for elderly patients.
We also performed an audit in the Netherlands on Dutch FLS quality using the 
Capture the Fracture® (CtF®) Best Practice Framework Standards of Care. FLS 
attendance reported by 24 Dutch FLS’s was on average 49%, which obviously is too 
low. In FLS attenders the FLS’s complied for more than 90% on the 13 CtF® Standards 
of care and for more than 70% with fall prevention strategies. Currently there is no 
nationwide database on patients evaluated in Dutch FLSs. Based on the findings of 
this first audit in the Netherlands, we were able to bring the results to the attention of 
the Dutch governmental Health Council (Zorginstituut) focusing on the unacceptably 
low FLS attendance rates.
Reasons for ‘non-attendance’ were further assessed in two FLS studies, carried out 
in the Reinier de Graaf hospital. Frailty, male gender, having low general education, 
living alone, and low interest in bone health and subsequent fracture risk were 
independent determinants for FLS non-attendance. Adequate motivation of patients 
by the healthcare professional shortly after the fracture, or the lack of it, was the 
strongest determinant associated with both FLS attendance and non-attendance. 
Remarkably, still 25% of non-responders to FLS invitation consented with a home 
visit after one telephone call, and these were mainly older women with a major 
fracture, i.e. those who would most benefit from secondary fracture prevention. 
These patients could not recall any face-to-face patient information given to them in 
the hospital. Still FLS invitation by letter was recalled in more than 60%. FLS nurses 
and nurse practitioners could therefore ease the transition from hospital to GP care 
in the high-risk group of FLS non-responders/non-attenders to contact the GP for 
further evaluation and treatment. For the nurse in charge with FLS logistics it may be 
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advisable to contact the non-responding patients and organize further FLS care in 
collaboration with GPs. Care for the patient, wherever offered, is part of our mission 
and is directly in line with the vision propagated by Value Based Health Care (VBHC). 
Our study on dairy calcium consumption among fracture patients turned out to be 
very feasible. We found a shortage of daily dairy calcium intake in many fracture 
patients, independently of age, gender or residential area (urban or rural). A good 
nutritional history and advice is therefore part of the basic package of care that can 
specifically be offered by FLS nurses. 
Based on well reported follow-up strategies by 24 FLS’s in the Netherlands (as 
reported in our Dutch audit), we decided to study our own performance with regard to 
oral bisphosphonates-initiation and adherence. One telephone call at three months 
after treatment initiation was useful to discuss adherence, eventual side effects or 
medication discontinuation. Additional telephone calls during follow-up appeared 
not to be efficacious. Corrected bone turnover marker levels (P1NP and s-CTX) 
showed high agreements with pharmacies deliveries according to the Dutch Landelijk 
Schakelpunt database (LSP) by 12 months. Since LSP is accessible to all health care 
professionals, we propose that FLS nurses can use LSP to assure adherence to 
oral bisphosphonates at 12 months post-treatment initiation. Thus, one telephone 
call is advised for evaluating adherence, side effects and if applicable, reasons for 
medication discontinuation. The value of measuring and following bone markers is 
more complex, as it needs strict monitoring of timing of blood samples and additional 
studies on cost.
The work presented in this dissertation is based on nurse practitioner initiated 
studies. This should be a stimulus for nurse colleagues for initiating new FLs studies 
on their role in secondary fracture prevention. We foresee a challenging role for NPs 
to participate in future initiatives. Therefore, Dutch FLS nurses and nurse practitioners 
should further strengthen their vision and experience with implementation in the 
national professional association (VF&O) guaranteeing professional information 
and training for newcomers. Moreover, next to nurses, nurse practitioners act in a 
coordinative role in many FLS’s throughout the country. Their legal authorizations 
are not only confined to traditional aspects of nursery care, lifestyle aspects and 
nutrition, but also include initiation of medical therapies and consequent medication 
adherence. 
Finally, dedicated nurses and/or nurse practitioners support the vision of a FLS 
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nurse-led model in line with the concepts of Value Based Health Care (VBHC). Our 
professional association was privileged to participate in the national working group 
for the preparation of a national guideline and working group on standards of 
osteoporosis care. In this position, the nurses’ association can propagate their visions 
on transition of hospital care in the Zinnige Zorg Trajectory on Osteoporosis (Dutch 
governmental Health Council, Gezondheidsraad) and the National Guideline on 
Osteoporosis and Fracture prevention. 
In summary, this dissertation may serve as a blueprint of our motivation and scientific 
interest. I would like to commission my work to all colleague nurses and nurse 
practitioners who act according to care, cure and scientific reasoning.   
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Dit proefschrift zou niet tot stand zijn gekomen als ik daarin niet door collega`s, 
vrienden en familie met veel belangstelling zou zijn gesteund: ik ben iedereen 
daarvoor zeer dankbaar! 
Eigenlijk is dit proefschrift de ontknoping van jarenlange groei door alle werkzame 
jaren in de gezondheidszorg, toegespitst op de zorg voor fractuur patiënten. De basis 
daarvoor werd gelegd tijdens mijn opleiding tot verpleegkundige in het toenmalige 
St. Hippolytus ziekenhuis in Delft en vervolgens tot gipsverbandmeester in het 
Academisch Ziekenhuis Leiden, nu LUMC, in veel opzichten een leerzame periode. 
Maar pas de afgelopen 15 jaar ben ik gegroeid in het inzicht dat een fractuur op 
oudere leeftijd veel meer impliceert dan het gevolg van een trauma en daarmee ook 
vraagt om een veel bredere benadering dan vaak gebruikelijk.
Met grote dankbaarheid kijk ik terug op de voorbije jaren in het Delftse Reinier de Graaf 
Gasthuis waarin de kwaliteit van zorg altijd uitgangspunt was (en is!): dit topklinische 
ziekenhuis met al die prachtige collega`s die mij in staat stelden en motiveerden tot 
groei en ontwikkeling. Ik was bevoorrecht authentieke collega`s (verpleegkundigen, 
artsen en minstens zo belangrijk: al die andere ziekenhuis collega`s!) te mogen 
ontmoeten, van hen te mogen leren en met hen samen te mogen werken. De 
pionierende fase na de entree van de verpleegkundig specialisten was boeiend en 
heeft tot de huidige implementatie mogen leiden (dank Marieke, Colette, Nel, Sandra, 
Yvonne en Miep). Bijzondere dank aan orthopedisch chirurg Bernard Jansen die me 
uitdaagde zelfstandig na te denken, keuzes te maken en daar ook naar te handelen 
(“als jij je werk niet goed doet zal ik die patiënt toch moeten opereren”). Met wat heimwee 
maar ook voldoening zie ik terug op de `domein` discussies. Verpleegkundigen 
(en daarmee dus gipsverbandmeesters!) en verpleegkundig specialisten zullen zelf 
het domein moeten afbakenen en de transitie vervolgens blijvend en verantwoord 
moeten inrichten.
Een aantal mensen komt een bijzonder woord van dank toe.
Prof. dr. J.J.P. van den Berg, beste Joop, je bent gedreven en hebt een enorme parate 
kennis. Je overziet als geen ander de consequenties die de details soms kunnen 
hebben voor het grotere geheel. Secundaire fractuur preventie in Nederland heeft 
je volle aandacht en je ziet kans alle initiatieven met elkaar te verbinden. Je lijkt over 
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een vrijwel onuitputtelijke energie te beschikken om voortdurend present te zijn je 
kennis uit te dragen en daarmee secundaire fractuurpreventie de plaats te geven die 
het verdient. Altijd als ik dacht dat een artikel `af` was, had jij wel scherpe suggesties 
die opnieuw tot nadenken stemden. Ik ben je dankbaar voor de kansen die ik van je 
kreeg om in jouw groep te promoveren.
Prof. dr. P.P. Geusens, beste Piet, we hebben als promotiecommissie wat moeten 
wennen aan het moderne promoveren, de afstand en het werken met skype, maar dat 
verliep allengs steeds beter. Ik leerde je aanvankelijk kennen als getalenteerd redenaar 
op diverse bijeenkomsten. Onze eerste ontmoetingen tijdens en na het FFN congres 
in Berlijn illustreerden bij uitstek je creatieve denken over de Fractuurpreventie & 
Osteoporosepoliklinieken als “best model of care” voor de kwaliteitsverbetering van 
de secundaire fractuurpreventie. Tijdens onze waardevolle skype gesprekken leerde 
ik van je om hoofd- en bijzaken te onderscheiden en nam het onderzoek door jouw 
creatieve suggesties geregeld onverwachte wendingen. 
Dr. D.H. Schweitzer, allerbeste Dave, co-promotor maar vooral vriend: we made it! We 
hebben het voor elkaar gekregen, maar zonder jouw motivatie en échte ondersteuning 
zou dit proefschrift er nooit zijn gekomen! Jouw creatieve geest is een bruisende bron 
van inspiratie en je vrijwel ongelimiteerde inzet bij het nadenken over de aanpak en 
interpretatie van een onderzoek is een enorme stimulans voor de promovendus. 
Enorm veel dank voor je vele geïnvesteerde uren in het lezen en corrigeren van teksten 
waarin naast correcte verslaglegging de hoge kwaliteit van het taalgebruik erg belangrijk 
voor je was. Als team vullen we elkaar naadloos aan en zouden we met jouw creativiteit 
nog jaren als onderzoekers vooruit kunnen. Veel dank voor alle kennis waarin je me 
hebt meegenomen en die je onvermoeibaar met me deelt, maar vooral voor de plaats 
die ik als vriend in het leven van jou en Myra mocht gaan innemen. 
Dr. P.M.M. van Haard, beste Paul, statistische held, onze eerste ontmoetingen 
speelden zich af in jouw kantoor in Delft te midden van stapels papieren. Mijn eerste 
kennismaking met de échte statistiek maakte op mij grote indruk. Al snel vormden we 
met Dave een hecht team en steeds opnieuw bleek je inzet veel groter dan alleen de 
statistische analyse. Tijdens de diners met jou en Hennie bleek ook je grote algemene 
kennis en je beeldende culinaire bespiegelingen! Je meedenken bij de interpretatie en 
de verwerking van de data in een ongeëvenaard hoog tempo en je grote bijdrage in 
de correctie van papers: geweldig. Elke vraag om uitleg leverde mij naast antwoorden 
ook weer nieuwe statistische vragen en stapels verduidelijkende artikelen op. Ik heb 
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enorm veel van je geleerd en voel me erg bevoorrecht door je vriendschap. 
Veel dank ben ik verschuldigd aan de beoordelingscommissie en hun deskundige en 
weloverwogen oordeel: prof. dr. LW. van Rhijn, prof. dr. M.C. Zillikens, prof. dr. M.H. 
Emmelot, prof. dr. L.P.S. Stassen en dr. S.P.G. Bours.
Dank aan Marsha van Oostwaard voor alle gesprekken over het gestructureerde 
verpleegkundig aandeel in fractuurpreventie en osteoporose zorg. Met de 
oprichting van VF&O hebben we dat op gang gebracht en blijvend op de zorgkaart 
gezet. En nu ook jouw promotie: houd vol! Je ziet dat het kan, het lukt jou ook! 
Dank voor de inspirerende samenwerking met het huidige VF&O bestuur (Jennie, 
Hetty, Anja en Ingrid) waar ik opnieuw deel van uit ben gaan maken, nu in de rol 
van voorzitter. Mooi dat we met ons aller inzet (en dankzij de meer dan bereidwillige 
inzet van docenten) zo`n gave opleiding konden opzetten en dank voor de inzet 
van al die bevlogen VF&O verpleegkundigen en verpleegkundig specialisten die 
fractuurpreventie als dagelijkse zorg invulling geven.
Hartelijk dank aan de directe collega`s op de Fractuurpreventie & Osteoporose 
polikliniek Wil, Sabine, Yvonne en Astrid. Wil, dank aan jou als pionierende bevlogen 
kracht achter deze polikliniek in de beginjaren en door de start met onderzoek  tegen 
wil en dank ook  organisator van talloze administratieve zaken. We hebben heel 
wat samen moeten uitvinden en wanneer jij dan zorgde voor de uitwerking kwam 
het altijd goed. Sabine, dank voor de verdere stroomlijning en uitrol van polikliniek-
taken bij groeiende patiëntenstromen die nieuwe uitdagingen vormden, dank voor 
de uitwerking van onderzoeksdata en het organiseren van databases. Dank aan de 
huidige collega`s Yvonne en Astrid voor de verdere voortzetting van het werk op het 
stevig gelegde fundament door Wil en Sabine.
Een speciaal woord van dank richt ik aan Luc Huijskes. Luc is van meet af aan betrokken 
geweest bij de Delftse Fractuurpreventie & Osteoporose polikliniek en bouwde de 
basis database zodanig dat deze als managementtool geschikt was voor het doen van 
onderzoek maar - minstens zo belangrijk - ook geschikt als ingenieus instrument voor 
het monitoren van medicatietrouw. 
Dank aan alle gipsverbandmeesters op de mooiste afdeling van het Reinier de Graaf 
Gasthuis (en tevens van elk ziekenhuis in het algemeen): de gipskamer, inmiddels 
ook al jaren de vaste aanlandplek voor  een internist-endocrinoloog. Nicole, Evelien, 
Stephanie, Danny, Lisette, Anouk, Han, Christiane, Dirk, Lonneke (met een aantal 
van jullie gaat een hechte band al heel lang terug!) en de administratieve talenten 
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Kim en Amber: heel veel dank voor alle collegialiteit, luisterende oren en jullie 
support en de mooie afdeling die we in de afgelopen jaren met z`n allen mochten 
opbouwen. 
Dank past zeker ook aan de collegiale en betrokken ondersteuning door de vakgroep 
nucleair geneeskundigen waar de DXA onderzoeken werden gedaan. Grote dank ben 
ik verschuldigd aan de (voormalig) DXA laborante Jeanette van de afdeling Nucleaire 
Geneeskunde. Toen alles nog in ontwikkeling was en we de processen nog op elkaar 
moesten laten aansluiten was jij de drijvende kracht vanuit de afdeling Nucleaire 
Geneeskunde om de flow in dat  proces te brengen en het contact tussen de beide 
afdelingen te laten opbloeien, Loes heeft het goed van je overgenomen. Helaas zijn 
ons in die periode ook voor de afdeling belangrijke mensen ontvallen. Van groot 
belang is de inzet van jou en Marc geweest voor de studie naar ultrageluid en DXA: 
razend snel was je in staat alle noodzakelijke activiteiten te organiseren. Veel dank, 
patiënten waren altijd blij met je levenswijze Twentse aanpak.
Ik ben het bestuur van de Stichting Evidence Based Fracture Care (inmiddels 
Stichting Fragility Fracture Care Delft) erkentelijk waarin ik - na oprichting door (de 
te vroeg overleden) Ron te Slaa, Maarten van der Elst en ikzelf - nog steeds mag 
samenwerken met de bestuursleden Dieu Donné, Maarten en Dave (orthopedisch 
chirurg, traumachirurg, internist-endocrinoloog en een verpleegkundig specialist: FLS 
team in optima forma!) met inmiddels focus op “fragility fracture care”: geïntegreerde 
fractuurbehandeling en secundaire fractuurpreventie door de specialismen heen. 
Onze stichting is nauw verbonden met het internationale Fragility Fracture Network 
(FFN) waarvan Dieu Donné bestuurslid is. We beogen de komende jaren een verdere 
uitbouw van deze internationale samenwerking. 
Dank voor de betrokken belangstelling van de zijde van de orthopedisch chirurgen 
en traumachirurgen van het Reinier de Graaf Gasthuis. Het zoeken naar verbinding 
is uitgangspunt voor alle beleid in het Reinier de Graaf Gasthuis en ik ben er trots 
op dat ik zo lang ‘verbindend’ in dit ziekenhuis heb mogen werken. Mede door de 
verbindende gedeelde visie op secundaire fractuurpreventie en de consensus daarover 
binnen fractuur-behandelende specialismen konden we de Fractuurpreventie & 
Osteoporose polikliniek maken tot wat deze vandaag is. In de geest van de Delftse 
Evidence Based Fracture Care congressen van indertijd moet dat perspectief bieden 
voor de Multidisciplinaire Trauma Unit (MTU) in ons ziekenhuis zoals deze per januari 
2021 van start zal gaan. 
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Dank aan alle vrienden (Bram, Ada, Lex, Arna, Peter, Thuly, Ferry en Carla) die ik geregeld 
te kort heb gedaan omdat er weer eens te weinig tijd was of omdat m`n hoofd er 
weer niet goed bij was. Ondanks dat bleven jullie me uitnodigen! Dank ook aan al m`n 
fietsmaten (Ronald, Astrid, Marcel, Marlies, Frans, Ton, Ward, Lars en natuurlijk Paul†) 
voor jullie betrokkenheid en het accepteren van mijn achterblijvende prestaties en het 
overslaan van de beurt bij `t kopwerk. We pakken de draad weer op! 
De paranimfen Jurriën, mijn zoon, en Peter, één van mijn ‘ouwe trouwe’ vrienden, 
beiden ook vaste volgers van het hele promotieproces vanaf het prille begin: dank dat 
jullie deze rol op jullie wilden nemen! 
Dank aan Sophie, mijn zus en haar echtgenoot Chris, en ook alle schoonzussen en 
zwagers en alle andere familieleden voor de niet aflatende belangstelling gedurende 
dit hele proces!
Lieve ma, als inmiddels 90 jarige vrouw ben je dapper doorgegaan na het overlijden 
van pa, nu 10 jaar geleden. Pa en ma: ik ben er zo trots op jullie zoon te mogen zijn. Ma, 
je geest is helder en ik weet dat je je snel bezorgd maakt, de laatste diagnose maakte 
dat ook niet beter. Deze ziekte wint het langzaam van je en dat doet me veel verdriet. 
Je was tot op het laatst erg betrokken bij je kinderen, maar minstens zo begaan met 
en geïnteresseerd in de ontwikkeling van je klein- en achterkleinkinderen. Ook met de 
eenzaamheid leerde je omgaan, steeds meer van je leeftijdsgenoten vielen de laatste 
jaren weg en nu was zelfs je wekelijkse kerkgang (én het koffiedrinken daarna!) niet 
meer mogelijk. Ik houd van je, we houden allemaal van je en bewonderen je sterke 
levenshouding. 
Lieve Maria, mijn meisje, als laatste maar beslist de allerbelangrijkste ben ik jou 
dankbaar dat je me de ruimte hebt gegeven zoveel tijd in de promotie te hebben 
mogen investeren. Je accepteerde meestal zonder bezwaren vele uren afwezigheid 
(“ga je weer naar boven”) en mijn beperkte beschikbaarheid voor activiteiten samen en 
bezoek aan onze vrienden. We zijn al lang samen en gaan dat ook nog een hele tijd 
zijn, ik beloof je meer tijd en oprechte aandacht. Dank aan onze prachtige kinderen, 
dochter Maaike, haar echtgenoot Fred, zoon Jurriën en vriendin Monique, en zeker 
ook aan onze geweldige en sportieve kleinkinderen Noa en Tom als ik weer eens tijd 
tekort dacht te hebben om naar jullie sportwedstrijden te komen kijken.  
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Peter van den Berg was born in Delft, the Netherlands, on May 28th 1955. After 
graduating from secondary school (Dr. Kuyper MULO) he served in the Dutch military 
and in 1981 he graduated as nurse at the St. Hippolytus Hospital, Delft, The Netherlands. 
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early episode in Delft was followed by a full traineeship at the University Hospital Leiden 
for his cast-technician traineeship that ended by 1986. His fully graduated professional 
career was continued at the Reinier de Graaf Gasthuis, meanwhile a merged hospital 
of three former Delft hospitals, and soon he was elected  to become a board member 
(secretary) of the Dutch national cast-technicians association (VGN). 
He obtained a bachelor degree in Healthcare Management (Leiden Hogeschool 2005) 
and the degree of Master of Advanced Nursing Practice (Leiden Hogeschool 2007). 
In January 2015, a PhD trajectory started at NUTRIM  (Maastricht University Medical 
Center), which resulted in the present dissertation (promotores: prof. dr. J.P. van den 
Bergh and prof. dr. P.P. Geusens; co-promotor dr. D.H. Schweitzer). The scientific 
work described in this dissertation has been published in peer reviewed medical 
journals and presented at national and international conferences. He also was co-
founder of VF&O, the Dutch  association of FLS nurses and nurse practitioners (2008) 
and was elected as president of VF&O. Today, he is head coordinator of the Fracture 
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